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Abstract 
Ingestion of vegetables rich in inorganic nitrate (NO3
-) content has emerged as an 
effective method, via the formation of a nitrite (NO2
-) intermediate, for acutely 
elevating vascular nitric oxide (NO) levels.  As such a number of beneficial effects of 
NO3
- ingestion have been demonstrated including the suggestion that platelet 
reactivity is reduced. I initially investigated whether inorganic NO3
- supplementation 
might also reduce platelet reactivity in healthy volunteers and have determined the 
mechanisms involved in the effects seen. I conducted a randomised crossover study 
in 24 (12 of each sex) healthy subjects assessing the acute effects of potassium 
nitrate capsules (KNO3, 8 mmol) vs placebo (KCl) control capsule ingestion on 
platelet reactivity. Inorganic NO3
- ingested via supplementation raised circulating 
NO3
- and NO2
- levels in both sexes and attenuated ex vivo platelet aggregation 
responses to adenosine diphosphate (ADP) and, albeit to a lesser extent, collagen 
but not epinephrine in male but not female volunteers. These inhibitory effects 
were associated with a reduced platelet P-selectin expression and elevated platelet 
cyclic guanosine monophosphate (cGMP) levels. In addition, I have shown that NO2
- 
reduction to NO occurs at the level of the erythrocyte and not the platelet. These 
results demonstrate that inorganic NO3
- ingestion, whether via the diet or through 
supplementation, results in a modest decrease in platelet reactivity in healthy 
males.  
 
I then sought to examine the effects of 6 weeks daily intake of NO3
--rich beetroot 
juice versus a placebo NO3
--deplete juice on endothelial and platelet function in a 
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cohort of otherwise healthy non-diabetic untreated hypercholesterolaemics. In this 
randomised double blind placebo controlled parallel study 69 subjects were 
recruited.  The primary end point was change in endothelial function determined 
using ultrasound flow-mediated dilatation (FMD). Secondary endpoints included 
change in pulse wave analysis (PWA), aortic pulse wave velocity (aPWV), platelet P-
selectin and platelet monocyte aggregate (PMA) expression and plasma, urine and 
salivary NO3
- and NO2
- levels. Baseline characteristics, including lipid levels, were 
similar between the groups.  
 
Dietary NO3
- caused an improvement in FMD of ~24% from 4.6%±2.2% to 
5.7%±2.6% in the treatment group (p<0.001) not seen in the placebo group 
(4.5%±1.9% versus 4.3%±1.8% p=0.07). This improvement in FMD was also noted 
following acute administration of dietary NO3
-. Small but significant improvements 
also occurred in aPWV and PWA augmentation index (p=0.04). The % of platelet 
monocyte aggregates was significantly reduced in the NO3
- limb by 7.6% versus an 
increase of 10.1% in the placebo group (p=0.004). No adverse effects of dietary NO3
- 
were detected. 
 
In this study population, chronic dietary NO3
- ingestion improves endothelial 
function, vascular stiffness and platelet markers of atherogenesis in a cohort of 
hypercholesterolaemics who are otherwise at increased risk of cardiovascular 
disease (CVD).  
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This thesis provides strong support for assessment of the potential of dietary NO3
- 
as a primary prevention strategy to prevent atherothrombotic and atherogenic 
complications in larger cohorts.  
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cGMP  Cyclic guanosine monophosphate 
CNG  Cyclic nucleotide-gated 
CADP-CTs Collagen adenosine diphosphate closure times 
Cu  Copper 
DOH  Department of health 
DBP  Diastolic blood pressure 
DASH  Dietary approaches to stop hypertension 
DOH  Department of health 
ecto-ADPase Ectoadenosine diphosphatase 
ECG  Electrocardiogram 
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e-  Electron 
EPR  Electron paramagnetic resonance 
EC  Endothelial cell 
ECM  Endothelial cell matrix 
EDHF  Endothelium derived hyperpolarising factor 
EDRF  Endothelium derived relaxing factor 
eNOS  Endothelial nitric oxide synthase 
EGF  Epidermal growth factor 
EDTA  Ethylenediaminetetraacetic acid 
NO2
*  Excited nitrogen dioxide 
FAD  Flavin adenine dinucleotide 
FMN  Flavin mononucleotide 
FITC  Fluorescein isothio cyanate 
FMD   Flow-mediated dilatation 
GDN  Glyceryl dinitrate 
GTN  Glyceryl trinitrate 
GPIb/IX/V Glycoprotein Ib/IX/V 
GPVI  Glycoprotein VI 
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GP1bα  Glycoprotein 1b alpha 
GPIIb/IIIa Glycoprotein IIb/IIIa 
G  Gram 
GTP  Guanosine triphosphate 
GC  Guanylate cyclase 
Hb  Haemoglobin 
HDL  High-density lipoprotein 
hr  Hour(s) 
HCl  Hydrochloric acid 
HMG-CoA 3-hydroxy-3-methyl-glutaryl-CoA 
ICAM-2 Intercellular adhesion molecule-2 
IL-1β  Interleukin-1-beta 
i.m.  Intramuscular 
Fe  Iron 
JAM-3  Junctional adhesion molecule-3 
KO  Knock out 
LV  Left ventricle 
LVEF  Left ventricular ejection fraction 
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L-NAME L-NG-nitroarginine methyl ester 
L-NMMA L-NG-monomethyl-arginine 
LTA  Light transmission aggregometry 
LDL  Low-density lipoprotein 
Mac-1  Macrophage 1 antigen 
MIP-1α Macrophage inflammatory protein-1-alpha 
MMP-2 Matrix metalloproteinase -2 
metHb  Methaemoglobin 
MQ  Milli-Q 
min  Minute(s) 
MI  Myocardial infarction 
nNOS  Neuronal NOS 
NMDA  N-methyl-D-aspartate 
NHS  National health service 
NICE  National institute of clinical excellence 
NADPH Nicotinamide adenine dinucleotide phosphate 
NO3
-  Nitrate 
NO  Nitric oxide 
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NOA  Nitric oxide analyser 
NOS  Nitric oxide synthase 
NO2
-  Nitrite 
NOx  Nitrite + nitrate 
NG  Nitroglycerin 
HNO2  Nitrous acid 
oxyHb  Oxyhaemoglobin 
ODQ  [1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one] 
O2  Oxygen 
O3  Ozone 
PPB  Parts per billion 
ONOO-  Peroxynitrite 
PBS  Phosphate buffered saline 
PDE  Phosphodiesterase 
PAI-1  Plasminogen activator inhibitor-1 
PAF  Platelet-activating factor 
PDGF  Platelet-derived growth factor 
PF4  Platelet factor 4 
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PMA  Platelet monocyte aggregate 
PPP  Platelet-poor plasma 
PRP  Platelet-rich plasma 
PEG-SOD Polyethylene-glycolated SOD 
KCl  Potassium chloride 
PGI2  Prostaglandin I2 
PKG  Protein kinase G 
PSGL-1  P-selectin glycoprotein ligand-1 
K+  Potassium 
KNO3  Potassium nitrate 
KNO2  Potassium nitrite 
PWA  Pulse wave analysis 
PWV  Pulse wave velocity 
ROS  Reactive oxygen species 
RBC  Red blood cell 
RANTES Regulated on Activation, Normal T cell Expressed and secreted 
S  Second 
NaNO2  Sodium nitrite 
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SNP  Sodium nitroprusside 
SMC  Smooth muscle cell 
sGC  Soluble guanylate cyclase 
Sper-NO Spermine-NONOate 
O2
-∙  Superoxide 
SOD  Superoxide dismutase 
SBP  Systolic blood pressure 
BH4  Tetrahydrobiopterin 
Tx  Thromboxane 
TGF-β  Transforming growth factor beta 
US  United States 
UK  United Kingdom 
VASP                Vasodilator stimulated phosphoprotein 
vWF  Von Willebrand factor 
WBC  White blood cell 
XOR  Xanthine oxidoreductase 
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Materials 
Materials Manufacturer/City/Country 
Antibodies  
Anti-human CD14-FITC Becton, Dickinson & company, New 
Jersey, USA 
Anti-human CD42b-APC Biolegend, San Diego, USA 
Anti-human CD62P-FITC Serotec, Oxford, UK 
Isotype controls  
Iso-CD14-Mouse IgG2aK Becton, Dickinson & company, New 
Jersey, USA 
Iso-CD42b-Mouse IgG1x Biolegend, San Diego, USA 
Iso-CD62P-Mouse IgG1                     Serotec, Oxford, UK 
Isotype controls  
Iso-CD14-Mouse IgG2aK Becton, Dickinson & company, New 
Jersey, USA 
Iso-CD42b-Mouse IgG1x Biolegend, San Diego, USA 
Iso-CD62P-Mouse IgG1 Serotec, Oxford, UK 
Solutions/Drugs/Interventions  
Ascorbic acid Sigma-Aldrich Company Ltd, Dorset, UK 
Beetroot juice and placebo James White Drinks Ltd, Ipswich, UK 
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Calcium chloride Sigma-Aldrich Company Ltd, Dorset, UK 
Citric acid-sodium phosphate dibasic Sigma-Aldrich Company Ltd, Dorset, UK 
Glacial acetic acid    Sigma-Aldrich Company Ltd, Dorset, UK 
HEPES powder Sigma-Aldrich Company Ltd, Dorset, UK 
Hydrochloric acid Prolabo VWR, Lutterworth, UK 
Immunolyse solution Beckman Coulter, California, USA 
3-isobutyl-1-methylxanthine Sigma-Aldrich Company Ltd, Dorset, UK 
Isotonic glucose    Nycomed, Zurich, Switzerland 
Milli Q NOx-free water      Millipore Corporation, Billerica, USA 
ODQ Sigma-Aldrich Company Ltd, Dorset, UK 
Paraformaldehyde powder Sigma-Aldrich Company Ltd, Dorset, UK 
Potassium chloride Sigma-Aldrich Company Ltd, Dorset, UK 
Potassium iodide Sigma-Aldrich Company Ltd, Dorset, UK 
Potassium nitrate capsules Martindale Pharmaceuticals Ltd, Essex 
Potassium nitrite   Sigma-Aldrich Company Ltd, Dorset, UK 
Phosphate buffered saline                        Sigma-Aldrich Company Ltd, Dorset, UK 
Spermine-NONOate Cayman Chemical Company, Ann 
Arbour, US 
Sodium hydroxide     Sigma-Aldrich Company Ltd, Dorset, UK 
Sodium nitrate Sigma-Aldrich Company Ltd, Dorset, UK 
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Sodium nitrite Sigma-Aldrich Company Ltd, Dorset, UK 
Sodium chloride Sigma-Aldrich Company Ltd, Dorset, UK 
Trisodium citrate Sigma-Aldrich Company Ltd, Dorset, UK 
Vanadium (III) Chloride Sigma-Aldrich Company Ltd, Dorset, UK 
Water (nitrate free) Zepbrook Ltd, London, UK 
Platelet Agonists  
ADP Chrono-log Corp, Havertown, USA 
Collagen Nycomed Ltd 
Epinephrine Chrono-log, Manchester, UK 
Instruments/Equipment  
Blood sampling  
19 or 21 gauge butterfly needle Becton, Dickinson & company, New 
Jersey, USA 
BD vacutainer blood collection set Becton, Dickinson & company, New 
Jersey, USA 
4ml vacutainer blood collection tubes    Becton, Dickinson & company, New 
Jersey, USA 
Flow cytometry  
FACSCalibur flow cytometer Becton, Dickinson & company, San Jose, 
USA 
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Fortessa flow cytometer Becton, Dickinson & company, San Jose, 
USA 
Centrifugation   
Ultracentrifuge 5417R Eppendorf Ltd, New York, USA 
Sigma 4KIS Centrifuge Sigma-Aldrich Company Ltd, Dorset, UK 
Blood pressure  
Omron 705IT blood pressure reader Omron Healthcare, Netherlands 
FMD  
ECG Hennige Medical Company, UK 
7.0 MHz linear array ultrasound 
transducer and a standard Acuson XP10 
system 
Acuson, California, UK 
Hokanson AG101 cuff inflator air source 
and E20 rapid cuff inflator 
PMS Instruments Ltd, Berkshire 
Ozone chemiluminescence  
Vivaspin 500, 3000 MWCO filters GE Healthcare UK Ltd, Buckinghamshire   
NO chemiluminescence analyser Sievers Instruments, Colorado 
Platelet function testing  
Multiplate Aggregometer Dynabyte Medical, Munich, Germany 
Multiplate Test Cells                              Verum Diagnostica GmbH 
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Tecan Sunrise absorbance plate reader       Tecan Trading AG, Switerland 
 
PWA and PWV     
Vicorder physiologic vascular tester and 
software 
Skidmore Medical Ltd, Bristol 
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1.1 Preface 
In recent years, the management of cardiovascular disease (CVD) has greatly 
improved. However, it remains the top cause of death worldwide (Lim et al., 2012) 
with huge economic implications to developing countries as western lifestyles 
continue to be adopted, in addition to ongoing burden to developed countries 
including the United Kingdom (UK). This health burden is estimated to cost £31 
billion in the UK alone (Allender et al., 2008). The UK remains one of the most 
affected countries in Europe in terms of CVD with almost 180,000 deaths per year 
with the majority (80,568) a consequence of coronary heart disease (CHD) 
(Townsend, 2012). 
 
That said, overall figures for mortality in the UK continue to improve each year. 
Since the early 1970’s death rates from CVD have been on the decrease. In those 
under 75 years death rates have fallen by 44% in the last ten years 
(http://www.bhf.org.uk/research/statistics/mortality.aspx). This has largely been 
due to highly efficacious treatment advances following an acute event. Presently, 
timely percutaneous coronary intervention with stent implantation coupled with 
prolonged (1 year) anti-platelet therapy remains the most effective treatment 
strategy for limiting secondary events and improving clinical outcomes (Kastrati et 
al., 2005, Stone et al., 2013). However, despite these advances, as mentioned, 
substantial morbidity exists. Thus, there is an urgent imperative to identify and 
develop efficacious and sustainable approaches for primary and secondary 
prevention. Importantly, a strategy for which there is growing and substantial 
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support is to utilise dietary approaches. In particular there is strong evidence 
supporting dietary reductions in low-density lipoprotein (LDL) cholesterol level, with 
improved diet  particularly coupled with improved consumption of fruit and 
vegetables (Lichtenstein et al., 2006, Bogovski and Bogovski, 1981). The UK initiative 
of the “5 a day”  campaign approved by the Department of Health (DOH) and 
implemented within the National Health Service (NHS) has underpinned the drive to 
encourage increased intake of fruit and vegetables amongst the entire population 
as a result of compelling evidence pointing to a reduced incidence of many modern 
day diseases namely some cancers and CVD (DOH, 2003). 
 
1.2 Diets rich in fruits and vegetables confer beneficial effects against CVD 
Diets rich in fruits and vegetables reduce cardiovascular morbidity and mortality 
(Joshipura et al., 1999, Joshipura et al., 2001). These beneficial effects have in part 
been attributed to previously well documented reductions in blood pressure. The 
Dietary Approaches to Stop Hypertension (DASH) study (Appel et al., 1997) showed 
that the implementation of 7 portions of fruit and vegetables a day more than a 
control diet (average American diet at that time) resulted in a small but significant 
decrease of 2.8 mmHg  in  systolic blood pressure (SBP) and 1.1 mmHg in diastolic 
blood pressure (DBP) in pre-hypertensive individuals. It has been suggested that 
such a reduction if translated to a population level is likely to have a marked effect 
on cardiovascular mortality. It has been estimated that a 1 mmHg increase in SBP 
increases cerebrovascular incident mortality by 2% and a 1 mmHg increase in DBP 
increases stroke mortality by 3% (Palmer et al., 1992). In addition, a large scale-
43 
 
meta-analysis of 354 studies totalling 56,000 patients has demonstrated that a 
decrease in SBP of 5 mmHg results in a decrease in incidence of stroke of 34% in 
addition to a 21% reduction in incidence of acute myocardial infarction avoiding any 
morbidity altogether (Law et al., 2003). Similarly Lewington demonstrated, in a 
meta-analysis of 1 million adults in 61 prospective studies, that a 2 mmHg increase 
in SBP is associated with 10% increase in stroke and 7% increase in MI (Lewington et 
al., 2002). It is possible that the reduction in BP caused by fruit and vegetable rich 
dietary ingestion underlies the associated reported decreases in CHD and stroke. In 
the Health Professionals and Nurses’ Health study cohorts, risk of ischaemic stroke 
was significantly reduced in individuals consuming 5 portions of fruit and vegetables 
a day (Joshipura et al., 1999) as well as reducing risk of coronary artery disease 
(CAD) (Joshipura et al., 2001). 
 
Despite substantial research efforts focusing on identifying the exact mediator of 
the beneficial effects of fruits and vegetables on cardiovascular health, the issue still 
remains unresolved. The belief that anti-oxidant vitamins may be accountable for 
these effects has lost favour with several large scale clinical trials of different 
antioxidant vitamins failing to reproduce the effects of a diet rich in fruits and 
vegetables, an observation reinforced by recent meta analyses (Bjelakovic et al., 
2007, Bjelakovic et al., 2012). Fruits and vegetables are also rich in a number of 
minerals and in particular potassium (K+). There is a large body of evidence 
supporting the view that K+ supplementation exerts beneficial effects within and 
upon the cardiovascular system particularly with respect to BP lowering (He et al., 
2006). Although challenging this view, it has recently been demonstrated that 
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supplementing hypertensive patients with K+, magnesium and fibre does not 
account for the beneficial effects of a diet rich in fruits and vegetables on BP and 
vascular function in such cohorts (Al-Solaiman et al., 2010). Perhaps a clue to the 
key elements of healthy diets was provided by Willett’s group who found in The 
Nurses Health and Health Professionals cohorts that the greatest benefits conferred 
by a fruit and vegetable rich diet, in preventing complications of atherosclerosis, 
was actually provided by green leafy vegetables (Joshipura et al., 1999, Joshipura et 
al., 2001). Considering these observations, there has been recent interest in the 
possibility that inorganic (dietary) nitrate (NO3
-) might underlie the protective 
effects of a fruit and vegetable rich diet (Lundberg et al., 2006) via generation of 
nitric oxide (NO) following sequential reduction of inorganic NO3
- to nitrite (NO2
-) 
and then NO2
- to NO (see section 1.11). This possibility has been proposed since 
green leafy vegetables are particularly rich in the NO3
- anion. Indeed, all vegetables 
contain some inorganic NO3
- since it is required for plant growth. Analysis of a range 
of foodstuffs demonstrates that the highest levels occur in vegetables such as 
cabbage, lettuce and rocket (Santamaria, 2006). In addition very high levels are also 
found in beetroot with lesser amounts in other root vegetables such as carrots and 
potatoes (Chan, 2011). Assessment of the DASH  diet suggests that it contains high 
levels of NO3
- with estimates indicating up to 20 mmol of NO3
- daily (Hord et al., 
2009a). 
In terms of the mechanism of protection provided by fruit and vegetable rich diets 
there have been a number of pathways proposed. In particular it has been shown 
that fruits and vegetables reduce circulating LDL cholesterol levels and in this way 
reduce CHD burden (Djousse et al., 2004). In support of this is that cholesterol 
45 
 
lowering, via statins, has been a highly effective treatment in secondary prevention 
of CVD for almost 20 years (Kjekshus and Pedersen, 1995). Moreover, clinical 
studies demonstrate significant reductions in all-cause mortality with meta-analyses 
of 14 studies demonstrating particular efficacy in patients at high risk (Baigent et al., 
2005). As such, the statins now have a prominent place in primary prevention of 
ischaemic heart disease as per the National Institute of Clinical Excellence (NICE) 
guidance (http://www.nice.org.uk/TA094). However, statin “intolerance” is an issue 
in 5-10% of the population (Ahmad, 2014) and identification of novel targets and 
therapeutics that overcome the problems associated with statin use are needed 
(Vandenberg and Robinson, 2010). Whether or not inorganic NO3
- might modify 
cholesterol profiles is of interest.  
 
Finally, it is well known that platelets play a key part in the acute events associated 
with thromboembolism in CHD and stroke, however, in addition increased platelet 
activity is thought to contribute also to the formation and extension of 
atherosclerotic plaques (Ruggeri, 2002, Wagner and Burger, 2003, Davi and 
Patrono, 2007). Indeed platelet reactivity is enhanced in individuals with increased 
risk of CVD. For example, ex vivo platelet aggregation is increased in those with 
hypercholesterolaemia (Wolf et al., 1997), in those with CAD (Diodati et al., 1990), 
as well as in hypertensive individuals (Nyrop and Zweifler, 1988). Fruits and 
vegetables have been shown to exert important modifications of platelet function. 
Ingestion of grape juice was found to attenuate platelet activity in stenosed canine 
coronary arteries (Demrow et al., 1995) as well as in a cohort of 
hypercholesterolaemic rabbits (Shanmuganayagam et al., 2007). Berry consumption 
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in middle aged unmedicated subjects with risk factors for development of CAD was 
associated with a significant inhibition of platelet function as measured by collagen 
and adenosine diphosphate (ADP) closure times (CADP-CTs) using the platelet 
function analyser (Erlund et al., 2008). Garlic has also been shown to inhibit platelet 
aggregation in humans in the short term (1h) (Boullin, 1981) and after 5 days 
consumption (Bordia, 1978), findings confirmed by in vitro studies highlighting the 
inhibition of whole blood platelet aggregation by compounds in garlic clove extracts 
and commercial garlic products (Lawson et al., 1992). Other studies have shown 
fruits such as kiwi (in humans) and pomegranate (in mouse models and in humans) 
modify platelet aggregation. In addition to reduction in blood triglyceride levels, in 
healthy volunteers consuming two or three kiwi fruit per day for 28 days reduced 
platelet aggregation in response to collagen and ADP by 18% compared with 
controls (Duttaroy and Jorgensen, 2004). Pomegranate juice consumption has been 
shown to reduce aggregation of human platelet and platelets of atherosclerotic 
apolipoprotein E (ApoE) deficient mice (Aviram et al., 2000, Mattiello et al., 2009).  
 
Of relevance to this thesis are suggestions that dietary NO3
- might also influence 
platelet reactivity. Richardson et al. reported that 2 mmol of oral potassium nitrate 
(KNO3) ingestion in humans inhibited ex-vivo platelet aggregation responses 
(Richardson et al., 2002). Similarly Webb et al. in 2008 showed that consumption by 
healthy volunteers of a single dose of 500 ml of beetroot juice delivering ~ 17 mmol 
of inorganic NO3
- significantly reduced ex vivo platelet aggregation in response to 
both ADP and collagen (Webb et al., 2008b). Further assessment of the possibility 
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that dietary NO3
- might offer a therapeutic strategy that impacts on both 
cholesterol and platelet reactivity are aims that I have considered in this PhD.  
 
1.3 Atherosclerosis 
A disease of the blood vessel wall, atherosclerosis is defined by deposition of lipid, 
cell recruitment and plaque formation. When this process manifests in the coronary 
arteries and is complicated by plaque rupture and subsequent thrombosis, 
myocardial infarction (MI) results, when cerebral arteries are affected, stroke 
ensues. Atherosclerosis is initiated through endothelial cell activation, a 
consequence of infiltration and retention of LDL into the arterial intima (Ku et al., 
1985, Steinberg, 1997, Skalen et al., 2002), which is exacerbated in areas of 
turbulent blood flow, for example at bifurcation branches (Ku et al., 1985, Malek et 
al., 1999). Adhesion molecules are expressed subsequently by activated endothelial 
cells at these sites of turbulence resulting in leukocyte and platelet rolling and 
adhesion at these sites (see section 1.7.1). Ultimately, the recruited monocytes 
differentiate into macrophages with uptake of oxidised LDL to form lipid rich foam 
cells resulting in fatty streak formation and development into an atherosclerotic 
plaque (Ross, 1999, Libby, 2002). 
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Figure 1.1: Schema of the evolution of CAD in humans. Those with risk factors tend to 
develop advanced atherosclerosis. Modified from (Libby, 2002) and (Fuster et al., 1985). 
 
1.4 The relationship between hypercholesterolaemia and atherosclerosis 
The relationship between hypercholesterolaemia and atherosclerosis has long been 
established via convincing epidemiological, laboratory and clinical trial data. In 1908 
Ignatowski described an important model for the study of atherosclerosis where           
rabbits fed “high cholesterol diet” expressed subsequent atheroma formation 
(Yanni, 2004). It was in 1916 that a Dutch scientist first noted that cholesterol levels 
differ between cohorts and that hypercholesterolaemia underlies atherosclerosis in 
addition to other metabolic diseases (Kromhout et al., 2002). It was later shown 
that atherosclerosis could be induced in a reproducible manner in laboratory 
animals, if fed a diet rich in cholesterol and saturated fat, and that adoption of a low 
fat and low cholesterol diet could reverse these effects (Anitschkow, 1933). In the 
1950s-1960s several observational studies were performed assessing the influence 
of various factors on CHD. These studies identified an increased risk of developing 
CAD in association with age, arterial BP and serum cholesterol concentration (Keys 
et al., 1963, Kannel et al., 1971, Chapman and Massey, 1964, Doyle et al., 1959, Paul 
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et al., 1963, Stamler et al., 1960, Morris et al., 1966, Gordon and Kannel, 1971). 
However, it was in 1962 that Still and O’Neal from electron micrographs reported 
macrophages “clinging to and apparently penetrating” the aortic intima of rats fed 
diets rich in butter (Still and O'Neal, 1962); heralding the first hint that inflammation 
may be involved in the atherosclerotic process. 
 
A key contributor to our understanding of the pivotal role of cholesterol in 
atheroma formation was the work of the Keys Group. In 1963 Keys and co-workers 
conducted a study in men in the Minnesota region, where it was found that in 
addition to age and SBP, cholesterol levels were associated with cardiovascular 
events (Keys et al., 1963). This study was followed on by, and in part precipitated, 
the ‘International Cooperative Study on the Epidemiology of Cardiovascular 
Disease’ initiated in 1958 which recruited 11,132 European and American men aged 
40-59 years who were free of coronary disease on entry into the study. The men 
were followed up for a 5 year period and cholesterol, in addition to body mass 
index (BMI) and BP, was shown to predict risk (Fidanza et al., 1970, Aravanis et al., 
1970, Buzina et al., 1970, Taylor et al., 1970a, Taylor et al., 1970b, Blackburn et al., 
1970, Kimura and Keys, 1970, Keys et al., 1972). Similarly serum cholesterol levels 
were found to impact on six year mortality, from non-haemorrhagic stroke and total 
CVD, in the multiple risk factor intervention trial in 35 American men aged 35-57 
years with no history of CVD on entry into the trial. In this study, levels of LDL were 
associated with increased events (Iso et al., 1989). Serum cholesterol across 
cultures was also linearly related to CAD mortality in the twenty-five year follow-up 
of the Seven Countries Study (Verschuren et al., 1995). It was shown that this 
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association was not limited to the United States (US) with recruitment from within 
Europe. These cohorts formed the basis of the Framingham study (Kannel et al., 
1976b) which has been conducting follow up of 5,209 individuals assessing risk on 
an annual basis and indeed of annual risk here too the associations of cholesterol 
levels with CVD is also evident. 
 
Over the years multiple randomised controlled primary and secondary prevention 
clinical trials have been performed assessing the effect of different treatment 
regimens used to achieve reductions in cholesterol including drugs such as 
cholestyramine (LIPID, 1984) and gemfibrozil (Frick et al., 1987) where significant 
reductions in LDL cholesterol result in significant reductions in atherosclerosis 
development or number of cardiovascular events. Trials subsequently utilised 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) in both 
primary prevention (Downs et al., 1998, Shepherd et al., 1995) and secondary 
prevention (4S, 1994, Sacks et al., 1996, LIPID, 1998) of CVD, endorsing the 
importance of lowering cholesterol to reduce atherosclerosis burden. Interestingly, 
the mechanisms by which statins mediate their beneficial effects are not thought to 
be entirely dependent on cholesterol lowering alone (Vaughan et al., 1996, 
WOSCOPS, 1998). It is widely believed that direct effects of statins possibly via 
effecting the NO and endothelin system influences the development of vascular 
dysfunction, an early pathogenic event in atherosclerosis (Hernandez-Perera et al., 
1998, Laufs et al., 1998). Of course it is also clear that dietary approaches and 
interventions can reduce cholesterol levels and disease burden. In the Seven 
Countries Study it was clearly demonstrated that the average consumption of 
51 
 
animal foods (except fish) is positively associated with CHD mortality. However, in 
addition the evidence also indicated an inverse association with vegetables 
(Menotti et al., 1999). The identity of the exact constituent of vegetables 
responsible for additional cholesterol lowering is uncertain but proposed 
possibilities include plant sterols, viscous fibres and possibly nuts (Jenkins et al., 
2011). Whether NO3
- in the diet might have a role to play is unknown.   
 
1.5 The healthy endothelium 
The healthy endothelium, a monolayer of endothelial cells (ECs) lining the lumen of 
all blood vessels separating the vascular wall from the circulation, is a major 
regulator of vascular homeostasis. Endothelial factors regulate vascular tone, 
smooth muscle proliferation, leukocyte activation, thrombogenesis and fibrinolysis. 
This activity is sustained through the release of various mediators of which NO is 
arguably the most important (see below, section 1.6). Other factors originating from 
the endothelium that might contribute to the protective role of the endothelium 
include bradykinin and prostacyclin (Drexler, 1998). Prostacyclin is the primary 
vasodilator product of vascular cyclooxygenase activity and has also been shown to 
act synergistically with NO to inhibit platelet aggregation (Luscher and Barton, 
1997). Prostacyclin, and endothelium derived hyperpolarising factor (EDHF), are 
activated by bradykinin, another inhibitor of platelet aggregation and stimulator of 
the serine protease tissue plasminogen activator, an important fibrinolytic (Drexler 
and Hornig, 1999). 
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The endothelium under pathological conditions can also produce and release 
various substances such as endothelin and angiotensin II that contribute to 
atherosclerosis. Endothelin is an extremely potent endogenous vasoconstrictor, the 
production of which is activated by various stimuli including hypoxia, low shear 
stress and hormones such as angiotensin II (Masaki, 2004). Both substances are 
implicated in atherosclerosis formation through smooth muscle proliferation. In 
addition the smooth muscle cells (SMCs) and activated macrophages generate more 
endothelin resulting in a vicious cycle of ongoing plaque formation. Increased 
endothelin levels have been identified in both atherosclerosis (Lerman et al., 1991) 
and in hypercholesterolaemia (Lerman et al., 1993, Boulanger et al., 1992).  
 
Figure 1.2: The healthy endothelium. (NO=nitric oxide; PGI2=prostaglandin I2; O2=oxygen; 
SMC=smooth muscle cell). 
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1.6 An introduction to NO 
Joseph Priestly, a British chemist and clergyman discovered NO in 1772. NO has 
historically been credited as being an atmospheric pollutant produced via 
combustion of fossil fuels. However, this view was transformed with the discovery 
of mammalian NO and its vast array of biological effects. Furchgott, Ignarro and 
Murad were awarded the Nobel Prize in Physiology or Medicine in 1998 for 
discovering that NO was a major signalling molecule in the cardiovascular system.  
 
The significance of NO as a critical signalling molecule came from studies conducted 
by Robert Furchgott who discovered the importance of maintaining an intact 
endothelium in order for endothelium-dependent vasodilatation to occur 
(Furchgott and Zawadzki, 1980). Furchgott was perplexed by the apparent paradox 
of acetylcholine (ACh) instigating potent vasodilation and BP reduction in vivo but 
not in vitro where it appeared to vasoconstrict isolated preparations of blood 
vessels.  He reported, 
 “For example, in the helical strip of the rabbit descending thoracic aorta, the only 
reported response to ACh has been graded contractions, occurring at concentrations 
above 0.1 µM and mediated by muscarinic receptors.”  
 
However, Furchgott and his team subsequently observed that in a ring preparation 
from the rabbit thoracic aorta, ACh produced marked relaxation at concentrations 
lower than those required to produce contraction. He discovered that the loss of 
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relaxation to ACh in the case of the strip was the result of unintentional rubbing of 
its intimal surface against foreign surfaces during its preparation. If care was taken 
to avoid rubbing of the intimal surface during preparation, the tissue, whether ring, 
transverse strip or helical strip, always exhibited relaxation to ACh, and hence the 
discovery that rubbing of the intimal surface had removed endothelial cells (ECs). So 
it was demonstrated that relaxation of isolated preparations of rabbit thoracic aorta 
and other blood vessels by ACh requires the presence of ECs, and that ACh, acting 
on muscarinic receptors of these cells, stimulates release of a substance(s) that 
causes relaxation of the underlying vascular smooth muscle (Furchgott and 
Zawadzki, 1980). The term endothelial-derived relaxing factor (EDRF) was used by 
Furchgott to describe the unknown soluble mediator made by the endothelium that 
was responsible for smooth muscle relaxation (Cherry et al., 1982, Furchgott, 1983).  
 
Of note in the 1970’s Murad and his colleagues investigated the actions of several 
vasodilator molecules including glyceryl trinitrate (GTN), and how these affected 
soluble guanylate cyclase (sGC) activity. They showed that sGC, a haem-containing 
protein, from rat liver and bovine tracheal smooth muscle was stimulated by the 
organic nitrates and nitrites, causing an increase in cGMP resulting in vascular 
relaxation. Although the mechanism was not fully understood, Murad suggested 
that this increase in cGMP may occur through formation of NO because it also 
increased sGC activity (Katsuki et al., 1977, Arnold et al., 1977). So it was of great 
interest when the so called EDRF was demonstrated to activate sGC to elevate 
tissue levels of the signalling molecule, cGMP, in various vascular tissues including 
bovine coronary artery (Holzmann, 1982), rat aorta (Rapoport et al., 1983), rabbit 
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aorta (Diamond and Chu, 1983) and bovine pulmonary artery preparations (Ignarro 
et al., 1984). The discovery that both methylene blue (Gruetter et al., 1981, Ignarro 
et al., 1984) and haemoglobin (Hb) (Furchgott et al., 1984) inhibited the effect of 
both EDRF and the nitrovasodilators/NO on smooth muscle and cGMP accumulation 
was key in identifying EDRF as NO (Palmer et al., 1987). Moncada’s group utilised  
chemiluminescence in these experiments in which  reaction of ozone (O3) and NO 
produces a detectable signal (Downes et al., 1976), thus performing the first direct 
measurement of NO production. In their experiments bradykinin caused 
concentration-dependent release of NO from endothelial cells attributable to the 
biological activity of EDRF (Palmer et al., 1987).  
 
1.6.1 NO and NO-related chemistry 
NO is a small diatomic amphiphilic molecule which freely diffuses across 
membranes. It is a free radical that is attracted to species containing unpaired 
electrons (e-) such as oxygen (O2), forming NO2
-  and NO3
- in aqueous solutions 
(Ignarro et al., 1993) and radicals such as O2
-∙. Interaction with the latter results in 
the formation of peroxynitrite (ONOO-). It is the potent oxidative and reductive 
potential of NO that underlies its ability to generate various nitrogen species 
including NO2
- and NO3
- (equation 1.1). NO also terminates radical-type reactions, 
including that of lipid peroxidation (Rubbo et al., 1996). 
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Equation 1.1: NO and other nitrogen species – the redox relationship. 
 
NO reacts with metals such as iron (Fe) and copper (Cu) to form nitrosyl complexes. 
Of importance is the Fe-nitrosyl reaction which activates sGC. Other haem-
containing proteins of significance with respect to NO include Hb and cytochrome 
P450 (Fukuto, 2000). NO also reacts with thiols to form nitrosothiols in vivo. 
Nitrosothiols have been postulated to be NO donors, expending NO on coming into 
contact with other thiols (Williams, 1999, Ignarro et al., 1980a, Ignarro et al., 1980b, 
Ignarro and Gruetter, 1980, Jia et al., 1996).  
 
NO is quenched and its action terminated in vivo through its oxidation reaction with 
oxyhaemoglobin (oxyHb), as discovered by Hermann in 1865, to produce NO3
- and 
methaemoglobin (metHb; Equation 1.2)  (Gladwin et al., 2005). 
NO3
- NO2
- NO HNO NH2OH
v III II I -I -III
NITRATE NITRITE
NITRIC
OXIDE HYDROXYLAMINE AMMONIA
NH3
NITROXYL
(Nitrogen redox 
State)
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Equation 1.2: NO activity is terminated through oxidation with Hb. 
 
The extremely fast nature of this reaction (Feelisch and Noack, 1987, Eich et al., 
1996, Herold et al., 2001) led some to postulate that NO could not be a functional in 
vivo EDRF (Lancaster, 1994). However, these concerns have somewhat been 
appeased by the discovery of a cell-free layer of blood next to the endothelium 
(Liao et al., 1999). Additionally, it has been recognised that the erythrocyte 
encapsulates Hb and it is thought that necessary diffusion of NO through its 
membrane limits the speed of the reaction of NO with Hb (Vaughn et al., 2000, Liu 
et al., 1998, Vaughn et al., 1998). 
 
The oxidation of NO is slow in pure aqueous solutions, generating mainly NO2
-. 
However, generation of NO3
- is more abundant than NO2
- in aqueous solutions in 
the presence of oxyhaemoproteins such as oxyHb (Ignarro et al., 1993). 
Ceruloplasmin, a Cu containing enzyme, has recently been shown to have NO 
oxidase/NO2
- synthase function although the relevance of this pathway in 
terminating NO activity and regulating basal NO levels is yet to be fully established 
(Shiva et al., 2006). 
NO HbO2 MetHb NO3
-+ +
NITRIC OXIDE
MET 
HAEMOGLOBIN
OXY
HAEMOGLOBIN
NITRATE
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1.6.2 Conventional endogenous NO synthesis 
The amino acid L-arginine was confirmed as a soluble activator of sGC using 
electroparamagnetic resonance (EPR) spectroscopy  and chromatography (Deguchi 
and Yoshioka, 1982). Thereafter, it was discovered that production of NO2
- and NO3
- 
(collectively termed NOx) was also dependent on the presence of L-arginine (Hibbs 
et al., 1987a, Iyengar et al., 1987) and that L-NG-monomethyl-arginine (L-NMMA) 
which has a structure chemically similar to that of L-arginine (Hibbs et al., 1987b) 
inhibited this process. In 1988 Palmer at al showed release of NO from cultured ECs 
induced by bradykinin and the Ca2+ ionophore, A23187, was reversibly enhanced by 
infusions of L-arginine and L-citrulline, but not D-arginine (Palmer et al., 1988). In 
addition the same group used 15N-labeled L-arginine and mass spectroscopy to 
show that NO was generated from the terminal guanidino N-atom of L-arginine. 
This “L-arginine: NO pathway” (equation 1.3) was shown to be Ca2+-dependent 
through use of Ca2+ chelators (Knowles et al., 1989, Palacios et al., 1989) and the 
requirement for O2 was demonstrated using 
18O2 and mass spectroscopy, which 
showed that NO synthase (NOS) incorporates O2
 into both NO and citrulline (Leone 
et al., 1991). 
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Equation 1.3: L-arginine is oxidised to generate NO (NO=nitric oxide; H2O=water; 
O2=oxygen; NADP
+/NADPH=nicotinamide adenine dinucleotide phosphate). 
 
NO activation of sGC catalyses the conversion of guanosine triphosphate (GTP) to 
the intracellular secondary messenger cGMP (Murad, 2006, Bryan et al., 2009) 
(Figure 1.3). cGMP in turn activates protein kinase G (PKG), which was first 
identified by Greengard in 1975 (Greengard, 1975) and is thought to underlie many 
of the effects of NO within the CV system.  
 
 
Figure 1.3: Classical NO production and the effector signalling of NO through the sGC/cGMP 
pathway in the vasculature (cGMP=cyclic guanosine monophosphate; NO =nitric oxide; 
PKG=protein kinase G; sGC=soluble guanylyl cyclase). 
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However, the direct action of cGMP on non-specific cation ion channels termed 
cyclic nucleotide-gated ion channels (CNGs) has been found in retinal 
photoreceptors and olfactory sensory neurons (for detailed review see Kaupp and 
Seifert (Kaupp and Seifert, 2002)). In addition, cGMP also controls cGMP-dependent 
phosphodiesterases (PDEs) that are able to communicate with cyclic adenosine 
monophosphate (cAMP) another secondary messenger (Francis et al., 2010).  
 
1.6.3 eNOS 
The first NOS activity characterised was that of the neuronal isoform in suspensions 
of rat cerebella by Garthwaite’s group. In this study the authors demonstrated that 
the NOS activity was Ca2+-dependent and responsible for elevation in cGMP in cell 
preparations as well as in detector cells perfused in the medium from the 
stimulated cerebellar cells (Garthwaite et al., 1988). Neuronal NOS (nNOS) also 
known as NOS-1 although named NO synthetase at the time, was subsequently 
identified by affinity chromatography as the first enzyme with capacity to produce 
NO from L-arginine, an enzyme dependent upon calmodulin (Bredt and Snyder, 
1990). Subsequently 2 further NOSs have been described, inducible (i) NOS (NOS-2) 
(Stuehr et al., 1991) and endothelial (e) NOS (NOS-3) (Pollock et al., 1991). All 
isoforms of NOS require L-arginine and molecular O2 and are functional 
homodimers (Klatt et al., 1996, List et al., 1997). Of note a number of other co-
factors are needed to facilitate normal functioning of NOS. One such essential co-
factor is NADPH which acts as an e- donor (Knowles et al., 1989, Palacios et al., 
1989, Stuehr et al., 1989). Other co-factors include flavin mononucleotide (FMN) 
and flavin adenine dinucleotide (FAD) needed for e- transfer and the pterin co-
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factor, tetrahydrobiopterin (BH4), critical to coupling of haem and needed for O2 
activation and e- transfer in NO production (Marletta, 1993, Masters, 1994, Bredt 
and Snyder, 1994, Griffith and Stuehr, 1995, Stuehr, 1997). Each monomeric subunit 
of NOS is made up of a C-terminal reductase domain possessing binding sites for 
NADPH, FAD and FMN (Bredt et al., 1991), while the binding sites for haem, L-
arginine, and BH4 are found within the N-terminal oxygenase domain (Figure 1.4) 
(for review see (Forstermann and Munzel, 2006)). 
 
Figure 1.4: A schematic diagram of NOS and its cofactors. NADPH donates e- to the 
reductase domain of the enzyme and these e- are transferred through FAD and FMN redox 
carriers to the oxygenase domain. Once within the oxygenase domain they interact with 
the haem iron and BH4 at the active site resulting in catalysis of the reaction of oxygen with 
L-arginine, forming citrulline and NO as products. Bound Ca2+/Calmodulin is needed for 
electron flow through the reductase domain (e-=electrons; Fe=iron; 
BH4=tetrahydrobiopterin; FAD=flavin adenine dinucleotide; NADPH=nicotinamide adenine 
dinucleotide phosphate; NO=nitric oxide; O2=oxygen). 
 
Within the healthy circulation manufacture of NO occurs mainly via eNOS activity 
within the EC, the precipitants of NO generation being mechanical shear stress 
(Pohl et al., 1986, Rubanyi et al., 1986, Joannides et al., 1995) in addition to 
hormones within the circulation such as bradykinin but also ACh (Furchgott and 
Zawadzki, 1980, Cherry et al., 1982). The latter activate eNOS following G-protein 
coupled receptor activation (Flavahan et al., 1989, Liao and Homcy, 1992), 
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triggering Ca2+ influx (Busse et al., 1988, Danthuluri et al., 1988) and further release 
of intracellular Ca2+ stores (Freay et al., 1989). With respect to shear stress which is 
sensed by mechanoreceptors on the endothelial surface (Figure 1.5), eNOS activity 
triggered as a consequence (Lansman et al., 1987) is activated mainly through 
protein kinase B (Akt)-dependent phosphorylation of eNOS, which is independent of 
intracellular Ca2+ rises (Dimmeler et al., 1999).  
 
Figure 1.5: eNOS activity induced by shear stress (Akt=Protein kinase B; BK=bradykinin; 
CAM=calmodulin; eNOS=endothelial nitric oxide synthase; NO=nitric oxide; 
PI3K=phosphinositide 3-kinase). 
 
1.6.4 Atherosclerosis and endothelial dysfunction 
Vascular dysfunction is now recognised as an important pathogenic factor in CVD 
and there have been recent calls suggesting that identification of therapeutics 
targeting this phenomenon is warranted (Bonetti et al., 2003a). Perhaps the most 
well described feature of this vascular anomaly associated with CVD is a 
phenomenon termed endothelial dysfunction. 
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Endothelial dysfunction essentially denotes the disturbance in the activity of the 
inner lining of the blood vessel i.e. the endothelium. The term refers to a whole 
gambit of pathology common to many CVDs namely impaired vasodilator 
generation, impaired anticoagulant and anti-inflammatory properties of the 
endothelium, altered modulation of vascular growth and impaired regulation of 
vascular remodelling (Herbst et al., 1999). Human studies have revealed that 
various risk factors for development of atherosclerosis namely diabetes (Clarkson et 
al., 1996b, Poredos and Kek, 2000), hypertension (Zizek et al., 2001), smoking 
(Celermajer et al., 1993) and pre-existing atherosclerosis (Drexler and Hornig, 1999, 
Vita et al., 1990, John et al., 1998, Schachinger et al., 1999, Neunteufl et al., 1997) 
are all associated with endothelial dysfunction. Indeed, endothelial dysfunction is 
now accepted as an early marker for development of atherosclerosis, preceding 
ultrasonically and angiographically visible lesions (Schachinger et al., 1999, Halcox 
et al., 2002, Targonski et al., 2003).  
 
Importantly, both coronary and peripheral endothelial dysfunction predicts ensuing 
clinically significant manifestations of CVD highlighting the systemic nature of 
endothelial dysfunction. For example in the case of cerebrovascular accident (CVA), 
where coronary endothelial dysfunction predicts stroke in at risk patients (Targonski 
et al., 2003), brachial artery endothelial function is likewise predictive of incident 
cardiovascular events including MI and CVA in older adults (Yeboah et al., 2007). 
In fact it was the prospective data of the “Men born in 1914” cohort which provided 
the first study evidence of a prognostic effect of systemic endothelial dysfunction. 
Venous occlusion plethysmography was performed on this cohort in the late 1960’s 
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(Hedblad et al., 1994). In the 21 years of follow up in this study a higher incidence of 
cardiac events and all-cause mortality occurred in those with low pulse-wave 
amplitude during reactive hyperemia. Low pulse wave amplitude correlates 
negatively to arterial stiffness and endothelial dysfunction (Kinlay et al., 2001, 
Wilkinson et al., 2002c). However, since this time the techniques for measurement 
of endothelial function have advanced and today ultrasound based methods for 
assessment represent the gold standard. 
 
1.6.5 Measurement of endothelial function in humans 
The advent of endothelial function measurement began with measurements in the 
coronary circulation. In 1986, intracoronary ACh infusion with pre and post 
coronary artery diameter measurement resulted in the first assessment of coronary 
endothelial function measurements being made in humans with atherosclerosis 
(Ludmer et al., 1986). In this study graded concentrations of ACh were infused into 
the left anterior descending artery of 8 patients with advanced coronary stenosis, 4 
subjects with angiographically normal coronary arteries, and 6 patients with mild 
coronary atherosclerosis. Vascular responses were evaluated by quantitative 
angiography. In the normal coronary arteries ACh caused a dose-dependent 
dilatation compared to baseline coronary artery diameter. In contrast, all 8 of the 
arteries with advanced stenoses showed dose-dependent constriction, with 
temporary occlusion in 5. Vasoconstriction in response to ACh was also noted in 5 
of 6 vessels with minimal disease. In contrast all vessels dilated in response to GTN. 
The authors concluded that paradoxical vasoconstriction induced by ACh occurs 
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early as well as late in the natural history of coronary atherosclerosis and that the 
abnormal vascular response to ACh is likely representative of endothelial 
dysfunction. In 1989, Cox et al. demonstrated associated dysfunctional endothelium 
with the presence of coronary atherosclerosis. In this study an increase of blood 
flow through the coronary arteries was achieved through administration of 
intracoronary adenosine (Cox et al., 1989). In those with atherosclerosis the 
increase in flow was impaired compared to individuals with no evidence of 
atherosclerosis. Subsequent human studies have shown that a degree of coronary 
endothelial dysfunction is present in patients with apparently “normal” coronary 
arteries (although in reality many of these patients had known hypertension) 
(Werns et al., 1989, Hodgson and Marshall, 1989). Coronary endothelial dysfunction 
was also found to be present in hypercholesterolaemics with epicardially smooth 
arteries, but worsened in the presence of overt coronary disease (Zeiher et al., 
1991b, Zeiher et al., 1991a). Deficiencies in endothelium-dependent vasodilation 
are also associated with male sex, positive family history of CAD, and advancing age 
in angiographically normal coronary arteries (Vita et al., 1990, Yasue et al., 1990).  
 
This methodology of in vivo assessment of coronary endothelial function has also 
been used to assess the effects of therapeutic interventions in reversing endothelial 
dysfunction, with several studies assessing the effects of lipid lowering drugs. The 
first such study evaluated the effect of a lipid lowering regimen comprising of a 
change in diet and cholestyramine, which resulted in a 30% reduction in cholesterol 
and moderate increase in epicardial coronary artery dilatation compared to a pre-
treatment vasoconstriction in response to ACh (Leung et al., 1993). Another study 
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showed the benefits of pravastatin, a HMG-CoA reductase inhibitor, on ACh induced 
coronary vasoconstriction and coronary blood flow (Egashira et al., 1994). 
Combination of LDL-lowering  (lovastatin and cholestyramine) with antioxidant 
therapy in a cohort of hypercholesterolaemic patients improved coronary artery 
endothelial dysfunction (Anderson et al., 1995a) and separately lovastatin has been 
shown to improve endothelium-mediated responses in patients with coronary 
atherosclerosis (Treasure et al., 1995). 
 
The downside of coronary endothelial function measurement is that it is invasive 
and time consuming; it would be difficult to justify repeating a study or performing 
a study in an individual who has a non-clinical indication for angiography. It has 
therefore, been superseded by brachial artery FMD assessment using vascular 
ultrasound. This technique is non-invasive and cheap once the ultrasound machine 
and FMD software purchase have been accounted for. It is an operator dependent 
technique, so good training is essential if decent quality scans and accurate data are 
to be obtained. In addition FMD measurements do vary between vascular 
laboratories although a recent publication alluded to the very real prospect of 
ultrasound FMD being implemented in multicentre trials as long as a standardized 
training protocol is instituted (Charakida et al., 2013). 
1.6.5.1 Brachial artery FMD measurement 
This technique provides assessment of conduit artery vascular function in the 
systemic circulation and was first described in 1992 by Professor Deanfield’s group 
(Celermajer et al., 1992b). It utilises a reactive hyperaemia achieved by inflating a 
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sphygmomanometer cuff to 200-300 mmHg for 5 min and the subsequent shear 
stress generates the FMD which is predominantly dependent on endothelial NO 
release (Joannides et al., 1995) although a significant NO-dependent component 
has also been identified (Mullen et al., 2001). On applying inhibitors of NO synthesis 
the FMD response in both brachial and radial arteries is almost completely 
abolished highlighting the dependence on bioavailability of locally manufactured 
NO (Joannides et al., 1995). The technique facilitates contrast with sublingual 
nitroglycerin (GTN), a direct smooth muscle vasodilator, as is the case with coronary 
endothelial function testing, and has indeed been shown to correlate with coronary 
endothelial function testing (Celermajer et al., 1992c, Corretti et al., 2002b, 
Anderson et al., 1995b). Additionally, measurement of brachial artery FMD is 
extremely useful to track the course of endothelial dysfunction over time. Onset of 
endothelial dysfunction can start in early childhood, as was found in a cohort of 
children with familial hypercholesterolaemia (Sorensen et al., 1994). A decline in 
FMD has been noted to occur in response to increasing age with oxidative stress 
thought to be causative with improvement post ascorbic acid (Eskurza et al., 2004). 
There have now been dozens of clinical trials utilising brachial artery FMD as their 
primary endpoint to assess the effects of an intervention on endothelial function in 
both healthy volunteers and in those with cardiovascular risk factors, overt CVD and 
in older adults. As alluded to previously, brachial artery FMD is a useful tool that can 
be used in children and in adults of all ages.  
 
Particularly relevant to my thesis is that dietary interventions including flavonoid 
rich dark chocolate, and flavonoid rich apples and NO3
--rich spinach have all been 
68 
 
shown to improve FMD in healthy adults (Engler et al., 2004, Bondonno et al., 
2012). However, it is noteworthy that acute ingestion of inorganic NO3
- capsules did 
not improve FMD but did improve measures of compliance in a cohort of healthy 
volunteers (Bahra et al., 2012a). 
  
Brachial artery ultrasound FMD has been used to show that dietary interventions 
improve endothelial function in patients with CVD. Of note L-arginine, artichoke 
juice and walnuts have been shown to improve endothelial function in 
hyercholesterolaemic adults (Clarkson et al., 1996a, Lupattelli et al., 2004a, Ros et 
al., 2004), purple grape juice improves endothelial function and reduces the 
susceptibility of LDL cholesterol to oxidation in patients with CAD (Stein et al., 
1999), and beetroot juice and grape polyphenols improve brachial artery FMD in 
men with metabolic syndrome (Barona et al., 2012, Joris and Mensink, 2013). 
Clearly this method of assessment of endothelial function would be ideal to 
investigate the merits of a chronic dietary NO3
- strategy on endothelial function, 
which is pertinent to my thesis. 
1.6.5.2 Arterial stiffness 
Endothelial function is known to be associated with pulse wave velocity (PWV) and 
augmentation index (AI) in healthy humans (McEniery et al., 2006). Such  
measurements of arterial stiffness can be performed non-invasively by means of 
PWV (Avolio et al., 1983, Asmar et al., 1995) and pulse wave analysis (PWA) AI (for 
review see (O'Rourke et al., 2001) both of which are reproducible (Wilkinson et al., 
1998b). These measurements have been shown to be useful in predicting 
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cardiovascular events. Carotid-femoral PWV is the “gold standard” for arterial 
stiffness and is most clinically relevant when measured along the aortic and aorto-
iliac pathways because the aorta and its early branches are accountable for most of 
the pathophysiological effects of arterial stiffness. PWV has been shown to have a 
bearing on CV risk through its correlation with the Framingham risk score. The two 
were correlated in a mixed population of patients with and without clinical 
manifestations of atherosclerosis (Blacher et al., 1999). In subsequent studies it has 
been shown that PWV is an independent predictor of all-cause mortality in patients 
with end-stage renal disease and in essential hypertensives (Laurent et al., 2001) 
and an independent predictor of primary coronary events in hypertensive patients 
(Boutouyrie et al., 2002). Mattace-Raso et al. showed aortic PWV to be an 
independent predictor of coronary artery disease and stroke in apparently healthy 
subjects (Mattace-Raso et al., 2006). PWV has also been shown to correlate with 
coronary artery plaque load in humans (McLeod et al., 2004). Central PWA provides 
additional information concerning wave reflections. In contrast to PWV, PWA 
augmentation index is an indirect, surrogate measure of arterial stiffness and 
should ideally be coupled with the measurement of aortic PWV to determine the 
contribution of aortic stiffness to wave reflections (Laurent et al., 2006). 
Of relevance to my thesis it has been shown that inhibition of basal nitric oxide 
synthesis increases aortic AI and PWV in healthy males (Wilkinson et al., 2002a) as 
well as PWV measured invasively in a sheep model (Wilkinson et al., 2002c).  
Making the measurements as described in this section in an intervention study 
using inorganic NO3
- would certainly be worthwhile as endothelial function and 
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vascular stiffness are intimately related to NO generation and potentially improved 
via strategies that increase bioavailable NO. Sodium nitrite treatment has been 
shown to normalize aortic pulse wave velocity in old mice (Sindler et al., 2011). Of 
note clinical studies utilising vascular measurements tend to include measures 
platelet reactivity and function also regulated via NO and heavily implicated in 
causation and progression of atherothrombosis and atherosclerosis. For example 
Wilkinson et al. performed such a study which showed that oral vitamin C reduces 
arterial stiffness and platelet aggregation in humans (Wilkinson et al., 1999). Of 
relevance to my thesis it is currently unknown whether a dietary NO3
- strategy in 
hypercholesterolaemics could improve endothelial function, vascular stiffness and 
platelet function.  
 
1.6.6 Hypercholesterolaemia, atherosclerosis and endothelial dysfunction  
In animal models of hypercholesterolaemia, endothelium dependent vasorelaxation 
is impaired (Shimokawa and Vanhoutte, 1989, Kolodgie et al., 1990, Shimokawa et 
al., 1991). Similarly impaired endothelial function is a well-established finding in 
hypercholesterolaemic humans as previously discussed and moreover is apparent 
before lesions are clinically visible on angiography (Tsurumi et al., 1995). 
 
The cause of the endothelial dysfunction in hypercholesterolaemia appears to be 
multifactorial. However, oxidant stress, as a result of excessive production of 
reactive oxygen species (ROS), overwhelming innate antioxidant defence 
mechanisms is thought to play a critical role in the pathogenesis of 
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hypercholesterolaemia and the associated endothelial dysfunction (for review see 
(Cai and Harrison, 2000b)). Early studies in rabbit models of hypercholesterolaemia 
suggested that deficient vasorelaxant responses of arteries reflected impaired 
endothelium-dependent relaxation due to impaired vasodilator activity of 
endothelium derived relaxing factor (EDRF) and possibly NO (Minor et al., 1990). 
Early studies assessing the role of oxidative stress suggested that these deficiencies 
relate to an imbalance between intrinsic superoxide dismutase (SOD) activity and 
the generation of superoxide radicals in atherosclerotic arteries where additional 
supply of SOD in the form of polyethylene-glycolated SOD (PEG-SOD) partially 
restored endothelium-dependent relaxation of atherosclerotic arteries. These early 
studies have been followed by numerous observations supporting the view that a 
decline in NO bioavailability is a consequence of increased O2
-. formation occurring 
in hypercholesterolaemia (Cai and Harrison, 2000b). Multiple sources of the free 
radicals in hypercholesterolaemia have been identified including xanthine oxidase 
(Cardillo et al., 1997, Ohara et al., 1993), nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (Guzik et al., 2000), uncoupled NO synthase (Stroes et 
al., 1997) to name a few. Thus, identification of strategies that might improve 
oxidative stress and simultaneously improve endothelial function is of great 
interest.  
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1.7 Platelets and atherosclerosis 
1.7.1 Platelet activation 
The interaction between the endothelium and the platelet is thought to play a 
critical role in atherosclerosis. This process is a multi-step process that involves a 
number of molecular components. Selectins present on both ECs and platelets 
confer the initial loose contact that occurs between these cells resulting in “platelet 
rolling” along the endothelium. P-selectin (CD62P) originating from the membranes 
of storage granules (Weibel-Palade bodies) is rapidly expressed on the endothelial 
surface following an inflammatory stimulus (Frenette et al., 1995). Under high shear 
rates, platelet rolling to the endothelial monolayer is initiated via P-selectin 
glycoprotein ligand-1 (PSGL-1), a glycoprotein that keenly binds to P-selectin and is 
present on platelets (figure 1.6) (Frenette et al., 2000). This interaction is rapidly 
reversible and inadequate for stable adhesion with the integrins considered to be 
the main class of surface receptor mediating stable adhesion at high shear (Ruggeri, 
2002). The interaction between P-selectin and PSGL-1 is essentially important in the 
first tethering step. It appears to be an organised order of events involving “rolling”, 
binding of platelet PSGL-1 or Glycoprotein 1b alpha (GP1bα) with endothelial P-
selectin and subsequent beta-3 (β3) integrin mediated firm platelet adhesion (Figure 
1.6).   
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Figure 1.6: Platelet endothelium adhesion. Activated endothelium (yellow) expresses P-
selectin from its surface and platelet surface receptors GP1bα and PSGL-1 interact with 
endothelial P-selectin mediating platelet rolling. Firm adhesion then follows which is 
mediated through β3 integrins. (αvβ3=alpha 5 Beta 3; GP1bα=Glycoprotein 1b alpha; PSGL-
1= PSGL-1= P-Selectin glycoprotein ligand-1; vWF=Von Willebrand factor). 
  
Adhesion results in platelet activation and the release of inflammatory substances 
from the platelet, which alters the integrity of the vascular endothelium and 
supports the recruitment of monocytes to the inflammatory site, which will be 
discussed below.  
 
Platelets secrete inflammatory mediators in addition to  exposing adhesion 
molecules such as fibrinogen, fibronectin, Von Willebrand factor (vWF), 
thrombospondin, vitronectin, P-selectin, Glycoprotein IIb/IIIa (GPIIb/IIIa), growth 
factors including platelet-derived growth factor (PDGF), transforming growth factor 
beta (TGF-β), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), 
chemokines such as RANTES (regulated on activation, normal T cell expressed and 
secreted), platelet factor 4 (PF4), cytokines including interleukin-1-beta (IL-1β), 
CD40 ligand (CD40L), beta -thromboglobulin, and coagulation factors including 
factor V, factor XI, plasminogen activator inhibitor-1 (PAI-1), plasminogen and 
protein S. These proteins interact in a finely tuned capacity resulting in a range of 
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biological functions including cell adhesion, cell aggregation, chemotaxis, cell 
survival and proliferation, coagulation and proteolysis, all of which promote 
inflammatory processes and cell recruitment (Gawaz et al., 2005). IL-1β for example 
is responsible for initiating platelet induced activation of ECs as well as increasing 
endothelial expression of adhesion molecules (Hawrylowicz et al., 1991). 
 
Following recruitment to the vascular wall, platelets may promote inflammation by 
chemo attraction of leukocytes via platelet-activating factor (PAF) and macrophage 
inflammatory protein-1-alpha (MIP-1α), may stimulate SMC proliferation via TGF-β, 
platelet derived growth factor (PDGF) and serotonin (Ross et al., 1985), and may 
play a part in matrix degradation by secretion of matrix metalloproteinase -2 (MMP-
2) (Sawicki et al., 1997). Release of chemokines via activated platelets induces the 
release of chemokines from the vascular wall and these chemokines can amplify 
platelet aggregation and adhesion in concert with primary agonists resulting in 
monocyte recruitment. RANTES for example induces a P-selectin driven recruitment 
of monocytes and the subsequent pro-atherogenic interaction (Figure 1.7) (Schober 
et al., 2002).  
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Figure 1.7: Platelet monocyte interactions drive an atherogenic release of chemokines, 
cytokines and procoagulatory tissue factor. αIIbβ3=integrin αIIbβ3/glycoprotein IIb/IIIa;  
CD40L=CD40 ligand; IL-1β=interleukin 1 Beta; JAM-3=junctional adhesion molecule-3; Mac-
1=Macrophage 1 antigen (also known as CD11b/CD18, or integrin αMβ2); PSGL-1=P-Selectin 
glycoprotein ligand-1; RANTES=platelet factor 4; TGF-β=transforming growth factor Beta. 
Modified from (Gawaz et al., 2005). 
 
PF4, a second such platelet-derived chemokine, serves as a chemo attractant for 
monocytes and catalyst for monocyte differentiation into macrophages (Scheuerer 
et al., 2000). Interestingly, hypercholesterolaemia promotes atherogenesis in part 
through PF4 mediated retention of lipoproteins. (Sachais et al., 2002). Additionally 
CD40L, derived from platelets induces endothelial inflammatory responses (Henn et 
al., 1998). It is thought that the release of these chemokines is dependent on 
GPIIb/IIIa-mediated adhesion (May et al., 2002). 
 
Following activation, platelets aggregate with circulating leukocytes (Larsen et al., 
1989, Rinder et al., 1991) and platelets adherent to the vessel wall also facilitate 
leukocyte recruitment to the vessel wall (Figure 1.8) (Ross et al., 1985).  
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Figure 1.8: Endothelial cell inflammation is precipitated by adherent platelets exposing 
platelet P-selectin resulting in an inflammatory milieu that supports proatherogenic 
alterations of the endothelium and leukocyte activation. αIIbβ3=integrin 
αIIbβ3/glycoprotein IIb/IIIa; CD40L=CD40 ligand; IL-1β=interleukin 1 Beta. Modified from 
(Gawaz et al., 2005). 
 
PSGL-1-P-selectin interactions are responsible for tethering of leukocytes to 
adherent platelets and firm leukocyte adhesion occurs via binding of macrophage 1 
antigen (Mac-1) (also known as CD11b/CD18, or integrin αMβ2) to GPIbα and/or 
other receptors of the platelet membrane, comprising junctional adhesion 
molecule-3 (JAM-3) (Figure 1.7) and intercellular adhesion molecule-2 (ICAM-2) or 
bridging proteins such as fibrinogen (bound to GPIIb/IIIa) or high-molecular weight 
kininogen (bound to GP1bα) (Gawaz et al., 2005). 
 
The initial step in thrombus formation occurs when platelets adhere to the exposed 
endothelial cell matrix (ECM) where proteins such as vWF and collagen are exposed 
to the blood at the site of vascular lesions (Figure 1.9).  
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Figure 1.9: Adherence of activated platelets to vessel wall resulting in thrombus formation 
following damage to endothelium exposing collagen and vWF initiating the thrombogenic 
cascade (ADP=adenosine diphosphate; ECs=endothelial cells; vwF= Von Willebrand factor). 
 
Platelet adhesion to vWF occurs via the membrane receptor glycoprotein Ib/IX/V 
(GPIb/IX/V) (Ruggeri, 2002) and to collagen via glycoprotein VI (GPVI) (Massberg et 
al., 2003). Subsequent platelet activation and transformation of the integrin 
receptors alpha IIb beta 3(αIIbβ3) (also known as GPIIb/IIIa, fibrinogen receptor) and 
alpha 2 beta1 (α2β1) (also a collagen receptor) results in firm binding to the 
respective ECM components. ADP is subsequently released from internal stores 
following platelet synthesis of thromboxane (Tx) A2. ADP activates platelets via the 
G protein-coupled purinergic receptors, P2Y1, which initiates aggregation and 
reinforces P2Y12. P2Y1 coupled to the Gq alpha subunit (Gαq) regulates Ca
2+-
dependent signalling events initiating change in shape of platelets and fast, 
reversible αIIbβ3 dependent platelet aggregation (Andrews and Berndt, 2004). 
Additional platelets are then recruited via spread of platelets via fibrinogen bridges 
between αIIβ3 receptors supporting platelet aggregation and thrombus formation 
which accelerates the coagulation cascade and leads to subsequent stabilization of 
the clot by fibrin and αIIbβ3-dependent contraction (Gawaz et al., 2005). Activated 
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platelets also express surface P-selectin, a counter receptor for platelet GPIb/IX/V 
and leukocyte PSGL-1 (Frenette et al., 1995).  
 
It is clear that dampening platelet function may modify the linked processes of 
thrombosis and inflammation. As mentioned previously, current anti-platelet 
therapies have lost favour in primary prevention and don’t appear to have a major 
impact on atheroprogression in humans and there is a need for identification of 
novel therapeutic strategies (Andrews and Berndt, 2004). Interestingly, one of the 
main endothelial repressors of these pathways in health is the NO-soluble 
guanylate cyclase (sGC) pathway (see section 1.6.2) and it may be of benefit to 
modify this pathway to alter these damaging processes. 
 
1.7.2 Platelets and NO 
NO released both by platelets themselves and the endothelium itself has been 
proposed to exert an important repressive influence on platelet adhesion to the 
vessel wall (Gkaliagkousi et al., 2007). It is thought that through the tonic 
generation of NO by either cell type, this limits thrombus formation per se, as well 
as limiting worsening thrombosis (Shultz and Raij, 1992). 
 
The functional significance of the NO-sGC pathway on platelet function has been 
repeatedly demonstrated. In a dog model of coronary occlusion, thrombus 
formation was delayed and lysis promoted by an infusion of L-arginine, suggesting 
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that increasing NO production inhibits platelet function and reduces thrombus 
formation (Yao et al., 1992). Accordingly, in a rat model of thromboembolic stroke, 
infusion of the NOS inhibitor, L-NAME, resulted in an increase in platelet deposition 
and a reduction in global flow causing haemodynamic and thrombotic effects 
contributing to enhanced cerebral damage (Stagliano et al., 1997). Furthermore, 
experiments performed by Emerson’s group in rabbit and mouse models show 
endogenously generated NO to be an important regulator of agonist stimulated 
platelet function in vivo with NO appearing to play a critical role in reducing platelet 
activation and in accelerating platelet disaggregation in the pulmonary vasculature 
(Emerson et al., 1999). 
 
A number of mechanisms have been proposed to underlie this effect. It has been 
demonstrated that exogenously administered NO inhibits expression of platelet 
surface glycoproteins following platelet activation ie. P-selectin and the integrin  
GPIIb/IIIa complex (Figure 1.10)  (Radomski and Moncada, 1993).  
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Figure 1.10: NO effects on platelet signalling and function. NO derived from endothelial 
cells or from platelets suppresses platelet activation by means of GC activation, resulting in 
an increase in the conversion of GTP to cGMP, intensifying calcium ATPase-dependent 
refilling of intracellular calcium stores and inhibiting the activation of PI3K (dotted line= 
inhibition). As a result intracellular Ca2+ flux is suppressed, resulting in attenuation of P-
selectin expression and inhibition of conformational change of GPIIb/IIIa required for 
fibrinogen binding (Ca2+=calcium;  GC=guanylyl cyclase;   GTP=guanosine triphosphate; 
cGMP=cyclic guanosine monophosphate; NO=nitric oxide; PI3-K=phosphoinositide 3-
kinase). 
 
In 2004 Ahluwalia et al. demonstrated that the anti-adhesive properties of NO were 
predominantly mediated by the activation of sGC and the production of the second 
messenger cGMP. Moreover, cGMP was shown to cause specific down-regulation of 
the expression of P-selectin on endothelial cells and platelets (Ahluwalia et al., 
2004). In addition it has been suggested that NO-induced activation of PKG leads to 
a decrease in fibrinogen binding to GPIIb/IIIa and modulation of phospholipase A₂ 
and C-mediated platelet activation (Radomski and Moncada, 1993, Freedman and 
Loscalzo, 2003). NO also reduces the oxidation of arachidonate, inhibits the agonist-
dependent increase in platelet cytosolic free Ca2+ in a cGMP-dependent manner, 
and inhibits platelet PI3K resulting in enhanced dissociation of fibrinogen from 
GPIIb/IIIa (Radomski and Moncada, 1993, Freedman and Loscalzo, 2003). Platelet 
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surface expression of P-selectin and active glycoprotein GPIIb/IIIa also remain 
elevated in patients with MI, despite aspirin treatment suggesting persistent 
activation, however these elevations were subsequently reduced by treatment with 
NO donors (Langford et al., 1996). Additionally, systemic infusion in vivo of L-NMMA 
in healthy human subjects causes increased platelet reactivity to various agonists 
(Bodzenta-Lukaszyk et al., 1994). Thus, there is a considerable body of evidence 
demonstrating efficacy of both endogenous and exogenously derived NO in 
repressing platelet function.  
 
Within the cardiovascular system eNOS is expressed in endothelial cells but also 
thought to be present in cardiac myocytes, megakaryocytes, and also possibly in 
platelets. In 1990, Radomski and co-workers first described the influence of an L-
arginine: NO pathway on collagen-induced aggregation, starting the process of 
characterisation of a NOS isoform in platelets (Radomski et al., 1990). In 1994, a 
distinct platelet-specific constitutive NOS isoform was identified in cytosolic 
fractions generated from washed human platelets and the NO-producing activity of 
this enzyme was  shown to be dependent on L-arginine, NADPH and BH4 as well as 
calmodulin (Muruganandam and Mutus, 1994). These observations were followed 
by Sase and Mitchel who demonstrated the isoform present in platelets was eNOS 
(Sase and Michel, 1995); an observation confirmed by other researchers 
subsequently describing the presence of both the eNOS and iNOS isoforms (Mehta 
et al., 1995). Although evidence of iNOS in platelets exists (Chen and Mehta, 1996a) 
the mainstay of reports are related to an enzyme that can be detected by eNOS-
specific antibodies (for review see (Randriamboavonjy and Fleming, 2005)). 
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In support of platelets generating NO it has been shown that there is some 
enhancement of agonist induced platelet aggregation following incubation of 
purified platelets with inhibitors of NOS, and inhibition of platelet aggregation 
following incubation with L-arginine (Chen and Mehta, 1996b). Furthermore, NO 
release from resting and aggregating human platelets has been documented (Zhou 
et al., 1995) (Radomski et al., 1990) with the amounts measured leading to 
suggestions that the  level of platelet NO is comparable to endothelial generation of 
NO. Interestingly early evidence suggested markedly decreased bleeding times in 
eNOS-deficient mice, an effect that was proposed to be due to lack of platelet-
derived NO (Freedman et al., 1999). However, recently it has been suggested that 
studies identifying platelet eNOS expression and activity are flawed due to use of 
non-specific antibodies and potential contamination of platelet preparations with 
other circulating cell types such as leukocytes (Chris I. Jones. Natasha E. Barrett, 
2012). In addition there is some suggestion that the suppressive effect of in vivo NO 
on platelets actually comes from endothelial NO rather than platelet NO (Moore et 
al., 2010). Furthermore, that the increased platelet reactivity evident in eNOS-
deficient mice is a reflection of lost endothelial NO rather than platelet NO (Moore 
et al., 2011). 
 
As discussed earlier, a key pathogenic phenomenon implicated in the pathogenesis 
of CVD, including atherosclerotic and thrombotic disease, is endothelial 
dysfunction. This is characterised by a reduction in bioavailability of NO, which has 
been attributed to dysfunction of the eNOS isoform amongst other reasons. It has 
been reported that these abnormalities result in a loss of the normal NO-dependent 
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antithrombotic properties of the vessel (Freedman and Loscalzo, 2003). Thus, 
strategies that might restore NO levels and essentially restore the repressive 
influence over platelet reactivity are of clear therapeutic potential and a major 
focus of my PhD. 
 
1.7.3 Platelets and atherogenesis 
Importantly, platelet activation has not only been implicated in the later stages of 
atherosclerosis culminating in plaque rupture and vessel occlusion, but also in the 
earliest stages of atheroma development preceding any obvious endothelial 
compromise (Theilmeier et al., 2002). In the ApoE knockout (KO) mouse (which is a 
mouse model of atherosclerosis where the absence of ApoE protein results in 
hypercholesterolaemia evident very early in life (by 1-2 weeks post-weaning) 
(Plump et al., 1992) platelets were found to accumulate and adhere to the 
endothelium of atheroma prone sites at 6 weeks of age (Theilmeier et al., 2002) the 
authors speculated that this interaction between activated platelet and 
endothelium heralded the initiation of the pathogenic processes ultimately leading 
to plaque formation. Platelets have also been implicated in atheroprogression in 
humans (Schulz et al., 2008). In particular it has been suggested that the binding of 
the platelet collagen receptor GPVI to human atherosclerotic plaques and GPVI-
mediated platelet adhesion is a key mediator for atheroprogression in humans. 
Confirming such a key role for platelet adhesion are observations that enhanced 
systemic platelet activation correlates with intima media thickness of the carotid 
artery in type 2 diabetes (Fateh-Moghadam et al., 2005). The targeting of platelets 
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is key in therapeutics in the late stages of atherosclerosis i.e. an acute clinical event 
caused by plaque rupture and thrombosis (Lusis, 2000). Best clinical practice utilises 
current anti-platelet therapies such as aspirin and clopidogrel as mainstay 
therapeutics in secondary prevention following angioplasty and stent insertion. 
However, the evidence demonstrating that platelet activation is involved in the 
earliest stages of atherosclerosis suggests that anti-platelet therapies may also have 
a role in primary prevention and investigation of this possibility is warranted. 
Whether delivery of NO may be a strategy one might employ to address this issue is 
uncertain. 
 
1.8 Therapeutic delivery of NO in cardiovascular disease 
1.8.1 Organic nitrates and nitrites 
Organic nitrites and nitrates are NO generators which have been efficacious in both 
men and women and are of historical significance in supporting the potential 
benefits of restoring NO levels in CVD. In the late 19th century the organic nitrites 
and nitrates were the first compounds to be identified as nitrovasodilators, 
synthesised and used for medical purposes 100 years before the discovery of 
endogenous NO synthesis. Guthrie observed ‘flushing’ and ‘acceleration’ following 
exposure to amyl nitrite which led to Gamgee and Brunton to prescribe amyl nitrite 
for angina as reviewed by Fye and Marsh (Fye, 1986, Marsh and Marsh, 2000) and 
Murrell to prescribe GTN for angina with good effect (Marsh and Marsh, 2000). 
Organic nitrates also possess anti-thrombotic and anti-platelet effects although 
have not gained favour in the clinical arena as data have been conflicting and 
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because of issues of tolerance (McVeigh et al., 2002, Lundberg et al., 2004) (Muikku 
et al., 1995). 
 
Organic nitrites and nitrates are able to liberate NO through their –ONO2 group, the 
pharmacophore of these molecules (-ONO group in the case of ethyl nitrite). The 
pharmacophore can be bound to any organic residue and it is the stereochemistry 
and complexity of the organic residue that dictates lipophilicity and potency of 
these compounds (Thatcher et al., 2004, Koenig et al., 2007). The –ONO2 groups are 
covalently bound to the organic residue and hence enzymatic conversion is required 
for release of NO from the -ONO2 and bioactivation of organic nitrate to occur. 
There are 2 main pathways that have been proposed for organic nitrate 
bioactivation termed low and high potency. Measurable NO is generated from high 
doses of GTN via the low potency pathway (Kleschyov et al., 2003) through enzymes 
of the cytochrome P450 pathway (McDonald and Bennett, 1990). However, the 
presence of a high potency pathway for GTN bioactivation was reported in 2002 
requiring aldehyde dehydrogenase-2 (ALDH-2), a finding demonstrated through the 
use of specific ALDH-2 inhibitors (Chen et al., 2002). NO2
- and glyceryl dinitrate 
(GDN) production were blocked by the ALDH-2 inhibitors (Sage et al., 2000) and 
these were known to be important in facilitating NO mediated vasodilation. In a 
model of anaesthetised rabbits, the vasodilating and hypotensive effects of GTN 
were reduced via ALDH-2 inhibitors with no effect on NO release noted on NO 
donors such as sodium nitroprusside (Chen et al., 2002). Daiber showed that ALDH-
2 inhibitors abated elevations in cGMP and phospho vasodilator stimulated 
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phosphoprotein (phosphoVASP) and hence a reduced NO-dependent sGC/PKG 
signalling pathway propensity (Daiber et al., 2004). 
 
1.8.2 Organic nitrates and tolerance 
Unfortunately one of the major drawbacks with the organic nitrates is the problem 
of tolerance or tachyphylaxis. This progressive reduction in the haemodynamic 
effects of organic nitrates with continued treatment (Elkayam et al., 1987) has been 
shown to also be associated with endothelial dysfunction in patients with coronary 
disease (Caramori et al., 1998) and in healthy individuals alike (Gori et al., 2001). 
The mechanisms underlying this phenomenon are not fully agreed upon although 
ROS production involving O2
-∙ appears to play a role. In a rabbit model following a 3 
day application of transdermal GTN, twice as much O2
-∙ compared to controls was 
elicited via lucigenin chemiluminescence (Munzel et al., 1995). In a cohort of 
coronary artery bypass graft patients who had been pre-treated with GTN, 
increases in O2
-∙ associated with endothelial dysfunction was found in ex vivo graft 
segments (Schulz et al., 2002). Thus, the lack of efficacy of organic nitrates when 
used chronically may be accounted for by the issues of tolerance and endothelial 
dysfunction and these that have somewhat limited their use. Currently the mainstay 
of organic NO₃⁻ use in the clinic is in relief of anginal symptoms and in acute heart 
failure. Thus, alternative approaches that might deliver NO that are void of these 
limiting characteristics are needed. In this respect recent evidence suggests that 
inorganic NO₃⁻ and NO₂⁻ might provide this alternative. 
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1.9 Inorganic NO2
- and NO3
- 
The origin of the use of nitrites dates back to at least 850 BC. In 1880 after the value 
of amyl nitrite was realised in treating angina although limited by its short duration 
of effect, Reichert and Mitchell published detailed writings on the physiological 
actions of potassium nitrite (KNO2) in humans and animals. It was noted that a small 
dose of approximately 30 mg caused an increase in BP, followed by a moderate 
drop in BP and larger doses resulting in pronounced hypotension. Over the next 20 
years others expanded on these findings and in the early part of the twentieth 
century inorganic NO2
-  was marketed as a treatment for hypertension and 
vasospasm (for review see (Butler and Feelisch, 2008, Kevil et al., 2011)).  
 
Inorganic NO3
- which is the focus of my thesis has been used in traditional Chinese 
medicine for over a millennium to treat angina. In a manuscript discovered at the 
Buddhist grotto of Dunhuang the patient is advised to take KNO3
 under the tongue, 
then swallow the saliva. The advice to swallow the saliva is of particular importance 
as it is now known that the bioactivation of NO3
- requires bacterial NO3
- reductases 
which reside on the dorsum of the tongue (Duncan et al., 1995a, Lundberg et al., 
2004). Western physicians did not cotton on to the therapeutic worth of inorganic 
NO₃⁻ for many years although Edward Stieglitz identified that oral ingestion of 
bismuth subnitrate induced hypotension and the bacteria B. coli (known today as E. 
Coli) found in the intestine “breaks down bismuth subnitrate to cause liberation of 
considerable amounts of nitrite” (Stieglitz, 1936).   
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Irrespective of these promising early findings, the widely accepted view of NO3
- has 
been that of a chemically inert metabolite of endogenous NO metabolism that does 
not take part in any important chemical reactions (Ignarro et al., 1993), in contrast 
to NO2
- which does. Of note the reaction of NO2
- with oxyHb to form metHb and 
NO3
-  has been widely described in history namely by Gamgee in the 1800’s and 
formally by Kosaka in 1979 (Kosaka et al., 1979). This reaction remains of interest 
with respect to organic and inorganic NO2
--induced methaemoglobinaemia of which 
there have been a few case reports limiting the use of drugs such as amyl nitrite 
clinically (Pierce and Nielsen, 1989, Modarai et al., 2002). 
 
The vasodilatory properties of pharmacological doses of exogenous NO2
-  have long 
been known, however, it wasn’t until 2001 that it was shown that far from being an 
inert anion within the cardiovascular system at physiological levels, NO2
- at low µM 
levels could relax contracted rat aorta under acidic pH (6.6) conditions (Modin et al., 
2001). Subsequently, it was shown that an infusion of sodium nitrite (NaNO2) into 
the human forearm resulted in vasorelaxation with associated increased blood flow 
which was further increased with exercise at doses (400 nmol/min for 15 min) 
resulting in near physiological concentrations (Cosby et al., 2003). This effect of 
NO2
- has been attributed to its chemical reduction to NO within the circulation. 
 
1.10 Dietary NO3
- and NO2
- 
Daily NO3
- intake in European countries is estimated to be 1.5-2 mmol and 
approximately 80% of human NO3
- intake is derived from eating vegetables with a 
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minor contribution through drinking water, animal products and grain (EFSA, 2008, 
AICR, 2007). NO3
- intake is regulated with an accepted recommended daily intake of 
3.7 mg/kg per day, equivalent to ~4.2 mmol per day in a 70 kg person. Of note 
water supplies in the European Union are required to regulate their NO3
- content to 
contain less than 50 mg/L NO3
- equivalent to 0.8 mM NO3
- because of concerns over 
methaemoglobinaemia and carcinogenesis.  
In contrast to dietary NO3
-, dietary NO2
- intake isn’t as substantial and can be 
attributed to cured meat, cereal and vegetable intake with drinking water 
contributing only a negligible amount. Estimates of daily NO2
- intake approximate to 
0.3-0.9 mg/day in the Western world equating to 6-20 µmol NO3
-,  ingested daily 
(Schuddeboom, 1993). 
 
1.11 The alternative pathway of NO generation  
1.11.1 Metabolism of NO3
- 
In vivo, NO3
- is derived from either the oxidative metabolism of NO, and/or from 
dietary ingestion of NO3
- as mentioned above. NO3
- concentrations in the plasma of 
healthy individuals range from 20-40 µM (Gladwin et al., 2000, Lundberg and 
Govoni, 2004b, Webb et al., 2008b). Rapid absorption of orally ingested NO3
- occurs 
within the GI tract with almost 100% bioavailability of NO3
- due to the bypassing of 
first-pass metabolism (van Velzen et al., 2008). Following oral intake of an inorganic 
NO3
- salt or a dietary NO3
- load, plasma NO3
- levels are found to be significantly 
elevated within 15 min of ingestion with measurement of peak plasma levels within 
an hour (Lundberg and Govoni, 2004b, van Velzen et al., 2008, Webb et al., 2008b, 
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McKnight et al., 1997). Following ingestion of spinach, beetroot or lettuce all of 
which provide a vegetable source of NO3
-, the effective plasma t1/2 of NO3
- has been 
calculated to be  5.7-6.7 hours (van Velzen et al., 2008). The majority of plasma NO3
- 
is excreted in the urine (60-75%) with peak excretion occurring around 6 hr 
following supplementation (Pannala et al., 2003), with relatively small amounts 
excreted through perspiration and excreted in faeces (Bartholomew and Hill, 1984, 
Wagner et al., 1983). 
 
However, NO3
- is also extracted from the circulation to the salivary glands and is 
then secreted into the saliva resulting in 10-fold greater NO3
- levels than in plasma 
(Spiegelhalder et al., 1976a). It is within the oral cavity this NO3
- is metabolised 
thereafter. Salivary NO3
- levels increase within 30 min of oral NO3
- ingestion 
(McKnight et al., 1997) (Webb et al., 2008b) and approximately one quarter of 
ingested NO3
- is thought to be concentrated within the salivary glands 
(Spiegelhalder et al., 1976a, Tannenbaum et al., 1976). This process of the 
extraction of NO3
- and secretion into the saliva has been dubbed the entero-salivary 
circulation of NO3
- and is summarized in figure 1.11 (Duncan et al., 1995a). Recently 
sialin (a sialic acid transporter), has been identified as a 2NO3
-/H+ co-transporter in 
human cells (Qin et al., 2012b) responsible for the uptake of NO3
- into the salivary 
glands displacing the previous school of thought that NO3
- uptake was facilitated by 
means of competitive inhibition of the anionic iodide transporter in the salivary 
glands (Edwards et al., 1954).  
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Figure 1.11: The alternative pathway of NO generation utilising the enterosalivary circuit 
(NO3
-=nitrate; NO2
-= nitrite; NO=nitric oxide). 
 
1.11.2 NO3
- reduction to NO2
- 
Although the enterosalivary circuit was thought to be physiologically redundant it 
was noted that increases in salivary NO3
- concentration were accompanied by 
increases in NO2
-. This was found through studies looking to see if NO3
- ingestion 
would result in formation of potentially harmful nitrosamines (discussed earlier) via 
NO2
-. Ishiwata revealed an absence of NO2
- in saliva analysed directly from the 
salivary glands as opposed to saliva in the mouth indicating a conversion of NO3
- to 
NO2
- taking place within the oral cavity. These findings also suggested that the 
presence of NO2
- in the saliva may be a result of NO3
--reducing bacteria similar to 
the NO3
- reducing commensals in the gut (Ishiwata, 1975). Subsequently, it was 
discovered that a single use of anti-bacterial mouthwash resulted in significantly 
reduced salivary NO2
- levels following a dietary NO3
- load in the form of celery juice, 
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when compared to basal levels, providing further compelling evidence of oral 
bacterial NO3
- reduction (Tannenbaum et al., 1976). Studies in healthy volunteers 
confirmed the importance of the oral bacteria suggesting Veilonella strains to be 
the most prevalent and prominent in contributing to NO3
- reduction in the oral 
cavity (Doel et al., 2005). Using rat tongue samples and assessing local NO3
- 
reduction, the location of NO3
- reduction was confirmed to be confined to the 
posterior third of the dorsal aspect of the tongue (Duncan et al., 1995a). Recently 
further candidate NO3
--reducing species have been identified 7 of which were not 
previously thought to contribute to NO3
- reduction (Hyde et al., 2014).  
 
1.11.3 NO2
- reduction to NO 
2 independent groups concurrently demonstrated that following a dietary NO3
- load 
and conversion within the oral cavity, some of the swallowed NO2
- is directly 
protonated in the acidic environment of the stomach to release free NO (Benjamin 
and Vallance, 1994, Lundberg et al., 1994, Benjamin et al., 1994). In vitro studies 
incubating NO2
- with acid at pH 2 (the pH of gastric acid) found that NO generation 
was concentration-dependent, with approximately 600 nM generated from 200 µM 
NO2
-. These high levels of NO generated were speculated to provide a mechanism 
of preventing GI infection by exerting anti-microbial effects. Indeed separately it 
was shown that reduction exerted potent anti-microbial effects on both Candida 
and E. Coli growth (Benjamin et al., 1994). Indeed, the bactericidal properties of 
NO2
- derived NO have since been shown by many others (Palmer et al., 1987, Bjorne 
et al., 2006). Similarly in 1994 Lundberg et. al published their findings 
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demonstrating that ingestion of  NO3
-- rich lettuce resulted in production of NO that 
could be detected in expelled gastric air in healthy volunteers. This group also 
showed that NO production was pH dependent with very little NO produced if pH 
was above 3 in a set of in vitro experiments on acidified saliva or chewed lettuce. In 
addition they demonstrated the biological significance of this pathway through 
administration of a proton pump inhibitor prior to lettuce ingestion in vivo which 
prevented NO production (Lundberg et al., 1994).  
 
However, it is now known that not all NO2
- that is produced in the oral cavity and is 
swallowed is converted to NO in the gut. Some of this NO₂⁻ is thought to overcome 
passage through the stomach, to enter the systemic circulation. The process of NO2
- 
absorption from the gastric lumen is rapid with a halving of NO2
- levels within 10 
min (Licht et al., 1986). Curiously, it is not yet fully known how NO2
- enters the 
circulation. It has been postulated that in the acidic gastric lumen passive 
movement of nitrous acid (HNO2) into the neutral circulation may determine the 
apparent transport of NO2
- across the gastric wall (Webb and Ahluwalia, 2010), 
mirroring NO2
- transport across the erythrocyte membrane (Samouilov et al., 2007). 
It should be noted that tissue levels of NO2
- following ingestion of dietary NO3
- can 
differ greatly from plasma levels which tend to be the lowest in vivo, with the 
erythrocyte proposed to be the likely carrier of  circulating NO2
- (Dejam et al., 2005) and 
higher NO2
- levels being found at the blood vessel wall (Bryan et al., 2005). Despite 
all of the uncertainties pertaining to the mechanism behind NO2
- transport from the 
gut into the circulation, it is certain that as a consequence of ingestion and entero-
salivary processing of inorganic NO3
-,  plasma NO2
- levels rise steadily following a 
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dietary NO3
- load, peaking within the circulation within 2.5-3 hours (Lundberg and 
Govoni, 2004b, Webb et al., 2008b). 
 
The first demonstration that NO2
-
 in addition to endogenous conversion to NO in the 
gut, could also be reduced to NO in the cardiovascular system, came from Jay 
Zweier and colleagues in 1995. Zweier et al. performed experiments in the 
ischaemic Langendorff rat heart preparation and showed significant NO production 
despite NOS inhibition, implying the play of a NOS-independent mechanism of NO 
production. Through a number of iterative experiments Zweier demonstrated that 
this NO generation was attributed to the simple mechanism of disproportionation 
of stored tissue NO2
- due to the tissue acidosis (pH 5.5) that developed during the 
ischaemia (Zweier et al., 1995).  
 
1.11.3.1 NO2
- reductases 
However, in addition to simple acidic disproportionation (Zweier et al., 1995), in 
vivo a number of mammalian biochemical pathways have now been identified that 
also facilitate NO2
- reduction. Amongst others, deoxyhaemoglobin, myoglobin, 
eNOS, mitochondrial aldehyde dehydrogenase and XOR have all been identified as 
NO2
- reductases (van Faassen et al., 2009); the function and role of each being 
variable based on the environmental conditions, particularly pH and level of 
oxygenation. However, currently there is a growing perception that in acidotic 
hypoxic conditions, and in CVD pathology XOR predominates as the NO2
- reductase 
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whilst the globins are more likely to dominate in more physiological conditions 
(Gladwin et al., 2005). 
 
Importantly, the NO3
--NO2
--NO pathway has been shown to exert important effects 
on the cardiovascular system. Of particular relevance to this thesis there is evidence 
of beneficial activity in atherosclerotic disease as well as inflammatory platelet 
reactivity. 
 
1.12 NO2
- / NO3
- and hypercholesterolaemia 
NO2
- has been shown to modify the oxidation of LDL-cholesterol. Atherogenic 
modifications of LDL by a cell-free macrophage myeloperoxidase/hydrogen 
peroxide/chloride system were prevented following incubation of LDL with NO2
- 
(12.5-200 µM)(Carr and Frei, 2001). More recent research has shown that C57BL6 
mice fed a high fat diet but supplemented with NO2
--free drinking water for 3 weeks 
exhibited reduced leukocyte adhesion and arteriolar endothelial dysfunction 
compared to those fed NO2
- deplete water. In addition a significant reduction in 
triglyceride levels was evident in the fat fed animals (Stokes et al., 2009b). Professor 
Ahluwalia’s group have previously demonstrated that provision of oral NO3
- either 
as a supplement or through dietary ingestion elevates circulating NO levels and 
simultaneously protects against a transient endothelial dysfunction induced 
experimentally by an ischaemia/reperfusion insult in the brachial artery of healthy 
volunteers. These data suggest that dietary NO3
- may provide an approach to 
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improve endothelial function in at risk cohorts and it is currently not known if these 
beneficial effects can be reproduced in humans and such studies are needed. 
 
1.13 NO2
- / NO3
- and platelet reactivity 
As mentioned previously it is widely accepted that NO suppresses platelet adhesion 
to intact vascular endothelium and also platelet aggregation (Radomski et al., 
1987a, Radomski et al., 1990). Studies in healthy volunteers have shown a reduction 
in ex vivo platelet aggregation following NO3
- ingestion. In one such study ingestion 
of oral KNO3 (2 mmol) in a small cohort of seven healthy volunteers resulted in 
inhibition of platelet aggregation in response to collagen (Richardson et al., 2002). 
This was followed in 2008 by a study demonstrating that platelet aggregation in 
response to ADP and collagen were inhibited 2.5 hours after consumption of 500 ml 
of beetroot juice (Webb et al., 2008b). This juice was used since it had a high NO3
- 
content (45 mM) and was used as a means to administer a dietary NO3
- dose. In this 
study the apparent anti-platelet effects of NO3
- were absent when the entero-
salivary circuit of NO3
- was interrupted therefore implicating NO₂- in the effects. 
NO2
- has been found to inhibit platelet aggregation in ex vivo studies although 
varying results have been reported. Ex vivo incubation of platelet-rich plasma (PRP) 
with supraphysiological concentrations of NO2
- (~60 µM) attenuated platelet 
aggregation in response to ADP, arachidonic acid and collagen (Schafer et al., 1980), 
although no such effect was noted in another study incubating human platelet rich 
plasma with NO2
- concentrations up to 100 µM (Radomski et al., 1987c). Whether 
inorganic NO3
- and its resulting bioconversion to NO2
- and thence NO might prove a 
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useful pathway in potentially reducing the platelet reactivity in atherothrombotic 
and atherogenic cardiovascular events is unknown and warrants investigation. 
 
1.14 Hypothesis 
Inorganic NO3
- ingestion via sequential reduction to NO2
- and thence NO suppresses 
platelet reactivity in health and suppresses platelet reactivity and improves 
endothelial function in atherosclerotic disease. 
 
1.15 Aims 
1. To determine the effects of dietary NO3
- on platelet function in healthy 
volunteers. 
2. To investigate the anti-aggregatory and anti-adhesive effects of NO2
- on ex 
vivo platelet reactivity in healthy volunteers. 
3. To investigate the effects of dietary NO3
- on endothelial and platelet 
function in a cohort of hypercholesterolaemics. 
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Chapter 2 
 
 
 
 
General Methods 
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2.1 Volunteer recruitment 
During the tenure of the PhD 3 distinct studies have been conducted in humans 
requiring recruitment of healthy volunteers or patients with hypercholesterolaemia. 
Full ethical approval from a local Research Ethics Committee was obtained (healthy 
volunteer REC reference no: 05/Q0512/145, hypercholesterolaemic volunteer REC 
reference no: 11/LO/0715). All studies took place in the William Harvey Research 
Institute in a temperature-controlled environment (22-24°C). For all studies, 
subjects attended visits after adhering to an overnight fast and observing a low-NOx 
containing diet for the 24 hour period preceding each visit, apart from any 
interventions provided (Tables 2.1, 2.2, 2.3). All subjects were expected to be 
caffeine free for at least 12 hours prior to study visits (24 hours with respect to the 
hypercholesterolaemia study) and free from strenuous exercise 24 hours prior to 
study visits. All subjects gave informed, written consent. 
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VEGETABLE TYPES AND PRODUCTS TO AVOID 
 
High NO3
-  content Medium NO3
-  content 
   
  Mixed-leaf or green salad  Mixed vegetable stock 
 Beetroot  Chinese cabbage 
 Lettuce  Endive 
 Spinach  Fennel 
 Rocket  Kohlrabi 
 Celery  Leek 
 Watercress  Parsley 
 Chervil  Dill 
 Mixed vegetable juice  Turnip 
 Pomegranate juice  Savoy cabbage 
 Cranberry juice  Broccoli 
 Mixed vegetable soup  Carrot (and juice) 
 Coleslaw  Cauliflower 
 Celeriac  Cucumber 
 Desiccated vegetable dietary  Pumpkin 
 supplement (Nature's way garden  Endive 
 veggies capsules)  Chicory 
   
PROCESSED MEAT TO AVOID   
  
 High NO2
-  content Medium NO2
-   content 
    
  Bacon  Prosciutto 
  Hot dog  Corned beef 
  Pork tenderloin  Luncheon meats 
  Ham  Sausages 
  Salami   Canned and cured meats 
     
 
Table 2.1: Foods to avoid 24 h pre study visits listed on the diet sheet provided to 
participants.  
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ACCEPTABLE FOODS 
  Artichoke  Chicken 
  Asparagus  Seafood 
  Broad beans  Tuna 
  Aubergine  Salmon 
  Onion, garlic, spices…   Mackerel, sardines and oily fish 
  Green beans  Rice 
  Mushrooms  Noodles 
  Peas  Pasta 
  Bell pepper  Bread 
  Potato  Cheese 
   Courgette and summer squash  Eggs 
  Sweet potato  Tofu and quorn 
  Tomato  Porridge and cereals 
  Raisins  Milk 
   Apples, pears, citrus and stone fruits  Yoghurt 
  Corn  Citrus fruit juices 
   Chickpeas and all legumes  Cordials 
     
 
Table 2.2: Acceptable foods suitable for consumption 24 hours pre study visits listed on the 
diet sheet provided to participants. 
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Table 2.3: An acceptable menu 24 h pre study visits listed on the diet sheet provided to 
participants.

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2.1.1 Healthy subjects 
Healthy subjects were recruited through word of mouth and via circulation of email 
advertisements within the university. 
Inclusion criteria for healthy volunteers:  
1. Healthy male or female adults aged between 18 and 45 years.  
2. Clinic BP < 135/85. 
3. Body mass index (BMI) 18-30 kg/m2.  
4. Non-smoker. 
5. No use of systemic medications with the exception of the oral contraceptive 
pill. 
Exclusion criteria for healthy volunteers:  
1. Past serious medical illnesses including infectious diseases.  
2. Systemic medication use including NSAIDS and paracetamol within one week 
of the study.  
3. Caffeine in the past 12 hours prior to study visit. 
 
2.1.2 Hypercholesterolaemic subjects 
Hypercholesterolaemic subjects were recruited from the Hyperlipidemia clinic at 
Barts and The London, through poster advertisements within primary care and 
through poster advertisements in local libraries and health food shops. 
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The inclusion criteria for hypercholesterolaemic participants were:  
1. Participants aged between 18-80 years of age, newly diagnosed with 
hypercholesterolaemia (total serum cholesterol ≥ 6 mmol/L or any elevation 
of total cholesterol, LDL cholesterol or triglycerides with QRISK 2 score > 
15%).  
2. Patients with familial hypercholesterolaemia and intolerant of statins 
qualified for inclusion.  
3. To be eligible, female subjects were required to state they were not 
pregnant, and would not become pregnant during the course of the study. 
4. BMI between 18 and 40 kg/m2. 
5. Able to understand and comply with protocol requirements. 
The exclusion criteria for hypercholesterolaemic participants were: 
1. A history of symptomatic ischaemic heart disease (angina, previous MI, 
acute coronary syndrome) or other known atherosclerosis.  
2. A history of heart failure (New York Heart Association (NYHA) class 2-4 or 
severe LV dysfunction LVEF < 30% regardless of symptom status).  
3. Use of anti-inflammatories except aspirin if participants were taking this as a 
primary prevention measure. 
4. Use of statins or any other cholesterol-lowering medication for at least 2 
months prior to screening visit. 
5. A history of diabetes. 
6. Systemic autoimmune disease such as rheumatoid arthritis, connective 
tissue disease, or other conditions known to be associated with chronic 
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inflammation such as inflammatory bowel disease.  
7. Subjects with any acute infection, or significant trauma (burns, fractures); 
subjects who have donated > 500 mls blood within 56 days prior to study 
medication administration. 
8. Anaemia with Hb < 10 g/dl, or any other known blood disorder or significant 
illness that may affect platelet function, and coagulation.  
9. NB. Known essential hypertension on antihypertensive medication was not 
an exclusion criteria. However any such individual would have maintained a 
stable medication profile for at least one year prior to screening.   
10. Any history of malignancy within the past 5 years other than non-melanoma 
skin cancer.  
11. Any current life threatening condition including severe chronic obstructive 
airways disease, HIV infection, life threatening arrhythmia that may prevent 
the subject completing the study.  
12. Any history of alcohol/drug abuse within the past 6 months of screening 
visit.  
13. Excess alcohol consumption defined as regular weekly consumption of >28 
units male and >21 units female (Department of Health Guidelines).  
14. Use of an investigational device or investigational drug within 30 days or 5 
half-lives (whichever is longer) preceding the first dose of study medication.  
15. Any non-stable dosing of ongoing medication regimens throughout the 
study trial or any commencement of any new medications or addition of 
vitamin or food supplements during the study. 
16. A history of chronic viral hepatitis (including presence of hepatitis B surface 
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antigen or hepatitis C antibody or other chronic hepatic disorder).  
17. Abnormal liver function due to acute or chronic liver conditions 3 times 
upper limit of normal at screening.  
18. Renal impairment with creatinine clearance (eGFR) of < 50 ml/min at 
screening.  
19. Pregnancy at time of screening or intention of getting pregnant during the 
course of study. 
20. Current smokers or ex-smokers who stopped smoking < 3 months prior to 
administration of study medication. 
21. BMI < 18.5 or > or = 40 kg/m2. 
22. Any recent/ongoing participation in any other clinical study. 
 
2.2 Interventions 
All study interventions were stored in a temperature-controlled refrigerator (4-7 °C) 
as recommended by the manufacturers.  
 
2.2.1 KNO₃ / KCl capsules 
For studies utilising inorganic NO₃- salt administration capsules were purchased 
from Martindale, UK. Capsules were composed of either 2 mmol KNO₃ or 2 mmol 
KCl for the placebo. Capsules were consumed with 2 slices of dry wholemeal toast 
and 250 ml low-NO3
- containing water (Zepbrook Ltd., London, UK). This water has 
previously been checked with respect to containing neglible NO3
-. 
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2.2.2 Dietary NO₃⁻ 
For dietary NO3
- ingestion commercial supplies of beetroot juice were purchased 
from James White Drinks (Sussex, UK).  Naturally NO3
--rich beetroot juice or placebo 
NO3
--depleted beetroot juice was used. The placebo juice was generated by the 
juice supplier using a standard anion exchange resin that extracted the NO₃-, as 
described previously (Lansley et al., 2011, Gilchrist et al., 2013). Visually there was 
no detectable difference between the juices. NO3
--rich or placebo juice was 
delivered to participant’s homes via a courier service. 
 
2.3 Blinding and randomisation 
All study personnel were blind to treatment allocation until each study had been 
completed and all analyses performed. The randomisation and packing of capsules 
or juice was undertaken by an individual not involved in patient contact or sample 
collection/analysis. Subjects were randomly assigned to either intervention via a 
computer generated randomization which was held by a source who was not 
involved in any of the studies performed. 
 
2.4 Blood sampling 
All blood samples for each time point of each study were taken from the same 
venepuncture. Venous blood was taken from the antecubital vein using either a 19 
gauge or 21 gauge butterfly needle connected to a syringe or vacutainer system (BD 
biosciences) respectively containing 3.2% trisodium citrate or 
108 
 
ethylenediaminetetraacetic acid (EDTA). Specific blood sample preparation for each 
protocol is described later in association with the technique used to analyse the 
relevant samples (NOx, platelet cGMP, red blood cell NO2
- reductase, platelet 
counts, plasma lipids).   
 
2.5 Urine and saliva samples 
Mid-stream urine samples were collected into sterile pots and an aliquot stored at -
80oc pending measurement of NOx levels at a later date. Unstimulated saliva was 
collected into sterile eppendorfs and centrifuged (14000g, 4oC, 10 min) and the 
supernatant was transferred to a separate eppendorf and stored at -80oC pending 
measurement of NOx levels at a later date. 
 
2.6 Measurement of plasma, urine and salivary [NOx] 
Following collection into EDTA tubes as described in section 2.4, blood samples 
were centrifuged immediately (1300g, 4oC, 10 min) and the supernatant then 
deproteinated. Deproteination was achieved by means of filtering through 
Microcon® Ultracel YM\3 (3kDa) (Millipore Corporation, Billerica, USA) filters via 
centrifugation at 15000g for 60 min at 4°C. Prior to deproteination, the filters were 
washed twice with NO3
-- and NO₂--free water to remove any possible NO3
-/NO2
- 
contamination. Deproteinated samples were then snap frozen until analysis using 
ozone chemiluminescence. 
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[NOx] of urine, saliva and deproteinated plasma samples was determined using 
ozone-based chemiluminescence as described previously (Ignarro et al., 1993). To 
quantify total [NOx], samples were added to 0.1 M vanadium (III) chloride in 1 M 
hydrochloric acid refluxing at 95oC under nitrogen. [NO2
-] was measured by addition 
of samples to 0.09 M potassium iodide in glacial acetic acid under nitrogen at room 
temperature. [NO3
-] was derived by subtraction of [NO2
-] from [NOx]. 
 
To perform chemiluminescence an NO analyser (NOA 280A, Sievers) was used 
utilising the chemiluminescent reaction between NO and ozone (O3). Essentially in 
any sample all of the NO2
- and NO3
- in the sample is reduced to NO and this 
measurement correlates directly to the levels of the anions. The NOA measures NO 
based on the principle that each mole of NO2
- or NO3
- will generate one mole of NO. 
This facilitates accurate assessment of levels of both anions in any given sample. NO 
gas mixed with O3 generates nitrogen dioxide in an excited state (equation 2.1). 
 
Equation 2.1: Reaction of NO with O3 to produce excited nitrogen dioxide (NO2*). 
 
The excess energy of NO2* can be consumed through reaction with other gas 
molecules (M, see equation 2.2) or released as a photon (hv) (equation 2.3) when 
the NO2* spontaneously returns to a stable ‘ground’ state (NO2). It is this photon 
that is then measured by chemiluminescence in this technique.  
 
Equation 2.2: Reaction of excited nitrogen dioxide with other molecules. 
 
NO O₃ NO₂* O₂+ +
NO₂* M NO₂ M+ +
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Equation 2.3: Stabilisation of excited nitrogen dioxide. 
 
In this system the photon that is emitted is directly proportional to the NO 
concentration and is detected by the NOA.  The equipment used to make these 
measurements is shown in figure 2.1. In essence N2 which is an inert gas bubbles 
through the reducing agent inside the purge vessel to rid any NO from the solution 
contained within the vessel. Standards and biological samples are then injected 
through the liquid sample inlet into the purge vessel where, depending on the 
reducing agent, NO2
- and/or NO3
- is reduced to NO. The NO produced which is in the 
gas phase, moves along the purge vessel and is detected by and quantified via the 
NOA. 
 
Figure 2.1: Diagram of the ozone chemiluminescence setup for NO2
- measurement. To 
determine the NO2
- concentration, samples were added to 0.09 M potassium iodide (KI) in 
glacial acetic acid refluxing under N2 at room temperature (equation 2.3). Initially a 
calibration curve is made based on the final dilutions from a stock solution of sodium nitrite 
(NaNO2). Refer to figure 2.2 for an example trace obtained from different injection volumes 
and concentrations of standards and figure 2.3 for a calibration curve after integration of 
each peak to the correct standard (NO2
-=nitrite; KI=potassium iodide; NaNO2=sodium 
nitrite). 
 
NO₂* NO₂ hv+
N2 gas in
(containing reducing agent)
Computer
Sievers 280i, NOA
Amplified signal
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Figure 2.2: An example trace produced when standards of known concentration are 
injected in to the purge vessel.  
 
 
 
Figure 2.3: A typical standard curve produced prior to the measurement of NO2
- in liquid 
samples (slope=6.5; intercept=1.2; R2=0.9999) (NO2
-=nitrite). 
 
 
112 
 
NO2
- is converted to the nitrosonium ion (NO+) in the presence of protons (H+) from 
the acid (see equation 2.4). 
 
Equation 2.4: Reaction of NO2
- with protons. 
 
 
The NO+ associates rapidly with anions but in the presence of iodide (I-) NO+ is 
converted to NO via a nitrosyl iodide (ONI) intermediate (see equation 2.6). 
 
 
Equation 2.5: The conversion of the NO+ to NO via an ONI intermediate. 
 
 
The overall outcome of the chain of reactions is that the reduction of one mole of 
NO2
- generates one mole of NO (equation 2.6). 
 
Equation 2.6:  The overall reduction reaction of NO2
- to NO.  
 
 
The above conditions are specific to the reduction of NO2
-. A much stronger 
reducing environment is required for the reduction of NO3
-. The amount of NO3
-  in 
the sample is determined by reducing the entire NO3
- and NO2
- in the sample 
(collectively termed NOx), hence the need for a stronger reducing environment.  
 
NO₂⁻ 2H⁺ NO⁺ H₂O+ +
NO⁺ I⁻ ONI+
2ONI 2NO I₂+
NO₂⁻ 2H⁺ NO H₂O+ ++ e⁻
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Total NOx was measured through addition of reducing agent 0.1 M vanadium (III) 
chloride (VCl3) in 1 M hydrochloric acid (HCl) refluxing under N2 at 95°C, achieving 
high conversion efficiency. These conditions achieve reduction of all NO3
- (equation 
2.7) and NO2
- (equation 2.6) to NO to give a total NOx value. 
 
Equation 2.7:  The overall reduction reaction of NO3
- to NO.  
 
 
Subtracting the NO2
- measurement from the NOx value gives a measure of the NO3
-. 
The equipment setup is adjusted to account for the more powerful reducing 
environment (figure 2.4). 
 
Figure 2.4: Diagram of the ozone chemiluminescence setup for NOx determination. A gas 
bubbler containing 1 M sodium hydroxide (NaOH) was installed between the purge vessel 
and the NOA to prevent HCl vapour damaging the NOA (NOA=nitric oxide analyser; 
HCl=hydrochloric acid; NaOH=sodium hydroxide). 
 
NO₃⁻ 4H⁺ NO 2H₂O+ ++ 3e⁻
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2.7 Measurement of NO2
- reductase activity of red blood cell (RBC) samples 
2.7.1 Protein determination 
Protein concentration of the RBC samples was determined using a Bradford protein 
assay (Bradford, 1976) prior to samples being used to measure NO2
- reductase 
activity. To do this, samples were diluted 1:1000. Bovine serum albumin (BSA, 2 
mg/ml) was used to generate a standard curve by means of serial dilution at 0.0625-
1 mg/ml (figure 2.5). 10 µL of each standard and 10 µL of each sample was loaded in 
duplicate on a 96-well plate. 200 µL of reagent (Bio-Rad, UK; diluted 1:5 in MQ H2O) 
was added to each well. The light absorbance was measured by means of a 
spectrophotometric plate reader (MRX-TC Revelation, Dynex Technologies, UK) at 
wavelength 570 nm. The protein concentration was determined by comparing the 
light absorbance of the unknown samples to the standards. 
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Figure 2.5: Typical standard curve generated from the Bradford protein assay.  
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2.7.2 NO2
- reductase activity of RBC samples. 
Blood was collected into an individual pre-chilled tube containing 3.2 % trisodium 
citrate ((BD, UK) as described in section 2.4) and immediately centrifuged at 1500 g 
for 5 min. The plasma and buffy coat layer (containing white blood cells (WBCs) and 
platelets) were removed. The remaining RBCs were washed 3 times in PBS and then 
snap frozen and stored at -80°C pending analysis.  
 
Gas phase ozone chemiluminescence was used to measure the NO2
- reductase 
activity of RBC pellets with the help of Mr. Suborno Ghosh. Experiments were 
performed in a sealed 10 ml glass reaction chamber containing citric acid-sodium 
phosphate dibasic (Na2HPO4) buffer (Sigma, UK) at physiological pH (pH 7.4) or 
within an acidotic environment (pH 6.8) and KNO2 (10-300 µmol/L) in a total volume 
of 1 ml (Figure 2.6). The citric acid-Na2HPO4 solution was bubbled with 100 % N2 gas 
via an NO. scrubbing air filter (Sievers, Boulder, USA). The headspace NO. 
concentration was measured in parts per billion (ppb) by continuous sampling (NOA 
280A, Sievers).  
 
Figure 2.6: The ozone chemiluminescence setup for the measurement of NO2
- reductase 
activity. 
N2 gas in
Injection port
Glass 
reaction 
chamber
Sievers 
280i,
NOA
Computer
Amplified signal
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A baseline NO level was obtained in all experiments under each pH condition prior 
to addition of 20 µL of RBC sample. The impact of RBCs on NO production from NO2
- 
was determined by thawing the pre-prepared samples on ice and then adding 20 µL 
of the RBC sample to the glass reaction chamber, followed by addition of KNO2 and 
subsequent measurement of NO production from NO2
- over the following 2 min. 
From this, the rate of NO. production (nmol per g of tissue per s) was calculated 
from the area under the curve. See Figure 2.7 for a typical trace with addition of 
NO2
- only, Figure 2.8 for a typical trace with just the addition of RBCs and Figure 2.9 
with the addition of NO2
- followed by the addition of RBCs. 
 
 
Figure 2.7: A typical trace of sampling of NO production following the addition of just NO2
- 
(300 µM) at pH 6.8 under anaerobic conditions. 
  
Time (min)
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Addition of 
NO2
-
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Figure 2.8: Typical trace of sampling of NO production following the addition of RBCs only 
at pH 6.8 under anaerobic conditions. 
 
 
Figure 2.9: Typical trace of sampling of NO production following the addition of RBCs 
followed by NO2
- (300 µM) at pH 6.8 under anaerobic conditions. 
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2.7.3 Analysis of chemiluminescence signals 
All data were corrected for protein amount in order to normalise data to enable 
comparison between groups and the rate of NO. production was therefore 
converted from ppb per s to nmol per g per s. The protein amount was calculated 
from the injection volume (µL) and the protein concentration (µg / µL) obtained 
from the protein assay. The protein amount was therefore calculated by multiplying 
these two values giving a protein amount in µg. A worked example determining the 
reductase activity of a 300 µg sample is described below: 
 
The NOA samples at a rate of 0.228 Lmin-1 and therefore 0.0038 Ls-1. Under 
standard laboratory conditions (25°C and 1 atmosphere) 1 mole of an ideal gas has 
a volume of 24.47 L, therefore the amount of pure gas in 1s=0.038=1.5529x10-4mol. 
For 1 ppb over 1s, 1ppb=1x10-9, the rate of NO. production from 1ppb=1.5529x10-4 
x1x10-9. 
Calculated rate = 1.5529x10-13mol-1. 
The value is then normalized for the amount of protein injected into the reaction 
chamber : 
Hence for a 300 µg sample the rate of NO. production = 1.5529x10-13 ÷ 3.0 x 10-4 
                                                                                                  = 0.5176x10-9molg-1s-1.  
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2.8 Measurement of [cGMP]  
2.8.1 Measurement of plasma [cGMP]  
Blood was collected into tubes containing the non-competitive non-selective 
phosphodiesterase (PDE) inhibitor, 3-isobutyl-1-methylxanthine (IBMX, 100 µM) 
prior to centrifugation at 14,000 g for 10 min. Plasma was then collected and 
immediately snap frozen and stored at -80°C pending measurement. An enzyme 
immunoassay (cGMP Enzymeimmunoassay Biotrak System RPN226) was used to 
determine cGMP levels in plasma samples using a 96-well plate spectrophotometer 
in accordance with the manufacturer’s instructions (GE Healthcare, Little Chalfont, 
UK).  This assay utilised competition between unlabelled cGMP and a fixed quantity 
of peroxidase labelled cGMP, for binding sites on a cGMP specific antibody (Figure 
2.10). Samples measured were compared to a standard curve created from known 
standards (Figure 2.11). 
 
Figure 2.10: A schematic representation of enzyme immunoassay for measurement of 
cGMP levels (cGMP=cyclic guanosine monophosphate). 
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Figure 2.11: Standard curve for determination of cGMP levels (%B/B0=% bound). 
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2.8.2 Measurement of platelet [cGMP]  
12 ml of blood was collected into 3 citrated tubes (BD Diagnostics, UK) as described 
in section 2.4 via the same puncture and IBMX (Sigma, UK) was added to give an 
end concentration of 100 µM. This blood was immediately centrifuged (170 g, 15 
min, 21 oC) to generate platelet rich plasma (PRP) which was transferred into a tube 
for further centrifugation (1800 g, 10 min, 4oC) to obtain a platelet pellet and 
platelet poor plasma (PPP) which were stored in separate aliquots and kept at -80oC 
pending platelet pellet cGMP measurement. 
 
Platelet cGMP samples were processed using the cGMP enzymeimmunoassay (RP 
N2265A, GE Healthcare, Amersham) according to the manufacturer’s instructions. 
The platelet pellets were first lysed as per manufacturer’s instructions and then 
subject to the identical procedure as for animal plasma cGMP levels. The assay is 
based on competition between unlabelled cGMP specific antibody as explained in 
the section 2.8.1.  
 
2.9 Platelet aggregation  
2.9.1 96 well plate light transmission aggregometry (LTA) 
For LTA, blood was collected into a 60 ml syringe pre-prepared with 3.2 % sodium 
citrate and mixed with the anticoagulant in a 10:1 ratio through a 19 gauge butterfly 
needle and then immediately centrifuged at room temperature (170 g, 15 min) to 
generate PRP which was decanted and kept at 37oC until use which was within 30 
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min. Of this PRP 1.5 ml  was then centrifuged (15000 g, 21 °C, 2 min) to generate 
PPP. PRP and PPP were then used to assess platelet aggregation in response to 
three agonists ADP, epinephrine and collagen according to previously published 
protocols (Bednar et al., 1995, Webb et al., 2008b). 10 µL of increasing 
concentrations of platelet agonists were added to each well of a flat-bottomed 96-
well plate (BD Biosciences, UK) at 10 x final concentration. The top row of the plate 
typically contained four wells of PRP (100 µl) and four wells of previously prepared 
PPP without agonists which were used to provide absorbance values corresponding 
to an equivalent of 0% aggregation and an equivalent to 100% aggregation 
respectively. To each well containing agonist 100 µl of PRP was added and the 96-
well plate immediately transferred to a Tecan Sunrise (Tecan Trading AG, 
Switzerland) absorbance plate reader.  
 
Figure 2.12: 96 well plate arrangement. 
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Absorbance was measured in 64 cycles over a period of 16 min at a wavelength of 
595 nm, following shaking of the plate for 7 s at 12.3 Hz in each cycle. Percent 
aggregation was calculated, as previously described (Armstrong et al., 2008) 
generating %aggregation*time units for extent of aggregation according to the 
formula: 
 
 
Figure 2.13: An example of typical aggregation data generated from the 96 well plate 
reader. (A) shows the aggregation over time (16 min) for each of the concentrations (0.1-30 
µM) of one agonist (ADP). Data are expressed as mean ± SEM. Calculating the area under 
the curve (AUC) for each individual at each concentration allows for the generation of a 
concentration-response curve (B) (where response=%aggregation*time), which can be 
statistically analysed for logEC50 and other curve-fitting parameters. 
 
Lyophylised ADP (2.5 mg, Chrono-Par #384, Labmedics) was reconstituted in sterile 
saline to give a 1 mM stock. This stock solution was stored at -80 °C in aliquots and 
fresh aliquots used daily for each experiment/study. For each experiment, ADP was 
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serially diluted in PBS to provide an end concentration range in the plate of 0.1-30 
µM. These dilutions were kept on ice until use on the day of the experiment and 
discarded after use. Figure 2.13 shows a typical concentration response curve 
generated with PRP and ADP-treatment. 
 
Horm Collagen Suspension (Nycomed #1130630) was supplied as 1 mg/ml in 
isotonic glucose. This stock was stored at 4 °C and used as required to make fresh 
agonist diluted accordingly in isotonic glucose supplied by the manufacturer to 
provide a concentration range of 0.1-30 µg/mL for the 96 well plate LTA. These 
dilutions were kept on ice the day of the experiment and discarded after use.  
 
Figure 2.14: An example of typical aggregation data generated from the 96 well plate 
reader. (A) shows the aggregation over time (16 min) for each of the concentrations (0.1-30 
µM) of one agonist (collagen). Data are expressed as mean ± SEM. Calculating the area 
under the curve (AUC) for each individual at each concentration allows for the generation 
of a concentration-response curve (B) (where response=%aggregation*time), which can be 
statistically analysed for logEC50 and other curve-fitting parameters. 
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2.9.2 Whole blood impedance aggregometry 
Blood was collected into citrated blood collection tubes (3.2 % sodium citrate) (BD 
Biosciences, UK). Platelet aggregation was assessed in whole blood or PRP 
(generated as described in section 2.6.2) in response to PBS (as control), ADP (10 
μM) and collagen (3 μM) using impedance aggregometry (MultiplateR analyzer, 
Dyabyte Medical, Germany). These concentrations were chosen based upon LTA 
experiments demonstrating sub-maximal maximal response. The technique of 
impedance aggregometry utilises the change in voltage between electrode wires, 
placed in blood aliquots, as aggregatory stimuli cause the platelets to activate and 
coat the electrode, generating a measure of impedance (Ω) that is measured over a 
6 min assessment period. Aggregation is measured as area under the curve (AUC) 
giving a measure of total Ω*time (Toth et al., 2006). Briefly 300 µL of citrated whole 
blood or PRP was added to a cuvette/test cell (see Figure 2.15) to 300 µL of normal 
saline containing 3 mM CaCl2. This was mixed for 3 min via a magnetic stirrer to 
allow equilibration of the solution before addition of agonist and commencement of 
platelet aggregation measurement over the 6 min (Figure 2.16). 
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Figure 2.15: Depicts the disposable test cell with magnetic stirrer containing blood aliquot. 
Quiescent platelets are shown in picture A and once activated following addition of platelet 
agonist they adhere to the electrodes as shown in pictures B and C resulting in an increase 
in impedance between the electrodes as the platelet aggregates form an insulation layer.  
 
 
Figure 2.16: Typical aggregation data. Whole blood is incubated with PBS in channel 1, with 
ADP, collagen and epinephrine in channels 2-4 respectively. 
 
To assess the effects of NO2
- directly on aggregation, blood was incubated with NO2
- 
or saline vehicle for 10 min in the cuvette at 37 °C before addition of aggregating 
agonist - epinephrine (10 µM), ADP (10 μM) or collagen (3 μg/mL) and 
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measurement of platelet aggregation. The ADP and collagen were made up as 
previously described in section 2.9.1. 
 
As with ADP and collagen a stock solution of Epinephrine (Chrono-Par #393, 
Labmedics) of 10 mM was made following reconstitution of lyophilised reagent in 
18 M milli-Q (MQ) H2O and this stock stored as aliquots at -80 °C until use. A new 
aliquot was used for each experiment/study. The stock solution was diluted in PBS + 
0.1 % ascorbic acid (Sigma, UK) to achieve a concentration of 10 µM. Dilutions were 
made and kept on ice on the day of the experiment and discarded after use.  
 
2.10 Flow cytometry 
Flow cytometry was used to assess platelet activation state by measurement of 
platelet P-selectin expression and platelet monocyte aggregation. Flow cytometry 
utilises a flow system to analyse single particles such as cells, mitochondria or 
chromosomes. Cell/particle subsets within a mixed population can be clearly 
identified and defined by size, structure, surface properties and intracellular 
composition and single cells counted. This technique involves the measurement of 
fluorescent signals on single cells within a flowing stream (Figure 2.17). These 
fluorescent signals are generated from fluorescent tagged antibodies that are 
bound to specific cell markers. Cells are carried to the point of measurement by 
sheath fluid where laser derived light of distinct wavelengths is focused. The 
fluorescent dyes become excited and then emit their own fluorescent light at 
distinct wavelengths which is detected by the photo detector. A small current is 
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generated and its associated voltage generates an amplitude proportional to the 
total number of light photons received by the detector. This voltage is then 
converted via logarithmic amplifiers and a computer into a graphical plot. 
Additional information regarding cell size and granularity can be gleaned by means 
of forward and side scatter (Ormerod, 2010).  
 
Figure 2.17: Schematic representation of flow cytometry setup. Adapted from (Abcam, 
2010). 
 
Gating is an important principle of flow cytometry which allows for the selective 
visualisation of the cells of interest while eliminating results from unwanted 
particles such as dead cells and debris. Cells of interest can be selected on their size 
and granularity utilizing graphs for forward and side scatter or on their fluorescence 
readings (Figure 2.18). 
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Data are usually displayed as either a histogram or a dot plot. A histogram records 
the number of events versus their intensities. Cells which stain positive for a species 
will emit at a higher intensity than negative cells. A typical data set contain 2 major 
populations of events representing stained and unstained samples and is usually 
displayed logarithmically. So it is valuable in determining the total number or 
percentage of cells that are positive for the marker of interest compared to the 
negative control. Of note linear scales can also be used. Logarithmic scales in 
contrast to linear scales provide better resolution of weak fluorescence signals.  
 
The dot plot gives the intensity of events hitting one detector versus the intensity at 
a second detector, where each event is denoted by a dot. As a result, a set of 
clusters are produced which correspond to the populations within the sample. The 
dot plot is analysed via computer software: boxes are drawn around regions of the 
plot and the percentage of total fluorescence events is calculated in each of the 
regions (Figure 2.18).  
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Figure 2.18: Typical gating of platelet population based on size and granularity (R1). R2 
defines the CD42b positive population and R3 the P-selectin positive subset of R2. 
 
2.10.1 Flow cytometric assessment of platelet P- selectin expression 
A 2-colour whole blood flow-cytometric technique was used to measure platelet P-
selectin expression.  The protocol was adapted from previously published protocols 
and recommendations (Knight et al., 1997, Ritchie et al., 2000, Sidhu et al., 2004). 
The platelet population was identified preliminarily based on forward and side 
scatter properties, then further delineated via labelling with CD 42b monoclonal 
antibody conjugated to allophycocyanin (APC), (Biolegend, UK) (Figure 2.18). Gates 
were used to isolate this population and CD62 (P-selectin; 0.4 ng/µL) monoclonal 
antibody conjugated to fluorescein isothiocyanate (FITC) (ABD Serotec, UK) was 
used to determine P- selectin expression.  Populations were further confirmed by 
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use of antibody negative isotypes to P- selectin and CD42b (1:25).  The 3 control 
tubes were as follows: 2 µL of P-selectin isotype control  in addition to 2 µL of 
CD42b were added to 41 µL of HEPES buffer (150 mM NaCl, 10 mM Hepes,  5 mM 
KCl, 1 mM MgSO4, 3 mM CaCl2, Sigma, made in MQ water). The second control tube 
contained 2µL of CD42b and 43 µL of HEPES buffer. The third control tube 
comprised of 2 µL CD42b isotype control and 43 µL HEPES buffer.  5 µL of citrated 
whole blood was added to each of the control tubes. For the samples in which P- 
selectin was to be measured,   2 µL anti-CD42b and anti-CD62 were added to 40 µL 
of HEPES buffer and finally 5 µL citrated whole blood. These samples were then 
treated with either ADP (10 µM), and PBS control and incubated for 20 min at room 
temperature (21-23 oC) after very gentle mixing before fixing with 500 µL of 1 % 
paraformaldehyde (Sigma, UK).  All samples were run in duplicate. Samples were 
analysed immediately following fixing using a Becton Dickinson FACSCalibur flow 
cytometer (Becton Dickinson, San Jose, Calif.). 10,000 platelets were acquired in the 
CD42b region. Results were expressed as the percentage of platelets positive for P- 
selectin. 
 
2.10.2 Flow cytometric assessment of platelet monocyte aggregate expression 
2-colour lysed blood flow-cyometry was used to measure platelet monocyte 
aggregates using a modification of previously published protocols (Harding et al., 
2007). The monocyte population was identified preliminarily based on forward and 
side scatter properties, then further delineated via labelling with CD14 monoclonal 
antibody (20 µL per test as per manufacturer’s instructions) conjugated to 
(fluoroscienisthiocyanate) FITC (BD Biosciences, UK). Gates were used to isolate this 
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population, and CD42b monoclonal antibody (1:25) conjugated to APC (Biolegend, 
UK) was used to determine platelets bound to the monocyte population, hence 
platelet monocyte aggregates.  
 
100 µL whole blood samples were incubated with fluorescent antibodies selective 
for the platelet marker CD42b and CD14 (dilutions stated above) in 5 ml polystyrene 
round bottom flow cytometry tubes (BD Falcon, UK) as per Table below (Table 2.4). 
  
 Antibody 1  Antibody 2  Blood 
1 - - 100µL 
2 CD14 - 100µL 
3 CD42b (1:25) - 100µL 
4 Isotype CD14 - 100µL 
5 CD14 Isotype 
CD42b(1:25) 
100µL 
6 CD14 CD42b(1:25) 100µL 
Table 2.4: Antibody combinations used for platelet monocyte aggregates. 
 
Thereafter 4 ml of PBS was added to each sample and all 6 samples were 
centrifuged at 400 g for 5 min at 21 °C. The supernatant was then discarded and 500 
µL of  Immunolyse solution (a whole blood lysing solution diluted in PBS (1:25)) was 
added to each sample. Samples were then vortexed twice with a 1 min interval. 
Thereafter fixative solution as supplied by the manufacturer was added (1:5) and 
each sample vortexed. Following this 3 ml of PBS was added to each sample before 
centrifugation. Post centrifugation, the supernatant was discarded and 4 ml of PBS 
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was added before a third and final centrifugation at 400 g for 5 min at 21°C. Finally 
the supernatant was discarded and the sample was resuspended in 300 µL PBS 
before flow cytometry analysis. Samples were analysed immediately using a Becton 
Dickinson Fortessa flow cytometer (Becton Dickinson, San Jose, Calif.). Using BD-
diva flow cytometry analysis software CD42b expression was measured as a 
percentage of the CD14+ population (see Figure 2.19). 
 
Figure 2.19: Typical gating of platelet population based on size and granularity (P1). P2 
defines the CD14 positive population and P2 the CD42b positive subset of P2. 
 
2.10.3 Development of flow cytometry 
The platelet P-selectin protocol was developed in house. Initially stock 
concentrations of the respective antibodies were purchased and tested according to 
manufacturer’s guidelines and then the amount of antibody down titrated ensuring 
there was no change in median fluorescent intensity. This developmental step was 
also completed for the platelet monocyte aggregate protocol. Isotope controls were 
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shown to be negative in all studies ensuring specific binding of the antibodies used. 
Isotype control antibodies have no specificity for target cells within a specific 
experiment; their purpose is to validate the specificity of the primary antibody 
binding that is independent of non-specific Fc receptor binding to cells or other 
cellular protein interactions. The isotype control antibody ideally matches the 
primary antibody’s host species, isotype, and conjugation format to accurately 
assess the level of specific staining (eBioscience, 2015). CD42b was added to all 
tubes to ensure specific platelet marking. This was a modification I made from a 
previously used protocol which added to the robustness of results obtained.   
2.11 FMD of the brachial artery 
Ultrasonography was utilised to assess FMD of the brachial artery. FMD was 
performed according to published protocols (Corretti et al., 2002b). FMD is affected 
by multiple factors including temperature, food, drugs, and sympathetic stimuli. 
Therefore, it was essential that the conditions for each study were identical on each 
occasion for each participant. Thus studies were performed in a quiet, dimly-lit, and 
temperature controlled room (22-24 °C). Participant skin temperature was 
measured by means of a temperature probe placed between the thumb and 
forefinger and a temperature of 30°C was required prior to performing the 
measurements. If a temperature less than 30°C was recorded, the hand was 
warmed using a heated microwave wheat pack. 
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2.11.1 Image acquisition 
The subject lay on a bed in a supine position with his or her right arm placed 
comfortably in a foam protected arm rest, to image the brachial artery. Figure 2.20 
depicts the FMD setup for every study. A 7 cm-wide BP cuff was placed ~1 cm below 
the antecubital fossa around the forearm (one thumbs-width from the medial 
epicondyle.) 
 
Figure 2.20: FMD set up. The participant adopted a supine position with his/her right arm 
outstretched and placed into the arm brace. 3-lead ECG was attached to participant’s chest 
and forearm cuff was placed one thumbs- width from the medial epicondyle. The 
participant maintained this position for the entire duration of the scan to minimise any 
changes to image clarity.  
A standard Acuson Aspen system (Acuson, Mountain View, UK) with a 7.0MHz linear 
array transducer was used to acquire a B-mode scan of the brachial artery in 
longitudinal section above the antecubital fossa. Once a stable image of the brachial 
artery was attained with distinct vessel edges (Figure 2.21), the position of the 
ultrasound transducer was fixed using a stereotactic clamp. The contrast was 
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adjusted so as to blacken the lumen of the vessel and whiten the edges. Small 
adjustments could be made to the ultrasound transducer position using the 
micrometers, shown in Figure 2.20. The image was synchronised with the 
participant’s ECG (electrocardiogram) R-wave, so that the recording captured an 
image every 3 seconds to avoid brachial artery pulsatile oscillations. Once an image 
was acquired, the cuff inflation period could commence. Following 1 min of baseline 
flow, the cuff was inflated to 300 mmHg (supra-systolic) for 5 min and then 
released. The subsequent reactive hyperaemia and resultant change in brachial 
artery diameter in response to blood flow were recorded for an additional 5 min. 
The total scan time was 11 min. Arterial diameter over a 1-2 cm section was 
determined for each image via automatic edge-detection software (Vascular 
Research Tools, Medical Imaging Applications LLC Iowa City, USA). 
 
The brachial artery dilatation was expressed as an absolute increase in diameter 
from baseline in mm and as a percentage increase from baseline diameter. The time 
to peak diameter in min was also recorded (Figure 2.22). For each scan 5 analyses 
along the vessel length were made and the mean calculated for % FMD, absolute 
change in diameter and time to peak and this mean value was used as an n=1. 
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Figure 2.21: Brachial Artery Ultrasound Image. The image was captured as described above. 
There is a clear definition between the vessel edges and the lumen, which is critical for the 
analysis software to provide accurate readings. The cursor is located exactly in the centre of 
the vessel and provides a marker from which to adjust the image if it becomes distorted 
following cuff inflation and subsequent deflation. The ECG enables the image to be 
synchronised with the R-wave of the cardiac cycle, and thus eliminates pulsatile oscillations 
from the recording.  
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Figure 2.22: Brachial Analyser Assessment. The analysing software generates a graphical 
representation of the image recording, as shown. The x-axis is the number of frames (each 
frame lasting 3 seconds) and the y-axis is brachial artery lumen diameter in millimetres. 
Ischaemia was induced by inflating the cuff after 1 minute (frame 20) of baseline recording, 
and releasing at 5 minutes (frame 120). A peak is seen after cuff deflation usually within 
frames 120-130 (within one min of cuff deflation; this is the FMD response to reactive 
hyperaemia). 
 
I underwent a consistent period of training in the year prior to the research study 
starting in order to gain full competence in brachial artery ultrasound FMD. I 
practised this technique for at least 2 hours daily on volunteers, performing dozens 
of practice scans during this period.  I have shown 15 sequential reproducibility 
studies to assess intra-operator variability in this section. A reproducibility study 
comprised of scanning the same individual on two separate occasions, with the aim 
of obtaining the same FMD response both times. Figure 2.23 shows the FMD 
response in 15 individuals on 2 separate occasions. 
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Figure 2.23: Reproducibility studies. The graph shows the % FMD response in 15 individuals 
on 2 occasions (30 scans). The mean ± SD FMD was 6.37% ± 2.45% (visit 1) and 6.45% ± 
2.15% (visit 2) p=0.62.  
 
2.11.2 Technical limitations of the use of FMD 
One major limitation of the protocol used was that the effect of NO3
- treatment on 
direct NO-stimulated increases in blood flow, conventionally assessed using GTN 
administration was not performed. This was omitted in order to prevent 
contamination of blood samples pertaining to platelet measurements. Therefore 
the potential contribution of smooth muscle to improved vascular function could 
not be excluded.  
Another major limitation was that the equipment setup used did not have the 
capacity to continuously measure blood flow velocity by pulsed-wave Doppler and 
display it as a spectral Doppler curve. It would therefore not possible to completely 
refute the theory that brachial artery flow may increase due to alterations in 
forearm resistance vessels from NO2
-.  
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2.12 aPWV and aPWA measurement 
PWA measurement facilitates the accurate recording of peripheral pressure 
waveforms and formation of the corresponding central waveform, resulting in 
derivation of augmentation index and central pressure. PWA has been shown to be 
a highly reproducible technique that can easily be applied in clinical studies 
(Wilkinson et al., 1998a). All arterial stiffness measurements were performed with 
the patient rested for 10 min in a supine position with their head at a 30 ° incline 
and awake. The pulse wave from the carotid and femoral arteries were 
simultaneously recorded using an oscillometric method within a Vicorder device 
(Skidmore Medical Ltd., Bristol UK) (Hickson et al., 2009). A small, inflatable neck 
pad was placed directly over a single carotid artery and secured around the neck via 
Velcro tab and a cuff placed around the subject’s ipsilateral upper thigh. A standard 
estimate for aortic length was made measuring the distance between the sternal 
notch and the thigh cuff. Both carotid and femoral cuffs were inflated automatically 
to 65 mmHg and the corresponding oscillometric signal from each cuff digitally 
analysed to extract pulse time delay. The aPWV could be derived automatically 
from aortic distance/pulse time delay.  
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Figure 2.24: Adapted from Boutouyrie (Boutouyrie, 2008). Determination of PWV using 
Vicorder device. Carotid and femoral oscillometric signals are detected and the time delay 
from the foot of the carotid pulse wave form to the foot of the femoral pulse waveform is 
used as the pulse transit delay (∆t). Estimation of aortic length by sternal-femoral distance 
is used as distance (d). Aortic distance/pulse transit delay =aortic PWV.  
 
For aPWA a mean brachial blood pressure reading was obtained from 2 readings 
made using an Omron 705IT and used for calibration of peripheral waveforms. The 
vicorder cuff was then placed over the left brachial artery and inflated to 70 mmHg 
generating a digitally computed brachial pressure wave trace. The vicorder software 
subsequently applied a brachial to aortic transfer function to calculate the 
waveform and values for central BP as previously described (O'Rourke, 1970). The 
Augmentation index (AIx) which is the difference in amplitude between the first and 
second systolic peak/pulse pressure x 100) was calculated automatically from the 
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first and second central systolic peaks which were automatically defined by the 
software.  
 
 
 
 
Figure 2.25: The Definition of AIx. (A) Aortic pressure pulse wave. (B) Peripheral arterial 
pressure wave. AIx=augmentation index; AP=augmentation pressure; PP=pulse pressure; P1 
represents the amplitude of the early systolic peak; P2 represents the amplitude of the late 
systolic peak (cited from (Shimizu and Kario, 2008). 
 
2.13 Met haemoglobin measurement 
A finger probe pulse oximeter (Massimo Signal Extraction technology) was used to 
measure Sp Met Hb level in all participants during each study visit. Pulse oximetry is 
based upon two physical principles. The light absorbance of oxygenated 
haemoglobin is different from that of reduced haemoglobin, at the oximeter’s two 
wavelengths, which include red and near infrared light; and the absorbance of both 
wavelengths has a pulsatile component, which is due to the fluctuations in the 
volume of arterial blood between the source and the detector.  
 
A 
B 
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2.14 Statistical analysis 
The data were analysed using Graphpad Prism software version 5. All data were 
expressed either as a mean ± SEM, SD or with 95% CI as stated. All p-values are 2-
sided. A more detailed description of the statistical analysis applied to each data set 
is given within in each results chapter.  
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Chapter 3 
 
Investigation of the in vitro effects 
of NO2
- on platelet aggregation in 
healthy males  
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3.1 Introduction 
Previous evidence suggests NO3
- alters platelet reactivity. The Ahluwalia group have 
shown that consumption of dietary NO3
- as beetroot juice attenuates ex vivo 
stimulated platelet aggregation; an effect that was lost if oral conversion of NO3
- to 
NO2
- was prevented (Webb et al., 2008b), thereby preventing elevations of systemic 
NO2
- levels. However the mammalian NO2
- reductase pathways that might be 
involved in these effects remains uncertain. The aim of this study was to establish 
the mechanism of NO2
- reduction with respect to this attenuation in platelet 
reactivity. 
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3.2 Protocol 
3.2.1 Investigation of the effects of NO2
- on stimulated platelet aggregation in PRP 
To determine whether NO2
- might exert effects directly on the platelet, the effect of 
in vitro NO2
- treatment on platelet aggregation responses was investigated. Blood 
was collected as described in section 2.9.1 from healthy male volunteers (n=6-8) 
and PRP generated as described in section 2.9.1.  PRP was then incubated with 
KNO2 (0.1-10 µM), spermine-NONOate (Sper-NO; 1-100 µM), or PBS as control for 
10 or 30 min at 37 °C. This range of NO2
- was chosen since it reflects the levels seen 
physiologically and also those levels achieved with NO3
- supplementation in healthy 
volunteers (Webb et al., 2008b, Kapil et al., 2010a, Cosby et al., 2003). Following the 
pre-treatment period platelet aggregation responses were assessed in response to 
ADP (0.1-30 µM) and collagen (0.1-30 µg/ml) by LTA. 
 
KNO2 (Sigma, UK) was made up freshly each day in 18 M MQ H2O. Dilutions were 
kept on ice before use and were used within 30 min of preparation. The PRP was 
incubated with the relevant drug at 37 °C in a separate 2 mL deep well plate prior to 
addition of the treated PRP to the 96 well plate.  
 
3.2.2 Investigation of the effect of NO2
- on platelet aggregation in whole blood 
To assess the effect of NO2
- on platelet aggregation in whole blood, blood was 
collected and incubated with KNO2 (0.3-3 µM) or Sper NO (0.1-10 µM) for 10 min 
prior to assessment of aggregation in response to ADP (10 µM), collagen (3 µg/ml) 
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or epinephrine (10 µM) using impedance aggregometry (n=11-13 males). These 
concentrations of activating stimuli were chosen since they represented an ≈ EC75-80 
concentration from the LTA experiments. In some cases whole blood was incubated 
with increasing concentrations of KCl (0.3-3 µM) for 10 min prior to the assessment 
of the aggregation response to ADP (10 µM) (n=5). Sper-NO (Cayman Chem, US) 
was stored at -80°C and made up freshly each day in a known volume of 18 M MQ 
H2O. KCl (Sigma, UK) was stored at room temperature and dissolved freshly in 18 
M MQ H2O each day. All dilutions were kept on ice before use and were used 
within 30 min of preparation. 
 
In addition, an aliquot of blood was collected from each volunteer. This blood was 
then incubated with NO2
- (1 µM, 10 min, 37°C) followed by isolation of a platelet 
pellet for determination of platelet cGMP levels using a commercially available 
ELISA kit (see section 2.8.2).  
 
3.2.3 Investigation of whether the effects of NO2
- relate to NO - induced activation 
of sGC 
Whole blood of males was incubated with the sGC inhibitor [1H-[1,2,4]oxadiazolo-
[4,3-a]quinoxalin-1-one] (ODQ; 1 µM) with NO2
- prior to assessment of aggregation 
in response to ADP (10 µM) using impedance aggregometry (n=15 males). This 
concentration of ODQ was chosen based upon previously demonstrated effective 
concentrations (Garthwaite et al., 1995). ODQ was dissolved in dimethyl sulfoxide 
(DMSO) (Sigma, UK) to achieve a stock solution and subsequent dilutions made in 
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normal saline with 3 mM CaCl2 to achieve a   final concentration of 1 µM ODQ.  
Blood was incubated for 15 min with ODQ at 37°C prior to addition of 3 µM KNO2. 
 
3.2.4 Statistical analysis 
All data were expressed either as a mean ± SEM. All p-values are 2-sided. NO2
- 
Incubation study LTA data were analysed using 2-way repeated measures ANOVA 
and Bonferroni post-hoc tests. NO2
- incubation WBA data were analysed using 1-
way ANOVA and Dunnett’s post-hoc test compared to control (PBS). NO2
- 
incubation study cGMP data were analysed using paired Student’s t-test. 
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3.3 Results 
3.3.1 Baseline demographic, haemodynamic and analytical parameters of subjects  
There was no significant difference in age, BMI or blood pressure in the healthy 
volunteer incubation studies (Table 3.1).  
 
Protocol PRP/whole 
blood 
 ODQ  
(n) (13)  (15) Significance 
Age (years) 28.1±1.1  27.3±1.1 0.60 
BMI (kg/m2) 22.1±0.5  21.9±0.5 0.75 
Mean baseline SBP  
(mm Hg) 
124.2±2.1  123.3±2.0 0.76 
Mean baseline DBP  
(mm Hg) 
68.7±1.5  67.9±1.5 0.72 
Table 3.1: Incubation studies. Average baseline demographic and haemodynamic 
parameters. Data are expressed as mean ± SEM. Significance shown for unpaired Student’s 
t-test between groups. 
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3.3.2 Effect of incubation of KNO2 and Sper-NO on LTA of PRP 
Treating PRP with increasing concentrations of NO2
- for 30 min had no effect on 
either ADP or collagen induced aggregation (Figure 3.1A and B).  In contrast 
treatment of PRP with Sper-NO resulted in concentration-dependent attenuation of 
both ADP and collagen induced-aggregation (Figure 3.1C and D).  
 
Since incubation with NO2
- at 30 min had no effect, the incubation period was 
reduced to 10 min to ensure that any potential effect had not been missed. The 
half-life of NO2
- has been estimated to fall somewhere between 10 and 45 min 
(Kapil et al., 2010b). However similar absence of effect of NO2
- was noted (Figure 
3.2A and B). As with the 30 min incubation, incubation of PRP with Sper-NO for 10 
min resulted in concentration-dependent attenuation of both ADP and collagen 
induced-aggregation (Figure 3.2C and D).  
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Figure 3.1: The effect of 30 min pre-treatment of PRP with KNO2 (0.3-10 µM) or vehicle 
(PBS) control. Platelet aggregation responses to (A) ADP (0.1-30 µM, n=13) or collagen (0.1-
30 µg/ml, n=13) using light transmission aggregometry. The effect of 30 min pre-treatment 
of PRP with sperm-NO (1-100 µM) or vehicle (PBS) control for 10 min on (C) ADP (0.1-30 
µM, n=13) and (D) collagen (0.1-30 µg/ml, n=13). Data are expressed as mean ± SEM. 
Significance shown as ##p<0.01 and ###p<0.001 for 2-way repeated-measures ANOVA. 
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Figure 3.2: The effect of 10 min pretreatment of PRP with KNO2 (1 µM) or vehicle (PBS) 
control. Platelet aggregation responses to (A) ADP (0.1-30 µM, n=13) or collagen (0.1-30 
µg/ml, n=13) using light transmission aggregometry. The effect of 10 min pretreatment of 
PRP with sperm-NO (10 µM) or vehicle (PBS) control for 10 min on (C) ADP (0.1-30 µM, 
n=13) and (D) collagen (0.1-30 µg/ml, n=13). Data are expressed as mean ± SEM. 
Significance shown as #p<0.05 for 2-way repeated-measures ANOVA followed by 
Bonferroni post tests shown as ** p<0.01 and *** for p<0.001. 
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3.3.3 Effect of incubation of KNO2 on whole blood  
Incubation of whole blood with KNO2 resulted in a concentration dependent 
reduction in platelet aggregation assessed by whole blood aggregometry in 
response to 10 µM ADP. This effect was not seen in response to 3 µg/ml collagen or 
10 µM epinephrine. An associated elevation in platelet [cGMP] was noted in the 
platelets isolated from whole blood incubated with 1 µM KNO₂ compared to PBS 
control (Figure 3.3). In contrast incubation of whole blood with KCl had no effect on 
platelet aggregation assessed by whole blood aggregometry in response to 10µM 
ADP (Figure 3.4). 
 
 
 
 
 
 
 
 
 
Figure 3.3: Platelet aggregation assessed by impedance aggregometry of whole blood of 
males incubated ex vivo with KNO2 in response to (A) ADP (10 µM) n=13, (B) collagen (3 
µg/mL) n=11, and (C) epinephrine (10µM) n=11. Data are expressed as mean ± SEM. 
Significance shown as *p<0.05 and **p<0.01 for Dunnett’s post-hoc test compared to 
control (PBS) following 1-way ANOVA. Figure (D) shows an elevation in platelet cGMP in 
whole blood of males (n=12) incubated with 1 µM KNO3 compared to PBS control. Data are 
expressed as mean ± SEM. Significance shown for paired Student’s t-test between groups as 
*p<0.05. 
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Figure 3.4: Platelet aggregation assessed by impedance aggregometry of whole blood of 
males incubated ex vivo with KCl in response to ADP (10 µM) n=5. Data are expressed as 
mean ± SEM. 
 
3.3.4 Effect of incubation of SGC inhibitor ODQ with KNO2 on whole blood 
Incubation of whole blood with KNO2 in the presence of sGC inhibitor ODQ 
appeared to block the inhibitory effect of NO2
- on platelet aggregation although the 
data were difficult to interpret due to the drug itself altering platelet aggregation 
independently of NO₂- (Figure 3.5). 
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Figure 3.5: Platelet aggregation assessed by impedance aggregometry of whole blood of 
males incubated ex vivo with ODQ and 3 µM KNO2 in response to ADP (10 µM) n=15. Data 
are expressed as mean ± SEM. Significance shown as ***p<0.001 for Bonferonni’s post-hoc 
test following 1-way ANOVA. 
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3.4 Summary 
1. Incubation of purified human platelets with NO2
- has no effect on platelet 
reactivity indicating that NO2
- has no direct effect on platelets. 
2. In contrast incubation of whole blood with NO2
- exposed NO2
--induced 
suppression of platelet aggregation responses. 
3. NO2
- incubation of whole blood reduced platelet aggregation responses to ADP 
and collagen.  
4. Treatment of whole blood with NO2
- resulted in significant elevations of platelet 
cGMP, supporting a role for NO2
- derived NO in the repressive effects on 
platelets.  
5. Incubation of purified human platelets with Sper-NO attenuates platelet 
aggregation, indicating sensitivity to NO. 
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Chapter 4 
 
 
Investigation of the effect of 
inorganic NO3
- salt 
supplementation on platelet 
reactivity in healthy volunteers 
including elucidation of any sex 
differences 
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4.1 Introduction 
Our group has previously shown that consumption of dietary NO3
- (as beetroot 
juice) attenuates ex vivo stimulated platelet aggregation; an effect that was lost if 
the oral conversion of NO3
- to NO2
- was prevented thereby preventing elevations of 
systemic NO2
- levels (Webb et al., 2008b). This latter observation supports the view 
that the NO3
- within the beetroot juice was responsible for this effect, however 
whether NO3
- salt supplementation might recapitulate this finding is unknown.  
 
Interestingly there is some suggestion that there might be sex differences in the 
activity of the NO3
--NO2
--NO pathway. In a clinic setting Kapil et al. showed that in a 
group of young normotensive volunteers, that dietary NO3
- caused dose-dependent 
increases in plasma NO2
- and NO3
- concentration following an inorganic NO3
- load, 
which was associated with subsequent reductions in blood pressure. However, in 
this study the functional effects appeared to be more prominent in males than 
females: post hoc analyses of the dataset revealed sex differences in the processing 
of dietary NO3
- through the enterosalivary circulation. Interestingly, resting systolic 
blood pressure was 25mmHg lower in females compared to males (Kapil et al., 
2010a). This effect has been credited, in part, to the beneficial effects of oestrogen 
on eNOS activity elevating levels of vasodilator NO in females (Haynes et al., 2000). 
There is also evidence suggesting that BP differences between the sexes might be 
due to  the detrimental effect of testosterone in the male (Kaushik et al., 2010).  
Subset analysis of the Kapil study revealed that female subjects had significantly 
higher baseline plasma NO2
- levels compared to male subjects, as well as higher 
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salivary NO2
- levels, coupled with significantly lower systolic blood pressure. The 
authors suggested that these differences indicate that women might produce more 
NO2
- via the enterosalivary circulation which may account for the reduced BP but 
also offer an additional beneficial effect that may underlie, in part, why women are 
protected against CVD. These findings highlight the need for more research with 
respect to investigation of sex differences and the effects of dietary NO3
- in humans. 
Whether sex might influence the platelet in terms of reactivity in CVD following 
utilisation of the NO3
--NO2
--NO pathway is unknown and was a focus of this study. 
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4.2 Protocol 
In a double blind, randomised, placebo controlled crossover study male (n=12) and 
female (n=12) volunteers received either 8 mmol KNO3 capsules (Martindale 
Pharmaceuticals, Ipswich, UK), equivalent to 496 mg of NO3
- or matched KCl placebo 
capsules (Martindale Pharmaceuticals, Ipswich, UK). Volunteers returned for the 
cross-over limb between 7 and 28 days later. Blood, urine and saliva were collected 
for analysis of [NO3
-] and [NO2
-] (see section 2.6) and blood was separately collected 
for determination of P-selectin expression under unstimulated conditions (see 
section 2.10.1). Platelet aggregation was assessed in whole blood in response to 
ADP (10 µmol/L), and PBS (as control) using impedance aggregometry (Multiplate ® 
Analyzer, Dynabyte Medical, Germany). All measures and sample collection were 
performed at baseline and at 3 h post intervention. This 3 h time point was selected 
in view of previous findings demonstrating that circulating levels of NO2
-, and the 
associated bioactivity, peak 3 h post NO3
- ingestion (Webb et al., 2008b) (see Figure 
4.1). 
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Figure 4.1: Flow diagram of capsule study protocol. Participants were randomised to blue 
or red pathway as indicated above (cGMP=cyclic guanosine monophosphate; NOx= 
nitrite/nitrate; WBA= whole blood aggregometry; KNO3= potassium nitrate; KCl= potassium 
chloride). 
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4.2.1 Investigation of any sex differences in the effect of NO2
- on platelet 
aggregation in whole blood  
To assess the effect of NO2
- on platelet aggregation in whole blood of females, 
blood was collected and incubated with KNO2  for 10 min prior to assessment of 
aggregation in response to ADP (10 µM), collagen (3 µg/ml) or epinephrine (10 µM) 
using impedance aggregometry (n=7 females). In a separate series of experiments 
the effects of Sper-NO (1-10 µM) on ADP or collagen induced aggregation of PRP in 
both sexes was determined using impedance aggregometry (n=5-6 males, n=5 
females). Sper-NO (Cayman Chem, US) was stored at -80°C and both KNO2 and Sper-
NO made freshly each day in a known volume of 18 M MQ H2O. Dilutions were 
kept on ice before use and were used within 30 min of preparation. 
 
In addition, an aliquot of blood was collected from each volunteer for in vitro 
incubation with NO2
- (1 µM, 10 min, 37°C) followed by isolation of platelet pellet for 
determination of platelet cGMP levels using a commercially available ELISA (see 
section 2.8.2).  
 
4.2.2 Assessment of the NO2
- reductase activity of RBC prepared from male and 
female healthy volunteers 
Blood was collected for erythrocyte isolation as per section 2.7.2 from 7 healthy 
male and 5 healthy female volunteers for assessment of NO2
- reductase activity 
using gas phase ozone chemiluminescence with increasing concentration of NO2
- 
(10-300 µM) and at pH 7.4 and 6.8. This range of pH was tested to simulate 
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physiological conditions (pH 7.4) but also to test activity in an optimum NO2
- 
reducing environment i.e. acidosis (pH 6.8). 
 
4.2.3 Statistical Analysis 
Power calculations were conducted using G-Power™ for this study. Our previous 
findings (Webb et al., 2008b, Kapil et al., 2010a) have demonstrated a peak increase 
in circulating NO2
- levels following dietary NO3
- administration in males of 0.615 µM 
versus 1.555 µM in females using an averaged SD of 0.309 µM an α =0.05 and a 
β=0.9, 11 individuals of each sex were required. In order to account for a 10% drop-
out, 12 individuals of each sex were recruited. All data were expressed as a mean ± 
SEM. All p-values are 2-sided. With respect to the KNO3 capsule study, baseline 
demographic and clinical variables were summarised for each arm of the study. 
Comparisons between the sexes were made in the KNO3 capsule study using 
unpaired Students t-test. All [NOx] data in the KNO3 capsule study were analysed 
using 1-way repeated measures ANOVA and Bonferroni post hoc tests for 
comparison of individual treatments. KNO3 capsule study WBA data were analysed 
using paired Student’s t-test. Erythrocytic NO2
- reductase activity in males 
compared to females was analysed using 2-way ANOVA. NO2
- incubation study 
cGMP data were analysed using paired Student’s t-test. Spermine-NO PRP 
impedance aggregometry data were analysed using 1-way ANOVA and Dunnett’s 
post-hoc test compared to control (PBS). 
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4.3 Results 
4.3.1 Baseline demographic, haemodynamic and analytical parameters of subjects  
All volunteers recruited completed both limbs of the study i.e. there were no 
dropouts. Females had a significantly lower baseline SBP compared to males 
(p<0.01), higher HR (p<0.02) but similar DBP compared to males. There was no 
significant difference in age or BMI between the sexes (Table 4.1). There were no 
significant differences in all other baseline measures between the limbs in either 
sex (Table 4.2). 
 
Male 
 
Female Significance 
(n) 12  12  
Age (years) 26.7±1.4  29.3±1.8 0.26 
BMI (kg/m2) 22.8±2.0  22.9±0.8 0.99 
Average baseline SBP  
(mm Hg) 
120.7±3.2  106.9±2.2 0.002 
Average baseline DBP  
(mm Hg) 
67.0±1.6  68.0±1.8 0.32 
Average HR (bpm) 61.2±2.4  68.6±1.8 0.02 
Table 4.1: KNO3 capsule study. Average baseline demographic and haemodynamic 
parameters. Data are expressed as mean ± SEM. Significance shown for unpaired Student’s 
t-test between groups. 
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Subjects (n=24)     
Male (n=12) Placebo  Inorganic NO3
- Significance 
Baseline HR (bpm) 60.5±2.4  63.0±2.7 0.50 
Baseline SBP (mm Hg) 120.3±3.2  121.0±3.7 0.80 
Baseline DBP (mm Hg) 67.2±1.8  66.8±2.0 0.77 
Plasma [NO3
-] (µM) 27.3±4.2  26.0±2.8 0.65 
Plasma [NO2
-] (µM) 0.07±0.03  0.10±0.03 0.32 
Female (n=12)     
Baseline HR (bpm) 73.5±2.1  68.7±1.6 0.05 
Baseline SBP (mm Hg) 107.8±2.6  106.1±2.3 0.44 
Baseline DBP (mm Hg) 68.8±2.0  67.29±2.2 0.35 
Plasma [NO3
-] (µM) 33.6±7.0  39.2±8.4 0.61 
Plasma [NO2
-] (µM) 0.1±0.1  0.1±0.4 0.27 
Table 4.2: KNO3 capsule study. Baseline demographic, haemodynamic and analytical 
parameters. Data presented as mean ± SEM. Significance shown for paired Student’s t-test 
between groups. 
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4.3.2 Effect of KNO3 capsule ingestion on plasma, urinary and salivary [NO2
-] and 
[NO3
-] in healthy volunteers. 
At 3 h post ingestion of inorganic NO3
- there was a significant elevation in plasma  
[NO3
-] and [NO2
-] in both males and females (Figure 4.1A - D). Plasma [NO3
-] was 
increased 9.0 ± 1.6 fold in males following KNO3 compared to an 8.5 ± 1.1 fold 
increase in females following KNO3
-. The fold increases in [NO2
-] were 3.3 ± 0.7 in 
males and 6.5 ± 1.5 in females (p = 0.07, unpaired t-test).  In addition there was 
similar elevation in urinary and salivary [NO3
-] and [NO2
-] in both males and females 
(Figure 4.2A - D and Figure 4.3A - D, respectively). Urinary [NO3
-] was increased 11.6 
± 2.4 fold in males following KNO3 compared to an 8.9 ± 2.4 fold increase in females 
following KNO3. The fold increases in urinary [NO2
-] were 2.8 ± 0.4 in males and 4.5 
± 1.4 in females. Salivary [NO3
-] was increased 12.7 ± 2.4 fold in males following 
KNO3 compared to an 18.2 ± 4.3 fold increase in females following KNO3. The fold 
increases in salivary [NO2
-] were 10.2 ± 2.5 in males and 6.8 ± 1.0 in females. There 
were no changes in plasma, salivary or urinary [NO3
-] and [NO2
-] following placebo 
in either sex. 
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Figure 4.2: KNO3 supplementation elevates plasma [NOx] in healthy males and females 
(n=24, 12 males, 12 females). The effects of KNO3 (8 mmol) or KCl (8 mmol) on circulating 
plasma NO3
- and NO2
- levels in healthy volunteers 3h post intervention. Significance shown 
for Bonferroni post-hoc tests between groups as ***p<0.001 following 1-way ANOVA. Data 
are expressed as mean ± SEM.  
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Figure 4.3: KNO3 supplementation elevates urinary [NOx] in healthy males and females 
(n=24, 12 males, 12 females). The effects of KNO3 (8 mmol) or KCl (8 mmol) on urinary NO3
- 
and NO2
- 3 h post intervention. Significance shown for Bonferroni post hoc tests between 
groups as ***p<0.001 following 1-way ANOVA. Data are expressed as mean ± SEM.  
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Figure 4.4: KNO3 supplementation elevates salivary [NOx] in healthy males and females 
(n=24, 12 males, 12 females). The effects of KNO3 (8 mmol) or KCl (8 mmol) on salivary NO3
- 
and NO2
- 3h post intervention. Significance shown for Bonferroni post-hoc tests between 
groups as ***p<0.001 following 1-way ANOVA. Data are expressed as mean ± SEM.  
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4.3.3 Effect of KNO3 on platelet counts 
Platelet counts were similar between the sexes and remained unchanged following 
either KNO3 or KCl placebo ingestion (table 4.3). There is no significant difference in 
male and female platelet counts per ml of whole blood respectively before and 3 h-
post KCl or KNO3 (p value 0.84 and 0.16 respectively in males and 0.19 and 0.75 
respectively in females following paired Student’s t-test within groups). Similarly no 
significant difference is noted in platelet counts between the sexes although female 
platelet counts are noted to be slightly higher than in males (table 4.3). 
 
Male (n=12)  Female (n=12) Significance 
 Platelet count/ml  Platelet count/ml  
Pre KNO3 2.19x10
8±9.82x106  2.31 x108±1.98x107 0.57 
Post KNO3 2.27 x10
8±2.0±8.13x106  2.38 x108±2.87x107 0.71 
Pre KCl 2.37 x108±1.06x107  2.48 x108±2.81x107 0.71 
Post KCl 2.39 x108±1.18x107  2.61 x108±2.55x107 0.44 
Table 4.3: Platelet counts. Data are expressed as mean ± SEM. Data analysed and p values 
documented following unpaired Student’s t-test between sexes. 
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4.3.4 Effect of KNO3 on platelet aggregation 
Each of the aggregation stimuli induced responses significantly above that achieved 
in response to PBS. These were similar between the sexes (Table 4.4).  
                                                   Aggregation (AUC) Significance 
Agonist Male (n=12)  Female (n=12)  
PBS  5.4±1.1  5.0±1.0 0.78 
ADP 52.5±3.8  58.5±3.1 0.17 
Collagen 70.7±4.3  73.5±3.8 0.65 
Epinephrine 10.9±1.8  12.2±3.2 0.73 
 
Table 4.4: Baseline aggregation to different stimuli prior to intervention. Data are 
expressed as mean ± SEM (averaged baseline values from both limbs). Data analysed and p 
values documented following unpaired Student’s t-test between sexes. 
 
KNO3 capsule ingestion resulted in a significant decrease in aggregation response to 
ADP (10 µM) in males but not females (Table 4.6). There were no changes in 
platelet aggregation following placebo in either sex (Table 4.6).  
 
In contrast no significant differences in platelet aggregation in response to collagen 
(3 µM) (Table 4.7) or epinephrine (10 µM) (Table 4.8) were seen. There were no 
differences in the impedance response to PBS in males or females post KNO3 
ingestion or KCl ingestion (Table 4.5). 
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PBS Male (n=12) Female (n=12) 
 Aggregation 
(AUC) 
Significance Aggregation 
(AUC) 
Significance 
KCl Placebo     
Baseline 4.3 ± 1.2  5.4 ± 1.6  
Post 5.5 ± 1.5 0.45 4.9 ± 1.9 0.75 
KNO3     
Baseline 6.4 ± 1.9  4.5 ± 1.4  
Post 2.8 ± 1.1 0.01 4.8 ± 1.4 0.90 
 
Table 4.5: Platelet aggregation assessed by impedance aggregometry of whole blood in 
response to PBS before and 3 h-post KCl (8 mmol) or KNO3 (8 mmol) in healthy male 
volunteers and female volunteers (n=24, 12 males, 12 females). Data are expressed as 
mean ± SEM. Significance shown for paired Student’s t-tests between groups. 
 
ADP Male (n=12) Female (n=12) 
 Aggregation 
(AUC) 
Significance Aggregation 
(AUC) 
Significance 
KCl Placebo     
Baseline 47.7 ± 4.5  57.9 ± 5.2  
Post 46.7 ± 5.8 0.82 53.8 ± 6.4 0.57 
KNO3     
Baseline 57.4 ± 5.9  59.0 ± 3.7  
Post 42.6 ± 3.7 0.004 59.0 ± 5.7 1.00 
 
Table 4.6: Platelet aggregation assessed by impedance aggregometry of whole blood in 
response to ADP (10 µM) before and 3 h-post KCl (8 mmol) or KNO3 (8 mmol) in healthy 
male volunteers and female volunteers (n=24, 12 males, 12 females). Data are expressed as 
mean ± SEM. Significance shown for paired Student’s t-tests between groups.  
  
172 
 
COLLAGEN Male (n=12) Female (n=12) 
 Aggregation 
(AUC) 
Significance Aggregation 
(AUC) 
Significance 
KCl Placebo     
Baseline 72.2 ± 7.2  76.3 ± 6.0  
Post 66.1 ± 22.7 0.44 71.4 ± 7.2 0.56 
KNO3     
Baseline 69.3 ± 4.9  70.7 ± 4.7  
Post 66.5 ± 4.1 0.55 77.3 ± 5.6 0.22 
 
Table 4.7: Platelet aggregation assessed by impedance aggregometry of whole blood in 
response to collagen (3 µM)  before and 3 h-post KCl (8 mmol) or KNO3 (8 mmol) in healthy 
male volunteers and female volunteers (n=24, 12 males, 12 females). Data are expressed as 
mean ± SEM. Significance shown for paired Student’s t-tests between groups. 
 
EPINEPHRINE Male (n=12) Female (n=12) 
 Aggregation 
(AUC) 
Significance Aggregation 
(AUC) 
Significance 
KCl Placebo     
Baseline 10.0 ± 2.7  9.7 ± 3.1  
Post 9.0 ± 2.4 0.38 5.4 ± 1.6 0.25 
KNO3     
Baseline 11.8 ± 2.5  9.3 ± 2.3  
Post 8.3 ± 1.9 0.05 13.3 ± 5.0 0.40 
 
Table 4.8: Platelet aggregation assessed by impedance aggregometry of whole blood in 
response to Epinephrine (10 µM) before and 3 h-post KCl (8 mmol) or KNO3 (8 mmol) in 
healthy male volunteers and female volunteers (n=24, 12 males, 12 females). Data are 
expressed as mean ± SEM. Significance shown for paired Student’s t-tests between groups. 
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4.3.5 Effect of KNO3 on platelet [cGMP] 
Platelet [cGMP] was significantly elevated in males post KNO3 but not KCl placebo, 
an elevation not evident in the platelets of females (Figure 4.5A + B). 
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Figure 4.5:  Platelet cGMP levels are significantly elevated in male volunteers (n=9) post 
KNO3 compared to placebo. In contrast platelet cGMP levels in females remain the same 
post inorganic NO3
- or placebo (n=9). Data are expressed as mean ± SEM. Significance 
shown for Paired Student’s t-test between groups as *p<0.05 following paired Student’s t-
test.  
 
4.3.6 Erythrocytic NO2
- reductase activity in males and females 
Since KNO3 did not appear to alter platelet reactivity ex vivo in females I next 
assessed whether this might relate to an inability for the erythrocytes of female 
volunteers to reduce NO2
- to NO. Figure 4.6 demonstrates no significant difference 
in erythrocytic NO2
- reductase capacity in males compared to females at pH 6.8 or 
at pH 7.4. 
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Figure 4.6: Erythrocytic NO2
- reductase activity at pH 6.8 (A) and pH 7.4 (B) in males (n=7) 
and females (n=5). All data are expressed as mean ± SEM. No significant differences in NO2
- 
reductase activity assessed using 2-way ANOVA. 
 
4.3.7 Effect of incubation of KNO₂ on whole blood in females 
Since the NO2
- reductase capacity of RBCs was identical between the sexes I 
assessed whether incubation of whole blood in vitro with NO2
- might be different 
between the sexes. As described in chapter 3 of this thesis incubation of whole 
blood of healthy males in vitro with NO2
- resulted in a significant attenuation of 
platelet aggregation with an associated elevation in platelet cGMP. In contrast 
figure 4.7 demonstrates that NO2
- did not affect ADP, collagen or epinephrine 
induced aggregation nor elevate cGMP in females.  
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Figure 4.7: Platelet aggregation assessed by impedance aggregometry of whole blood of 
females incubated ex vivo with KNO2 in response to (A) ADP (10 µM) n=7, (B) collagen (3 
µg/mL) n=7, and (C) epinephrine (10 µM) n=7. Data are expressed as mean ± SEM. Figure 
(D) shows no elevation in platelet cGMP in whole blood of females (n=6) incubated with 1 
µM KNO₂. Data are expressed as mean ± SEM. 
 
4.3.8 Effect of Sper-NO on PRP using impedance aggregometry 
To check whether platelet sensitivity to NO is still evident using impedance 
aggregometry in either sex, PRP containing purified platelets was incubated with 
Sper-NO. Figure 4.8 demonstrates that platelets from both male and female 
volunteers respond to Sper-NO, although the platelets of men may be slightly more 
sensitive since significant reductions in platelet aggregation were noted using a 
lower concentration of Sper-NO in males compared to females.  
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Figure 4.8: Platelet aggregation assessed by impedance aggregometry in response to (A) 
ADP 10 µM and (B) to collagen 3 µg/ml of PRP collected from male and (C) female 
volunteers incubated ex vivo for 10 min (n=5 each sex ADP, n=6 male collagen) with sperm-
NO. Data are expressed as mean ± SEM. Significance shown as *p<0.05, **p<0.01, 
***p<0.001 for Dunnett’s post-hoc test compared to control (PBS) following 1-way ANOVA. 
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4.4 Summary 
1. Inorganic NO3
- supplementation causes a rise in both circulating NO3
- and 
NO2
- levels in healthy males and females. 
2. Females have a higher fold increase in plasma NO2
- compared to males 
following inorganic NO3
- supplementation, although this did not reach 
statistical significance. 
3. Inorganic NO3
- supplementation attenuates ex vivo platelet aggregation ex 
vivo in response to ADP in males but not females. 
4. Inorganic NO3
- supplementation is associated with a rise in platelet cGMP in 
platelets of male but not female volunteers. 
5. In vitro NO2
- incubation reduces platelet reactivity of male blood only.  
6. The effects of sper-NO are greater in platelets of healthy males compared to 
females and this is associated with elevations in platelet cGMP. 
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Chapter 5 
 
Investigation of the effect of 
inorganic NO3
- on platelet and 
vascular function in 
hypercholesterolaemia: a 
prospective randomised double 
blind parallel study. 
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5.1 Introduction 
Endothelial dysfunction is thought to play a major role in the progression of CVD 
including in atherosclerosis and is the result of a change in the phenotype of the 
endothelium from anti-to pro-atherosclerotic (Deanfield et al., 2007). It is thought 
that this change in phenotype occurs at the very earliest stages of CVD 
development, even preceding any evidence of disease (Celermajer et al., 1992a) 
and is also associated with most risk factors for CVD, including 
hypercholesterolaemia (Bhatnagar et al., 2008, Steinberg et al., 1989, Kannel et al., 
1979). Of particular utility in clinical assessment of endothelial function has been 
the ultrasound measurement of brachial artery dilatation upon release of a cuff on 
the forearm, a response termed FMD (Corretti et al., 2002b). Importantly 
preventative strategies for CVD in hypercholesterolaemics such as statins improve 
FMD responses in addition to lowering cholesterol. These improvements are 
thought to reflect improved endothelial function in part through recovery of 
endothelial NO generation (Treasure et al., 1995, Vita et al., 2000). This 
improvement of vascular function has been proposed perhaps to reflect a slowing 
or even a stopping of the progression of atherosclerosis.  
 
It is also accepted that upregulated P-selectin plays a critical role for progression of 
atherosclerosis. Indeed, in mice a deficiency in P-selectin reduces formation of 
atherosclerotic lesions (Johnson et al., 1997, Nageh et al., 1997). In addition platelet 
P-selectin expression is associated with atherosclerotic wall thickness in carotid 
arteries in humans (Koyama et al., 2003) and is increased in coronary artery disease 
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patients (Fitzgerald et al., 1986, Trip et al., 1990, Furman et al., 1998).  Thus 
strategies that might improve platelet function may be of benefit in prevention. 
 
We have previously demonstrated that provision of oral NO3
- either as a 
supplement or through dietary ingestion elevates circulating NO levels and 
simultaneously protects against a transient endothelial dysfunction induced 
experimentally by an ischaemia/reperfusion insult in the brachial artery of healthy 
volunteers (Kapil et al., 2010a, Webb et al., 2008b). In addition, data within this 
thesis indicates that NO3
- therapy also decreases platelet reactivity in response to 
activating stimuli in healthy volunteers, including reduction of P-selectin expression.  
Thus, in this clinical experiment I tested whether NO3
- by providing a sustained 
elevation of NO, might improve endothelial and platelet function in patients with 
hypercholesterolaemia.  
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5.2 Protocol 
5.2.1 Study design and subjects 
This randomised double-blind, placebo controlled parallel trial was approved by 
NRES Committee London-Stanmore (Study No.11/LO/0715) and registered with 
clinical trials.gov (NCT01493752). 
 
69 non-smoking, non-diabetic otherwise healthy hypercholesterolaemic men and 
women aged 18-80 with BMI 18.5-40 kg/m2 were recruited. All subjects had a total 
serum cholesterol >6.0 mmol/L or any elevation of total cholesterol, LDL cholesterol 
or triglycerides with QRISK 2 score >15 %. All subjects were expected to continue 
their usual diet and exercise regime during the study and asked not to take any 
additional vitamin, food supplements or commence any new medications for the 
duration of the study. Known essential hypertensives were included in the study 
although required to be on a stable medication profile for at least one year prior to 
screening (refer to general methods for full inclusion and exclusion criteria section 
2.1.2). Subjects were screened by taking a medical history and physical 
examination, BP measurement, urine sample, full blood count and blood chemistry. 
 
Participants were invited to attend for their first study visit within 2 weeks of 
screening and were expected to withhold medications on the morning of study 
visits with any last medications consumed at least 12 hours prior in the case of anti-
hypertensives, and 24 hours prior in the case of aspirin. Participants were expected 
182 
 
to fast 12 hours prior to the study visits having consumed a low nitrate diet 24 h 
prior and refrained from any strenuous exercise 24 h prior to study visits. 
 
During each study visit height and weight were recorded, ultrasound FMD of the 
brachial artery, PWA and aPWV (using the non-invasive Vicorder see section 2.12) 
were performed, followed by a blood collection. All blood was collected using a 
vacutainer system (BD Biosciences, UK). Urine and saliva were collected for NO3
- 
and NO2
- measurement as described in section 2.5. At the end of visit 1 participants 
consumed their first dose of juice. A subgroup of 34 patients also consented to a 
repeat of all vascular and BP measurements 3 h following juice ingestion. 
Participants then consumed the juice once daily for the next 6 weeks and returned 
for their final study visit 6 weeks ± 1 week of study visit 1 and were expected to 
adhere to all the same pre-visit rules.  
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Figure 5.1: Flow diagram detailing study protocol. 
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5.2.2 Statistical analysis 
The primary outcome measure in this study was change in the FMD (%) response at 
6 weeks from baseline. Assuming an averaged improvement of FMD of 1.1% with no 
change in the control and an average SD of 1.45, 30 volunteers would be needed in 
each limb for statistical power of 0.8 at significance level of α=0.05 requiring a total 
of 60 volunteers.  If we assume a potential 10% drop-out rate (as per our 
experience) this results in a total recruitment target of 66 patients.  These 
calculations were based upon a number of previous published observations. 
Improvements in FMD were noted following six weeks of artichoke juice (Lupattelli 
et al., 2004b) and also by two further studies with walnuts (Katz et al., 2012) and 
one recent meta-analysis (Kay et al., 2012) assessing the effects of chronic 
polyphenol dietary interventions. The averaged improvement across all of these 
studies was an absolute increase of 1.1% (the average absolute FMD response in 
these studies approximates to 5% and a 1.1% absolute increase equates to an 
approximate improvement of 35%). These proposed numbers also provide sufficient 
power for the secondary outcome measure of improved FMD for within limb 
comparisons. Analysis was based on the intention-to-treat principle. Baseline 
demographic and clinical variables were summarised for each limb of the study. 
Statistical comparisons are between the dietary nitrate-treated and placebo 
control-treated limb for the primary and secondary outcomes. Paired Student’s t-
tests were used to compare pre and post-treatment changes within limbs and 
unpaired t-tests for changes between limbs. All p-values are 2-tailed. For data that 
have a non-parametric distribution (platelet P-selectin expression, aggregation 
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assays and PMA assessment) Wilcoxon matched-pairs rank test was used for within 
limb and Mann-Whitney U test for between limb comparisons.  
5.3 Results 
5.3.1 Baseline characteristics, blood biochemistry, and % metHb levels 
Of the 69 participants randomly assigned to NO3
- -rich beetroot juice or NO3
- -
deplete placebo juice 67 completed both study visits. 2 participants withdrew 
consent post screening at the time of the first visit. One participant wished to 
unblind the intervention prior to continuing and the other felt unwell at the time of 
the first visit.  1/67 was on 75 mg daily regular aspirin, 14/67 were hypertensive and 
on medication (see Table 5.1 below). 
 
Primary outcome measures of FMD were conducted in all participants, however full 
data sets for analysis were generated for only 65 participants due to loss of brachial 
artery measurements as a consequence of inadequate ECG gating during one visit in 
one participant and due to file corruption of one visit dataset for another 
participant. Thus, in total full data sets were obtained for 32 volunteers receiving 
placebo and 33 volunteers receiving the dietary NO3
- intervention (Figure 5.2).  
There were no differences in baseline demographics between the two limbs (Table 
5.1), including plasma lipid levels (Table 5.2), demonstrating effective 
randomisation between the two groups.  The interventions were tolerated well with 
no adverse effects other than beeturia. The dietary NO3
- dose for 6 weeks was 
(n=33, NO3
--rich beetroot juice, 250 ml of 24.1±7.7 mM) vs placebo (n=34, NO3
--
186 
 
depleted juice, 250 ml of 0.05±0.1 mM). Met Hb levels were not significantly 
changed post six weeks of NO3
--rich juice compared to placebo (Figure 5.3). 
 
 
Figure 5.2: Consort diagram of cholesterol study. 
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Variable 
NO3
- 
(33) 
Placebo 
(34) 
Age (years) 53.3±10.1 53.2±11.8 
Gender (male:female) 12:21 12:22 
BMI (kg/m2) 26.8±4.9 26.7±5.1 
Baseline SBP (mmHg) 125.2±15.1 122.7±15.2 
Baseline DBP (mmHg) 76.3±8.6 
 
77.9±11.1 
Treated hypertensives (n) 9 5 
Medications (n)   
 ACE inhibitor/ARB 3 4 
 Calcium antagonists 4 4 
 Beta- blocker 1 0 
 Thiazide diuretic 5 1 
Table 5.1: Baseline characteristics of participants. Data presented as mean ± SD or numbers 
(n). 
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NO3
- 
(33) 
      
P value 
Placebo 
(34) 
 
    P value 
 Baseline 6 weeks  Baseline 6 weeks  
Plasma [NO3
-
] 
(µmol/L) 
 
Plasma [NO2
-
] 
(µmol/L) 
 
29.5±12.0 
 
 
0.2±0.1 
228.3±102.1 
 
 
0.57±0.2 
<0.0001 
 
 
 <0.0001 
30.2±11.5 
 
 
0.3±0.2 
27.7±9.7 
 
 
0.3±0.2 
0.42 
 
  
 0.22 
Serum Na
+
 
(mmol/L)  
141.7±2.6 141.1±2.2 0.18 142.1±2.3 142.1±2.0 0.89 
Serum K
+
 
(mmol/L) 
4.4±0.4 4.4±0.3 0.85 4.4±0.3 4.5±0.4 0.11 
Serum Cl
- 
(mmol/L) 
102.7±3.2 102.5±2.3 0.75 103.3±2.3 103.6±2.4 0.52 
Total 
cholesterol 
(mmol/L) 
6.9±1.5 6.7±1.4  0.16 7.0±1.1 7.0±1.0 0.91 
LDL (mmol/L) 4.4±1.1 4.2±1.0 0.25 4.4±0.9 4.4±0.9 0.95 
HDL (mmol/L) 1.8[1.4-2.2] 1.7[1.4-2.2] 0.80 1.6[1.2-2.2] 1.7[1.3-2.2] 0.78 
Triglycerides 
(mmol/L) 
1.1[0.8-1.5] 1.1[0.9-1.9] 0.31 1.3[1.0-2.4] 1.2[0.9-2.1] 0.94 
Total (chol:HDL 
ratio) 
3.7[2.9-4.5] 3.8[3.0-4.2] 0.67 
 
4.3[3.2-5.0] 3.9[3.3-4.7] 0.61 
Table 5.2: Blood biochemistry. Plasma NOx, serum electrolytes, lipids. Levels at baseline and 
6 weeks. Data presented as mean ± SD if normally distributed and as median and IQR 
otherwise; p value for paired-Student’s t test or Wilcoxon matched-pairs rank test for pre 
and post 6 weeks dietary NO3
- treatment or placebo.  
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Figure 5.3: Levels of metHb pre and post NO3
- rich juice and placebo juice. MetHb levels 
measured using pulse oximetry. Data are expressed as mean ± SEM. 
 
5.3.2 The enterosalivary circuit is intact in hypercholesterolaemia 
There were no differences in baseline plasma cGMP (NO3
- limb: 15.47±2.91 nmol/L 
vs Placebo limb 15.28±3.92 nmol/L, p=0.82) or NOx levels between the limbs (Table 
5.2). Following 6 weeks ingestion of dietary NO3
- plasma, urinary and salivary [NO3
-] 
and [NO2
-] were all elevated (Figures 5.4 and 5.5 respectively). In contrast, there 
were no changes in plasma, salivary or urinary [NOx] in the placebo limb (Figures 5.4 
and 5.5). The changes in [NO2
-] and [NO3
-] anion were not accompanied by any 
changes in the other circulating electrolytes measured i.e. Na+, K+ or Cl- (Table 5.2). 
In addition, baseline lipid levels were similar at baseline between the groups and 
were not altered by either intervention (Table 5.2).  
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Figure 5.4: Dietary NO3
- supplementation elevates plasma, urinary and salivary [NO3
-]. 
Dietary NO3
- supplementation elevates plasma (A), urinary (B) and salivary (C) [NO3
-] 
respectively (n=33) with no change in the placebo group (n=34) Data are expressed as mean 
± SEM. Significance shown as ***p<0.001 following a paired Student’s t-test pre and post 
juice.  
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Figure 5.5: Dietary NO3
- supplementation elevates plasma (A), urinary (B) and salivary 
(C)[NO2
-] respectively (n=33) with no change in the placebo group (n=34). Data are 
expressed as mean ± SEM. Significance shown as ***p<0.001 following a paired Student’s t-
test pre and post juice.  
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5.3.3 Inorganic NO3
- improves vascular function 
There was no significant difference in baseline brachial artery diameter between 
the limbs and no difference in baseline diameters from the first to the final visit 
within each group (table 5.3).  
 
 
NO3
- 
(33) 
 
   p 
value 
Placebo 
(32) 
 
    p              
value 
 Baseline 6 weeks  Baseline 6 weeks  
Ultrasound       
Brachial artery  
diameter (mm) 
3.8±0.6 3.8±0.6 0.42 3.7±0.7 3.7±0.6 0.57 
Absolute  
Change  
diam (mm) 
0.2±0.1 0.21±0.1 0.002 0.2±0.1 0.2±0.1 0.05 
Time to peak  
diam (minutes) 
6.9±0.3 6.9±0.2 0.40 6.9±0.3 6.9±0.3 0.87 
 
Table 5.3: Ultrasound resting brachial artery diameter, absolute change in diameter, time 
to peak diameter across all visits. Data presented as mean ± SD; p value for paired Student’s 
t test pre and post 6 weeks treatment or placebo. (n=33 NO3
-, n=32 placebo FMD). 
 
However, the FMD response rose substantially (~24%) in the NO3
--treated limb with 
a trend for a small decrease (~6%) in the placebo limb (Figure 5.6, Table 5.3) and a 
significant difference in the primary outcome measure of change in FMD (Figure 
5.6). There were no differences in the time taken for the peak FMD to occur 
between the limbs (Table 5.3). 
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Figure 5.6:  Flow mediated dilatation. Baseline and 6 week data pre and post NO3
- rich and 
placebo juice; p values for paired-t test pre and post 6 weeks NO3
-- rich or placebo juice and 
also for change between groups after 6 weeks using unpaired Student’s t-test are quoted. 
Data presented as mean change ± SD (FMD n=33 NO3
-, n=32 placebo). 
 
In addition measures of arterial stiffness were improved by NO3
- and unchanged by 
placebo. Inorganic NO3
- improved both augmentation index and aPWV (Table 5.4), 
although comparison between the limbs whilst significant for the former did not 
achieve conventional statistical significance (Table 5.5) compared to placebo for the 
latter.  
 
 
NO3
- 
(33) 
 
  p 
value 
Placebo 
(32) 
 
    p   
value 
 Baseline 6 weeks  Baseline 6 weeks  
PWA 
AIx (%) 
aPWV (m/s) 
 
28.7±7.3 
8.1±1.4 
 
26.4±7.8 
8.0±1.1 
 
0.04 
0.02 
 
25.8±7.4 
8.01±1.1 
 
27.4±8.3 
8.1±1.1 
 
0.17 
0.68 
 
Table 5.4: PWA and PWV across all visits. Data presented as mean ± SD; p value for paired 
Student’s t test pre and post 6 weeks treatment or placebo (n=33 NO3
-, n=34 placebo PWA), 
(n=30 NO3
-, n=30 placebo PWV). (AIx=augmentation index;  aPWV=aortic pulse wave 
velocity) 
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Change from baseline 
NO3
- 
(33) 
Placebo 
(34) 
 
p value 
AIx (%) -2.4±1.1 1.5±1.1 0.01 
aPWV (m/s) -0.2±0.1 0.04±0.1 0.06 
Table 5.5: Change from baseline in PWA and PWV after 6 weeks.  Data presented as mean ± 
SD; p value for unpaired Student’s t test post treatment or placebo (n=33 NO3
-, n=34 
placebo PWA), (n=30 NO3
-, n=30 placebo PWV). (AIx=augmentation index;  aPWV=aortic 
pulse wave velocity) 
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5.3.4 Inorganic NO3
- improves SBP but not DBP 
In addition to the changes in vascular function there was a decrease in SBP, but not 
DBP or heart rate, in both limbs. However the SBP-lowering effect was more 
prominent and only significantly different from baseline in the NO3
- limb (~4 mmHg  
vs 2 mmHg in the placebo limb, giving a net decrease of ~2mmHg in the NO3
- limb) 
(Table 5.6) although comparison between the limbs did not reach statistical 
significance (Table 5.7).  
 
 
NO3
-
 
(33) 
 
   P 
value 
Placebo 
(32) 
 
   p 
value 
 Baseline 6 weeks  Baseline 6 weeks  
Clinic BP       
SBP (mmHg) 
DBP (mmHg) 
Heart Rate (BPM) 
125.2±15.1 
76.3±8.6 
67±8 
121.1±12.19 
75.0±8.3 
65±9 
0.004 
0.19 
0.18 
122.7±15.2 
78.1±11.2 
66±8 
120.1±15.4 
76.2±12.8 
65±8 
0.22 
0.12 
0.30 
Table 5.6: Blood pressure and heart rate across all visits. Data presented as  
mean ± SD; p value for paired Student’s t test pre and post 6 weeks treatment or placebo. 
 
 
Change from baseline 
NO3
-
 
(33) 
Placebo 
(34) 
 
p value 
SBP (mmHg) -4.1 ±7.6 -2.7±11.8 0.57 
DBP (mmHg) -1.5±5.2 -1.6±6.4 0.94 
HR (bpm) -1.5±7.1 -1.2±5.7 0.88 
Table 5.7: Change from baseline in blood pressure and HR after 6 weeks.  Data presented as 
mean±SD; p value for unpaired Student’s t test post treatment or placebo. (SBP=systolic 
blood pressure;  DBP=diastolic blood pressure; HR=heart rate) 
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Post-hoc analyses demonstrate that the changes in vascular function do not 
correlate with the decrease in SBP but do correlate with the changes in plasma NO2
- 
concentration (Figure 5.7).  
 
Figure 5.7: Associations between plasma NO2
- concentration and systolic blood pressure 
with vascular function measures. The change from baseline to the 6 week time point in 
plasma NO2
- concentration was correlated to the changes in FMD (A), however these 
changes in vascular function were effects occurring independently of the changes in BP 
(systolic blood pressure; SBP, B and C). Associations determined using Pearson’s correlation 
coefficient assessment. 
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5.3.5 Acute administration of dietary NO3
- elevates plasma, urine and salivary 
[NOx]. 
Changes in the levels of NO3
- and NO2
- were also evident at 3 h post dietary NO3
- 
administration on the very first day of NO3
- ingestion (see Table 5.8).  
 
 
NO3
-
 
(17) 
      
p value 
Placebo 
(17) 
 
     p value 
 Baseline 3 hours  Baseline 3 hours  
Plasma[NO3
-
] 
 (µmol/L) 
 
Plasma[NO2
-
]  
(µmol/L) 
 
Saliva [NO3
-
]  
(µmol/L) 
 
Saliva [NO2
-
] 
 (µmol/L) 
 
Urine [NO3
-
]  
(µmol/L) 
 
Urine [NO2
-
] 
(µmol/L) 
29.5±11.9 
 
 
0.28±0.1 
 
 
488±427 
 
 
375±310 
 
 
1499±1572 
 
 
0.19±0.17 
228.3±88.6 
 
 
0.57±0.2 
 
 
6308±3635 
 
 
2402±1217 
 
 
5924±3606 
 
 
0.78±0.41 
<0.0001 
 
 
 0.0005 
 
   
<0.0001 
    
   
<0.0001 
 
  
0.0003 
 
  
0.0001 
30.2.±11.5 
 
 
0.28±0.1 
 
 
433±415  
 
 
302±261 
 
 
1517±2060 
 
 
0.20±0.26 
27.7±9.7 
 
 
0.31±0.2 
 
 
439±353 
 
 
169±140 
 
 
771±473 
 
 
0.44±0.39 
0.21 
 
  
 0.38 
 
  
 0.95 
   
  
 0.02 
   
  
 0.16 
 
   
0.04 
Table 5.8: Plasma, saliva and urinary NOx. Baseline and 3 h data presented as mean ± SD; p 
value for paired Student’s t test for pre and post-treatment or placebo. 
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5.3.6 Acute administration of dietary NO3
- improves vascular function and arterial 
stiffness  
Acute administration of dietary NO3
- resulted in significant improvement in brachial 
artery FMD. In addition measures of arterial stiffness were improved by NO3
- and 
unchanged by placebo. Inorganic NO3
- improved both AIx and FMD, (Tables 5.9 and 
5.10) compared to placebo, whilst statistical significance was not achieved for 
aPWV. 
 
 
NO3
-
 
(n=17) 
p value Placebo 
(n=17) 
p value 
        
 Baseline 3 h  Baseline 3 h  
Clinic Blood Pressure       
SBP (mmHg) 
DBP (mmHg) 
Heart Rate (BPM) 
129.4±17.8 
78.6±9.4 
68±10 
122.2±18.2 
75.5±8.8 
70±11 
0.02 
0.03 
0.26 
127.1±15.7 
82.6±11.8 
68±7 
125.3±12.7 
79.3±12.9 
68±9 
0.43 
0.01 
0.88 
Ultrasound       
FMD (%) 
Brachial artery  
diameter (mm) 
5.3±2.3 
3.7±0.5 
6.8±2.3 
3.7±0.5 
0.01 
0.86 
4.8±2.0 
3.9±0.8 
4.9±2.1 
3.9±0.7 
0.86 
0.44 
Absolute  
change diam (mm) 
0.2±0.1 0.3±0.1 0.01 0.2±0.1 0.2±0.1 0.79 
Time to  
peak diam (minutes) 
6.9±0.3 6.9±0.3 0.63 6.9±0.3 6.8±0.2 0.35 
PWA 
AIx (%) 
aPWV (m/s) 
 
30.1±8.0 
8.1±1.4 
 
27.6±7.5 
7.9±1.2 
 
0.015 
0.023 
 
25.4±9.1 
8.4±0.9 
 
28.4±9.4 
8.8±1.5 
 
0.001 
0.725 
 
Table 5.9: BP, ultrasound FMD% increase, ultrasound resting brachial artery diameter, 
absolute change in diameter, time to peak diameter across all acute time points (baseline 
and 3 h post intervention) and PWA and PWV. Data presented as mean ± SD. (n=17 NO3
-, 
n=15 placebo FMD), (n=17 NO3
-, n=17 placebo PWA), (n=16 NO3
-, n=16 placebo PWV); p 
value for paired Student’s t test. 
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Change from baseline 
NO3
-
 
(17) 
Placebo 
(17) 
 
P value 
SBP (mmHg) -7.1 ±11.1 -3.3±10.7 0.31 
DBP (mmHg) -2.6±5.5 -3.4±4.7 0.68 
FMD (%) 1.5±2.2 0.1±1.8 0.05 
AIx (%) -2.5±3.8 3.0±3.2 <0.0001 
aPWV (m/s) -0.2±0.6 0.4±1.2 0.08 
Table 5.10: Change from baseline in blood pressure, FMD, AIx, and PWV to 3 h. Data 
presented as mean ± SD; p value for unpaired Student’s t test post treatment or placebo. 
(SBP=systolic blood pressure; DBP=diastolic blood pressure; FMD=flow mediated dilatation; 
AIx=augmentation index, aPWV=aortic pulse wave velocity). 
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5.3.7 Inorganic NO3
- treatment reduces PMA formation and P-selectin expression 
Flow cytometry analysis of circulating cells demonstrated that whilst baseline PMA 
levels were no different between the limbs at baseline, following 6 weeks of dietary 
NO3
- intake a reduction in PMA was evident that was not seen in the placebo limb 
(Figure 5.8). In addition, whilst platelet P-selectin expression was low but similar 
between the groups at baseline a trend for a reduction following NO3
- treatment 
was evident but this did not reach statistical significance (Figure 5.9). Stimulation 
with platelet agonists exposed a trend for reduced P-selectin expression in response 
to ADP (p=0.004) and epinephrine (p=0.06) but not in response to collagen (Figure 
5.10).  
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Figure 5.8: Dietary NO3
- reduces PMA formation. Figure A shows flow cytometry gating 
based on forward side scatter of monocytes, CD 14 positive monocytes and the subsequent 
positive population for CD42B expression from the CD14 positive gate. An example of a pre 
and post NO3
- juice is given. Figure B shows % Platelet monocyte aggregate formation pre 
and post juice in both the NO3
- and placebo limbs. Significance shown for paired Students t-
test pre and post NO3
- treated juice as **p<0.01. Figure C shows change in % PMA 
formation over 6 weeks in the 2 groups. Significance shown for unpaired Student’s t-test 
between groups as *p<0.01. Data are expressed as mean ± SEM (n=25 NO3
-, n=27 placebo). 
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Figure 5.9: Dietary NO3
- reduces unstimulated % P-selectin expression. Figure A shows flow 
cytometry gating based on forward side scatter of platelets, CD 42B positive platelets and 
subsequent positive population for P-selectin expression from the CD42B positive gate. An 
example of a pre and post NO3
- juice is given. Fig B shows unstimulated % P-selectin 
expression pre and post juice. Figure C shows change in % P-selectin expression over 6 
weeks in the 2 groups. Data are expressed as mean ± SEM. (n=31 NO3
-, n=33 placebo).  
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Figure 5.10: Dietary NO3
- reduces stimulated P-selectin expression in response to ADP 10 
µM (A), collagen 3 µg/ml (C), epinephrine 10 µM (E) before and post 6 weeks juice. 
Significance shown as **p<0.01 following paired t-test. Figures B, D and F show change in % 
P-selectin expression over 6 weeks in the 2 groups in response to the same agonists as 
labelled. Significance shown for unpaired Students t-test between groups. All data are 
expressed as mean ± SEM (n=31 NO3
-, n=33 placebo all data). 
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5.3.8 Inorganic NO3
- treatment did not significantly alter stimulus-induced 
aggregation responses.  
There were no significant differences between the groups with respect to stimulus-
induced aggregation responses (Table 5.11). 
 
 
                         NO3
-
                
                         (32)                  
       Placebo                  
(31) 
 
                      
 
 
Baseline 
 
6 weeks 
 
P val 
 
Baseline 
 
6 weeks 
 
P val 
PBS (U) 
ADP (U) 
Coll(U)  
Epi (U) 
       5.5[2.0-7.0] 
59.3±12.5 
73.5±14.7 
16.5[7.5-27.7] 
     5.0[3.0-7.7] 
56.2±13.2 
69.8.12±13.2 
13.0[7.2-16.7] 
0.80 
0.33 
0.50 
0.16 
4.0[1.0-11.0] 
57.5±13.3 
70.6±12.0 
9.5[5.0-16.5] 
6.00[2.0-8.5] 
58.4±14.2 
72.9±12.5 
8.5[4.0-15.0] 
0.36 
0.57 
0.21 
0.51 
Table 5.11: Whole Blood Aggregometry. Baseline and 6 week data presented as mean ± SD 
or median and inter-quartile range; p value for paired Student’s t-test pre and post juice or 
Wilcoxon matched-pairs signed rank test (n=32 NO3
-, n=31 placebo). 
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5.4 Summary 
1. In hypercholesterolaemic patients dietary NO3
- was associated with a 
significant rise in plasma NO2
- and NO3
- concentration at 3h post-intake and 
remained elevated with a once daily dose after 6 weeks. These results 
confirm the presence of an intact enterosalivary circuit in 
hypercholesterolaemia, with no evidence of tachyphylaxis or tolerance. 
2. This dietary NO3
- intervention was associated with a 29% and a 24 % 
improvement in FMD at 3 h and 6 weeks respectively in those who received 
the NO3
--rich juice compared to a 2% improvement and a 6 % decline 
respectively in endothelial function in the placebo cohort after 6 weeks. 
Importantly the changes in FMD were directly correlated to changes in 
plasma NO2
- concentration.  
3. An improvement in both AIx and aPWV was noted in those who received the 
NO3
--rich juice compared to no change in the placebo cohort at both 3 h or 6 
weeks.  
4. There was also a decrease in SBP but not DBP or heart rate in both limbs, 
however the effect was more prominent and only significantly different 
from baseline in the NO3
- limb. However, the decreases in SBP were not 
correlated with changes in vascular function. 
5. There was an associated significant reduction in circulating PMA numbers in 
the NO3
- limb at 6 weeks that was absent in the placebo limb and a trend but 
not statistically significant reduction in platelet P-selectin expression.  
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6. There were no statistical differences in cholesterol levels following 6 weeks 
dietary NO3
- compared to placebo. However, a trend to a reduction in LDL 
cholesterol was evident in the dietary NO3
- limb. 
7. There were no adverse effects of consuming dietary NO3
- beyond beeturia 
and faecal discoloration. Furthermore, there was no significant rise in metHb 
levels post ingestion of 6 weeks NO3
- rich juice. 
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Chapter 6 
 
 
Discussion 
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6.1 Introduction 
Dietary (inorganic) NO3
- may underpin the cardioprotective effects offered by fruit 
and vegetable rich diets (Joshipura et al., 1999, Joshipura et al., 2001, Kapil et al., 
2010b). In support of this possibility, recent studies in healthy volunteers, have 
shown a range of beneficial effects of acute administration of a dietary NO3
- load 
(Webb et al., 2008b) or inorganic NO3
- supplementation (Larsen et al., 2006, Kapil et 
al., 2010a, Larsen et al., 2011) on the cardiovascular system including some 
suggestion of reduced platelet reactivity (Webb et al., 2008b, Richardson et al., 
2002). In this thesis I show a modest anti-platelet effect of a single acute dose of 
inorganic NO3
- supplementation (in the form of NO3
- salt capsule) in male but not 
female healthy volunteers. This effect in males is dependent upon elevation of 
circulating NO2
- followed by reduction of NO2
- to NO, in part, at the level of the 
erythrocyte. In turn this NO suppresses platelet reactivity by elevation of cGMP. My 
results also suggest that whilst the enterosalivary circuit and NO2
- reductive 
pathways are intact in females, that the anti-platelet effect is absent in females due 
to an absence of platelet cGMP increase.  
 
I also show that similar effects are evident in patients with hypercholesterolaemia. 
In a 6 week trial of daily inorganic NO3
- (beetroot juice) ingestion versus a low NO3
- 
placebo juice in patients with hypercholesterolaemia, a 24% improvement in FMD 
occurred in those who received the NO3
--rich juice compared to a 6% decline in 
endothelial function in the placebo cohort. These effects were also associated with 
reductions in circulating PMA numbers and reduced P-selectin expression in 
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response to platelet agonists ex vivo. Together, these data suggest that a dietary 
NO3
- approach might be useful in improving endothelial function and platelet 
reactivity in individuals at risk of CVD.  
 
6.2 NO3
-/NO2
- bioactivity in healthy volunteers 
6.2.1 NO3
- supplementation raises circulating NO2
- in healthy volunteers 
Inorganic NO3
- administration in the form of a KNO3 salt caused a significant rise in 
both circulating NO3
-, and consequently NO2
- levels.  These changes in NOx are 
similar to those demonstrated in healthy volunteers previously (Webb et al., 2008b, 
Kapil et al., 2010a, Bahra et al., 2012a). It is accepted that, following its ingestion, 
inorganic NO3
- is rapidly absorbed across the intestine and then either excreted by 
the kidneys or extracted from the blood by the salivary glands (Qin et al., 2012a) 
and consequently secreted within the saliva into the oral cavity (Spiegelhalder et al., 
1976b, Tannenbaum et al., 1976). Here, facultative anaerobes on the dorsal surface 
of the tongue reduce the NO3
--rich saliva to NO2
- (Duncan et al., 1995b): a fact 
reflected in the saliva measurements shown in chapters 4 and 5. This NO2
- is then 
swallowed and as occurs in both healthy volunteers (Lundberg and Govoni, 2004a, 
Webb et al., 2008b) and hypertensive patients (Ghosh et al., 2013b) then enters the 
circulation. The results in chapter 4 demonstrate clear evidence of this pathway 
occurring in the healthy volunteers recruited into this clinical study.  
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Within the oral cavity approximately two-thirds of inorganic NO3
- is thought to be 
converted to NO2
- by bacterial NO3
- reductases (Webb et al., 2008b, Tannenbaum et 
al., 1976, Kapil et al., 2013): a view likewise supported by my findings herein. 
Previous evidence has suggested that the enterosalivary pathway may be more 
prevalent in females and some evidence of this also comes from my findings. The 
ratio of baseline NO3
- to NO2
- post 3 h was 1:5.84 in males and 1:6.35 in females 
However, following NO3
- ingestion the ratio of baseline NO3
- to NO2
- at 3 h post-
ingestion was 1:3 in males and 1:11 in females.  NO2
-, once swallowed enters the 
circulation with levels peaking at approximately 3 h following NO3
- ingestion (Webb 
et al., 2008b, Kapil et al., 2010a). Importantly, the biological effects of inorganic 
NO3
- ingestion correlate directly with the levels of NO2
- in the circulation, peak at 3 h 
simultaneously with the peak in circulating NO2
- levels and are thought to be due to 
the conversion of this NO2
-  to NO within the circulation (Kapil et al., 2010a).  It was 
upon this basis that all platelet function assessment in the study contained within 
this thesis was conducted 3 h following NO3
- ingestion in order to observe the 
maximum possible effects. However, in addition my data suggest perhaps an 
improved capacity to elevate circulating NO2
-   levels in females. Exactly which stage 
in the circuit might be improved in females is uncertain with increased NO3
- 
reduction or increased gastrointestinal absorption of NO3
- being at least 2 
possibilities. My data suggest that the former is unlikely since salivary NO3
- levels 
were similar between the two.  
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6.3 NO3
-/NO2
- and platelet reactivity in healthy volunteers 
The rise in circulating NO2
- levels following inorganic NO3
- capsule supplementation 
in healthy volunteers was associated with a reduction in ex vivo assessed platelet 
aggregation induced by either ADP or collagen. A  similar effect to this was also 
noted in a matched cohort given beetroot juice whose platelet aggregation was 
assessed using LTA (Velmurugan et al., 2013). Importantly, however, no effect on 
responses to the weak platelet activator epinephrine were evident. Both ADP and 
collagen, whilst activating distinct receptors (P2Y1/P2Y12 and GPVI) and molecular 
pathways within the platelet (Figure 6.1), trigger a number of common phenomena 
implicated in platelet activation, including platelet granule secretion, thromboxane 
A2 release and platelet aggregation. These events are also commonly associated 
with increases in phosholipase C and phosphoinositide-3-kinase activity (Li et al., 
2010). In contrast, epinephrine alters platelet reactivity by binding to α2 receptors 
coupled to Gi (figure 6.1) resulting in a reduction in intracellular cAMP levels.  
 
Figure 6.1: Diagram depicting the 3 agonists that I used in my thesis and their respective 
signalling cascades that each one activates within the platelet. 
Collagen
Ca2+
Fibrinogen binding via 
GPIIb/IIIa
GPVI
ADP
Ca2+
Fibrinogen binding via 
GPIIb/IIIa
P2Y1/12
Epinephrine
Ca2+
α2AR
Gq/s Gi
Fibrinogen binding via 
GPIIb/IIIa
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It has been suggested that per se epinephrine exerts little change in platelet 
response, however when present in combination with other stronger activating 
stimuli such as ADP or histamine, α2 receptor activation enhances the stimulatory 
effect of the agonist (Bevan et al., 1992, Saitoh et al., 1989). Since epinephrine was 
not used in combination with other agonists this may underlie the absence in effect 
of inorganic NO3
- on responses seen but also suggests that NO3
- acts to suppress 
pathways implicated in platelet activation commonly associated with stronger 
stimuli. 
 
It is likely that the repressive effects of inorganic NO3
- on platelet reactivity are due 
to the formation and activity of NO in vivo. NO is a potent inhibitor of platelet 
function and basal NO generation is thought to play a crucial role in suppressing 
platelet reactivity in physiology (Loscalzo, 2001). This activity of NO has been 
attributed, primarily, to activation of sGC and consequent elevation of platelet 
cGMP levels (Moro et al., 1996, Rukoyatkina et al., 2011, Radomski et al., 1990, 
Dangel et al., 2010). Although, there is also some suggestion that there may be sGC-
independent effects of NO and NO donor drugs on platelets (Pawloski et al., 1998, 
Zhang et al., 2011, Sogo et al., 2000, Marcondes et al., 2006) and also 
controversially pro-stimulatory effects of the NO-sGC-cGMP pathway in platelets 
(Zhang et al., 2011, Marjanovic et al., 2005, Stojanovic et al., 2006). More recently 
both of these possibilities have been challenged by demonstration of an absence of 
any anti-/or indeed pro-stimulatory platelet effects of NO in mice lacking the β1 
subunit of sGC (Dangel et al., 2010) or in mice with selective deletion of platelet sGC 
(Rukoyatkina et al., 2011). Although in contrast, using the same platelet-specific 
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mice, evidence for a stimulatory effect of NO-induced cGMP has also been 
proffered (Zhang et al., 2011). Nevertheless, irrespective of this controversy, my 
results support an inhibitory role for the NO-sGC-cGMP pathway in platelets. 
Indeed, I show that inorganic NO3
- ingestion in males elevates platelet cGMP levels 
implicating NO in the anti-aggregatory effects. This effect likely underlies the 
beneficial effects since in females where no change in platelet reactivity was 
evident there was likewise no change in platelet cGMP levels.  
 
The exact mechanisms involved in cGMP-induced suppression of platelet reactivity 
in the present study are uncertain. It has been suggested that elevation of cGMP in 
platelets results in PKG activation and consequent phosphorylation of a range of 
proteins that influence platelet function including inositol triphosphate receptors 
and phosphodiesterase 5 to name just two (for review see (Jones et al., 2012)). 
Irrespective of the exact molecular pathways involved, NO has been shown to cause 
a number of phenomena in platelets that would ultimately result in decreased 
activity including reduced granule secretion (Broekman et al., 1991, Michelson et 
al., 1996b) and platelet adhesion (Radomski et al., 1987a), phenomena shown to be 
both cGMP-dependent (Radomski et al., 1987b, Michelson et al., 1996b) and 
independent (Marcondes et al., 2006, Morrell et al., 2005). As an index of both of 
these characteristics I measured P-selectin expression and demonstrated that, in 
males treated with inorganic NO3
-, unstimulated platelet P-selectin expression was 
suppressed and accordingly in females where cGMP was not changed no difference 
in P-selectin expression was evident.   
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The delivery of NO to the platelet following NO3
- ingestion is likely due to elevation 
of circulating NO2
- which is then converted to NO. The conversion of NO2
- to NO 
within the circulation is thought to be facilitated by a number of distinct NO2
- 
reductases that have been localised to either the erythrocyte or the blood vessel 
wall. To determine whether the platelet itself might be the site of NO2
- reduction I 
assessed the effects of incubation of purified platelets with NO2
-, at similar 
concentrations to those achieved following oral inorganic NO3
- ingestion (i.e. 0.1-3 
µM), prior to assessment of aggregation using LTA. The data show no effect of NO2
- 
when incubated with platelets for 10 or 30 min despite clear evidence of sensitivity 
to NO, demonstrated by using the NO donor, Sper-NO. These observations are in 
agreement with recent studies, testing similar concentrations of NO2
- with human 
PRP, demonstrating no effect of NO2
- upon ADP or collagen-induced aggregation 
(Srihirun et al., 2012) and suggest that NO2
- has no direct effect on platelets. In 
contrast, there are some suggestions that NO2
- exerts direct inhibitory effects on 
platelets, however the in vivo relevance of these observations are uncertain since 
these effects of NO2
- were achieved with concentrations 10-100 times above that 
found circulating in vivo (Laustiola et al., 1991, Arora et al., 2009). Treatment with 
NO3
- results in a peak rise in circulating NO2
- concentration between 0.3-1 µM. Since 
baseline circulating NO2
- levels have been proposed to lie between 0.02 µM and 1 
µM I used a concentration range reflecting this NO2
- physiology (Webb et al., 2008b, 
Moshage et al., 1995, Pannala et al., 2003, Grau et al., 2007). Thus, in agreement 
with recently published observations (Srihirun et al., 2012), our findings indicate 
that whilst physiological concentrations of NO2
- in vivo exert anti-platelet effects 
this is not due to its conversion to NO at the platelet itself.  
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The focus on the erythrocyte as a site for NO2
- reduction comes from several studies 
suggesting that within the circulation this is a key site for this process. In particular 
studies in humans have identified the erythrocyte as critical for NO2
--induced 
reduction and vasodilatation (Cosby et al., 2003) with evidence proposing deoxyHb 
as the NO2
- reductase. However, later studies conducted by the Ahluwalia lab show 
that XOR, localised to the erythrocyte, may also play a critical role in erythrocyte 
mediated NO2
- reduction within the circulation (Webb et al., 2008b, Ghosh et al., 
2013a). To determine whether conversion of NO2
- at the level of the erythrocyte 
might be responsible for the NO2
--derived NO thus underlying the reduced 
responsiveness of platelets following dietary NO3
- administration, I assessed the 
effects of NO2
- incubation on platelet aggregation in whole blood. In these studies in 
vitro NO2
- incubation (for either 10 or 30 min) caused concentration-dependent 
inhibition of platelet aggregation in response to ADP when incubated with whole 
blood collected from healthy male volunteers. The inhibition was modest ~25 % 
matching the levels of suppression evident with in vivo NO3
- dosing. This effect of 
NO2
- was likely due to its conversion to NO since it was associated with elevations in 
platelet cGMP levels. In contrast I found no effect of NO2
- on ADP-induced platelet 
aggregation responses of whole blood collected from female healthy volunteers and 
likewise no alteration in platelet cGMP. This observation is in agreement with the 
findings of chapter 4 demonstrating no effect of dietary NO3
- on platelet responses 
in females.   
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Since I have shown that erythrocytes of males or females express similar NO2
-  
reductase capacity under varying pH conditions and NO2
- concentrations the data 
suggest that the pathways for NO signalling within the circulation might be different 
between the sexes. More specifically, my results suggest that the NO-sGC-cGMP 
pathway in platelets is impaired in females compared to males, resulting in a 
reduction of the anti-platelet effect of NO2
--derived NO in healthy females. Such a 
proposal is supported by a number of recent pre-clinical studies indicating a greater 
role for the NO-sGC-cGMP pathway in vascular reactivity in males compared to 
females.  Indeed, whilst male sGCα1 knockout mice are hypertensive, female 
knockouts are not (Buys et al., 2008). In addition, investigations from the lab 
suggest that whilst sGC activators cause potent vasodilatation and decreases in BP 
in male mice, that the activity is much reduced in females, an effect reflecting 
reduced sGC expression (Chan et al., 2012). The observations shown herein, suggest 
that this phenomenon identified in animals translates to humans, although further 
molecular investigations are required to confirm the exact pathways involved. 
 
The NO2
- reductase that might be involved in the beneficial effect on platelets is not 
certain. Very recent in vitro studies suggest that deoxyHb might be the NO2
- 
reductase on erythrocytes influencing platelet function since reductions in oxygen 
tension associated with increases in deoxyHb levels, resulted in improved NO2
- 
bioactivity (Srihirun et al., 2012). More recently Akrawinthawong et. al studied the  
effect of NO2
- on platelets, at different oxygen levels, using flow cytometric assays 
to detect platelet membrane surface markers upon activation. The P-selectin and 
activated GPIIb/IIIa expression on platelet membranes in response to ADP, collagen 
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and thrombin stimulation were measured at various haematocrit and oxygen levels. 
NO3
- (0.1 to 1.0 μM) significantly decreased the percentage of expression of  these 
surface markers on the platelet membrane at haematocrit values above 23 % and 
oxygen levels lower than 49 mmHg signifying the importance of the erythrocyte and 
hypoxia in instigating this NO2
- effect. The inhibitory effect of NO2
- on platelet 
aggregation was also augmented by increasing haematocrit values and decreasing 
oxygen saturation again highlighting the importance of the erythrocyte and hypoxia 
in catalysing and enhancing NO2
- reduction respectively.  In vitro studies 
demonstrate that 2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-
oxide (C-PTIO) (an NO scavenger) prevented the effects of NO2
- (Crawford et al., 
2006) whereas inhibitors of NO synthase (Webb et al., 2004) and xanthine 
oxidoreductase (in vivo) (Dejam et al., 2007) had no effect. These results support 
our observation that circulating NO2
- following its reduction to NO decreases 
platelet reactivity in the presence of partially deoxygenated erythrocytes through its 
reduction to NO (Akrawinthawong et al., 2014). 
 
6.4 NO3
-/NO2
- activity in hypercholesterolaemic patients 
The clinical study described in chapter 5 conducted in patients with 
hypercholesterolaemia demonstrates that the bioactivity of NO3
- and NO2
- evident 
in healthy volunteers also occurs in patients with raised cholesterol. 
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6.4.1 NO3
-/NO2
- supplementation raises circulating NO2
- in patients with 
hypercholesterolaemia.  
Previous studies and those in this thesis (chapter 4) have shown that dietary NO3
- is 
an effective approach that can be utilised to increase plasma NO2
- and consequently 
availability of NO in healthy volunteers (Webb et al., 2008b, Kapil et al., 2010a, 
Velmurugan et al., 2013). More recently, the efficacy of this pathway has also been 
demonstrated in overweight and slightly obese men (Joris and Mensink, 2013) as 
well as in individuals with disease including hypertension (Ghosh et al., 2013a) and 
type II diabetes (Gilchrist et al., 2013). The studies in this thesis now show that the 
same is true for hypercholesterolaemia. The rise in circulating NO3
- concentration of 
~7.5-fold and NO2
- concentration of ~2.5 fold, measured after 6 weeks of once daily 
NO3
- dosing of ≈ 6 mmol in these patients, is in accord with that achieved in healthy 
volunteers or hypertensive patients using similar doses on a single occasion. In 
hypertensives a single dose of dietary NO3
- (~3.5 mmol) ~200 mg, caused rises of 
NO2
-  ~5.5-fold and ~1.5-fold of NO3
- respectively. (Ghosh et al., 2013b). In healthy 
volunteers a dose of 5.5 mmol caused rises of ~8 fold and ~1.6 fold respectively 
(Kapil et al., 2010a). These observations demonstrate that as with other cohorts oral 
ingested inorganic NO3
- is an effective method for elevating circulating NO2
- levels in 
patients at risk of CVD, including hypercholesterolaemics, where the conventional 
pathways for NO synthesis are thought to be dysfunctional.  
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6.4.2 NO3
- treatment improves vascular function in hypercholesterolaemic 
patients 
Endothelial dysfunction, characterised by reduced bioavailable NO, is thought to 
represent a pivotal process in development of diverse CVD; a phenomenon that 
occurs prior to overt pathology and frank disease presentation (Brunner et al., 2005, 
Halcox et al., 2009). Previous studies demonstrate reduced endothelial function in 
individuals with hypercholesterolaemia (Chowienczyk et al., 1992) that are also 
predictive of risk of an event (Yeboah et al., 2009, Bonetti et al., 2003b). As such 
there has been support for the use of measures of endothelial function, particularly 
FMD, as indicators of cardiovascular health (Deanfield et al., 2007, Corretti et al., 
2002a), and calls for identification of strategies that might halt or indeed reverse 
this phenomenon (Deanfield et al., 2007). Pre-clinical studies in 
hypercholesterolaemic C57BL/6J mice indicate that dietary NO2
- treatment prevents 
the endothelial dysfunction caused by a diet rich in cholesterol (Stokes et al., 
2009b). Herein, the data demonstrate that sustained dietary NO3
- ingestion also 
results in an improvement in endothelial function in humans with 
hypercholesterolaemia. This improvement in FMD was independent of any changes 
in baseline diameter or time to peak FMD indicating that the increase in response 
likely reflects an improvement in endothelial function and NO activity. In support of 
this contention are the post-hoc analyses demonstrating a direct correlation 
between changes in plasma NO2
- and changes in FMD response at 6 weeks post-
treatment. However, I did not measure the effect of dietary NO3
- ingestion on direct 
NO-stimulated increases in blood flow that are conventionally assessed using GTN 
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administration. Therefore I cannot exclude the possibility that changes in the 
reactivity of the underlying smooth muscle might also contribute to the improved 
vascular function.  
 
Since FMD is thought to be due to the triggering of shear stress-induced endothelial 
NO generation, the improvements suggest an increase in NO bioavailability. Exactly 
why endothelial function might be improved by a dietary NO3
- intervention is 
uncertain. It is noteworthy that in previous studies whilst a single dose of inorganic 
NO3
- given as a supplement did not alter FMD per se in healthy volunteers (Bahra et 
al., 2012b), that when given either in a dietary form or as a supplement, the 
transient endothelial dysfunction, induced by an ischaemia-reperfusion insult in the 
forearm of healthy volunteers, was prevented (Kapil et al., 2010a, Webb et al., 
2008b). These results suggest that in an environment where endothelial function is 
sub-optimal that inorganic NO3
- can effect improvements. These findings do, 
however, differ from a study in 27 diabetics where a 2 week supplementation with 
dietary NO3
-, versus placebo control, was not associated with an improvement in 
endothelial function: a secondary outcome measure in that study (Gilchrist et al., 
2013). Exactly why no benefit was evident is unclear, however, it is possible that a 
longer treatment period is required, that the pathways for NO2
- reduction in 
diabetes might not support such an effect, but also possibly due to the fact that the 
study was powered for blood pressure and not FMD. In contrast the study in this 
thesis was powered for changes in FMD.  
In addition to improved FMD chronic ingestion of dietary NO3
- resulted in a modest 
but statistically significant improvement in both aPWV and AIx, both of which are 
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measures of arterial stiffness. This effect has likewise been demonstrated in 
response to a single dose of inorganic NO3
- in either healthy volunteers (Bahra et al., 
2012b) or patients with hypertension (Ghosh et al., 2013b). aPWV is a measure of 
arterial compliance determined by both the distending pressure and the intrinsic 
wall properties. In healthy volunteers, aPWV increases with age. In a study to 
establish normal values with over 16,000 subjects, in 40-49 year olds, a mean aPWV 
of 7.0 ms-1 was noted and in 50-59 year old healthy volunteers a mean of 7.6ms-1 
was found. The mean age of participants in the hypercholesterolaemia study 
described in this thesis was 52 years (Boutouyrie, 2010).  
 
The baseline levels of measures of AIx and PWV described in chapter 5 in patients 
are commensurate with other studies demonstrating vascular stiffness in 
hypercholesterolaemic but otherwise healthy individuals. A baseline AIx of 21 % was 
reported by Wilkinson et al. in a cohort of hypercholesterolaemics (Wilkinson et al., 
2002b). Further support of my baseline values can be found in another study 
performed by Wilkinson et al. where mean AIx in a group of subjects of mixed sex 
with risk factors for CVD and permanent pacemakers in situ was found to be 15.8 % 
in the group under 60 years of age and 29.8% in the group over 60 years of age 
(Wilkinson et al., 2000).  Recently a small study in a cohort of elderly volunteers 
with risk factors for cardiovascular disease found an improvement in PWV and AIx 
in the group who received sodium nitrate (NaNO3) versus sodium chloride (NaCl) 
control (Rammos et al., 2014) corroborating our findings. Other dietary strategies 
that have been tested using PWV include cranberry juice (Dohadwala et al., 2011), 
pomegranate juice (Lynn et al., 2012), oleic acid (Lithander et al., 2013) and green 
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tea (Ryu et al., 2006) amongst others with cranberry juice being noted to improve 
PWV in subjects with coronary artery disease from 8.3 ms-1 to 7.8 ms-1 in contrast 
with an increase after placebo (8.0 ms-1 to 8.4 ms-1). Again, baseline PWV in the 
study I conducted was comparable to the baseline measures in the above 
mentioned studies.  
 
AIx has been proposed as an independent risk marker for premature coronary 
artery disease (Weber et al., 2004), and although several studies also suggest similar 
relationships for aPWV (Duprez et al., 2011, Grey et al., 2003), a more recent meta-
analysis has found no association of aPWV with other classical risk factors for 
atherosclerosis, including lipid levels (Cecelja and Chowienczyk, 2009). Irrespective 
of this, improvement in both PWV and AIx do indicate that dietary NO3
- is effective 
in improving vascular function in these patients.  
 
The exact mechanisms underlying these improvements in vascular function are 
uncertain. However, it is thought that a reduced bioavailability of NO prevalent in 
CVD and specifically in hypercholesterolaemics indicates this dysfunction and 
relates to an increased oxidative stress (Cardillo et al., 1997, Cai and Harrison, 
2000a) and thus scavenging of NO by reactive oxygen species. It has been 
speculated that certain NO2
- reductases, particularly the enzyme XOR (Webb et al., 
2008a), also possesses the capacity to reduce oxygen and that provision of NO2
- to 
this enzyme alters oxidative stress by competing for electrons that are required for 
oxygen reduction by XOR (Tripatara et al., 2007). To begin to determine whether 
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this might be the case we measured markers of oxidative stress and inflammation in 
the plasma (data not included in thesis).  Our hypothesis generating analyses 
indicate that whilst hsCRP was not different between the limbs in the whole cohort, 
in those individuals within the cohort with high hsCRP levels a trend for a reduction 
was evident, although the numbers within this group are small. In addition we also 
measured the levels of the neutrophil chemokine CXCL1 since levels of this 
chemokine are thought to be elevated in human disease (Breland et al., 2008) and 
there is some evidence that nitrite might target neutrophils in inflammation 
associated with hypercholesterolaemia (Stokes et al., 2009a). In our cohort there 
was a trend for reduction of CXCL1 levels in plasma in the dietary NO3
- limb. 
Together the data support the suggestion that dietary NO3
- might improve vascular 
reactivity by lowering oxidative stress and thus consequently inflammation, 
however, appropriately powered studies designed to test this directly are required.   
 
Our assessments of lipid levels in the cohort show no statistical differences in LDL 
cholesterol levels following 6 weeks dietary NO3
- treatment compared to placebo 
and no changes in either limb compared to baseline. This suggests that the 
improvements in vascular function with dietary NO3
- treatment did not relate to 
alterations in lipid load. However, the study was not powered to detect small 
reductions in LDL of <0.5 mmol/L and since there does appear to be a trend in 
reduction of LDL cholesterol larger studies powered to detect differences in LDL 
cholesterol may be worthwhile.  Statins reduce LDL cholesterol by 20-40% 
depending on the dose and the drug (Gotto, 2002). This would equate to a 1 
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mmol/L reduction in LDL on average thus using my data as a guide, one would 
expect the effect of NO3
- to be more modest in comparison. 
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6.4.3 NO3
- ingestion improves platelet function in hypercholesterolaemic patients 
In hypercholesterolaemic patients the rise in circulating NO2
- levels following dietary 
NO3
- supplementation was associated with reductions in baseline PMA and ex vivo 
stimulated but not baseline platelet P-selectin expression. Importantly, a significant 
increase in the levels of P-selectin expression over the 6 weeks of the study was 
noted in unstimulated and stimulated platelets in the placebo groups; an effect not 
seen in the NO3
- group.  Suppression of such platelet markers by dietary NO3
- may 
indicate a beneficial effect since it is accepted that upregulated P-selectin is critical 
for progression of atherosclerosis. In mice a deficiency in P-selectin reduces 
formation of atherosclerotic lesions (Dong et al., 2000, Collins et al., 2000, Johnson 
et al., 1997, Nageh et al., 1997) and platelet P-selectin expression is associated with 
atherosclerotic wall thickness in carotid arteries in humans (Koyama et al., 2003) 
and is increased in coronary artery disease patients (Fitzgerald et al., 1986, Trip et 
al., 1990, Furman et al., 1998). Such studies imply that lowering platelet P-selectin 
levels in hypercholesterolaemia using dietary NO3
- may be of therapeutic benefit.  
 
In line with these reductions in P-selectin is the finding that in the dietary NO3
- limb 
significant reductions in PMA levels were observed. This is of substantial clinical 
significance since PMA levels have been proposed to be a superior (more sensitive) 
marker of platelet activation compared to surface P-selectin since degranulated 
platelets rapidly lose surface P-selectin (Michelson et al., 1996a, Michelson et al., 
2001). Pre-clinical studies in mice suggest that targeting PMA may yield therapeutic 
benefit as these aggregates play a crucial role in inducing endothelial dysfunction 
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and consequent atheroma formation (Huo et al., 2003). Surprisingly, I found no 
difference in ex vivo platelet aggregation induced in response to a range of different 
stimuli. Exactly why no difference was seen despite clear indications of reduced 
activation (PMA and P-selectin expression) is uncertain. It is possible that a further 
larger trial assessing the effect of NO3
- on platelet function as the primary outcome 
measure may provide some clarity on the issue. 
 
 It is noteworthy that the hypercholesterolaemic cohort was composed of a two 
thirds female to male bias. Interestingly, reductions in P-selectin were noted unlike 
in the healthy volunteer study of inorganic NO3
- in which an effect on P-selectin 
expression was seen only in males. It is possible that this effect was observed in this 
cohort of females due to a differing hormone profile: In the hypercholesterolaemics 
mean age was 52 compared to 27 years in the healthy volunteer study respectively. 
It is well documented that postmenopausal women have higher rates of CAD than 
premenopausal women (Colditz et al., 1987) and sex differences in rates of CAD 
morbidity and mortality are largest in magnitude prior to menopause (Kannel et al., 
1976a). Consequent oestrogen deprivation is thought to be at the centre of these 
findings (Barrett-Connor and Bush, 1991). Oestrogens reduce the serum levels of 
several markers for inflammation including E-selectin (Stork et al., 2002) and P-
selectin in postmenopausal women (Farzati et al., 2002). Furthermore, NO is 
decreased in postmenopausal women and work by Rosselli et al. showed that 
estradiol treatment in postmenopausal women was accompanied by a significant 
increase of circulating NO2
- and NO3
- levels, with levels restored to approximately 
those observed in premenopausal women. (Rosselli et al., 1995). Indeed, aging 
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decreases NO synthesis and responsiveness in human platelets and increases 
formation of PMAs (Goubareva et al., 2007). Thus, the apparent hypersensitivity of 
the predominantly female hypercholesterolaemic cohort in contrast to female 
healthy volunteers may relate to the effects of menopause and is an issue that 
warrants further investigation. 
 
Finally, there were no adverse effects of consuming dietary NO3
- except for 
beeturia, supporting the view that dietary loading with NO3
- is a safe method for 
elevating circulating NO2
- levels. In particular, our assessments of safety included 
metHb measurement. The absence of any significant rise in metHb levels confirms 
the view that the circulating levels of NO2
- required to achieve beneficial functional 
effects upon the cardiovascular system is substantially below the levels associated 
with detrimental effects. The safety profile of NO3
- and NO2
- has been much 
discussed of late particularly with respect to metHb levels and associations of NO2
- 
consumption with gastric cancer (Hord et al., 2009b, Sindelar and Milkowski, 2012). 
It was the use of bismuth subnitrate in unwell children with diarrhoea that 
highlighted the potential for fatal methaemoglobinaemia as NO3
- is converted to 
NO2
- by bacteria and then this NO2
- reacts with Oxy-Hb leading to metHb formation 
(Beck, 1909, Roe, 1933). Ordinarily in adults it was recognised large doses of NO3
- 
could be tolerated with no side effects however in the scenario of ingestion in 
children the tolerance is lowered. Parallels could be drawn between the 
complications of methaemoglobinemia following NO3
- ingestion and those of NO2
- 
ingestion first described by Gamgee and reported in an infant by Roe (Roe, 1933). 
NO3
- content in the water was subsequently regulated. However, this study 
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supports a growing view that the toxicity concerns regarding modest dietary NO3
- 
consumption are not supported by evidence (Fao/Who, 2003), although assessment 
of NO3
- safety over prolonged periods of time in larger cohorts is warranted.  
 
Reassuringly, concerns with respect to consumption of dietary NO3
- from green 
leafy vegetables and carcinogenesis remain unfounded. NO3
- requires in vivo 
conversion to the chemically related NO2
- anion and then further reaction with 
secondary amines to form N-nitrosamines in order to demonstrate any degree of 
carcinogenic potential (Speijers, 2003). N-nitrosoamines were discovered to be 
carcinogenic over 60 years ago. Hepatocellular carcinoma was induced in rats fed 50 
ppm dimethylnitrosamine after 6 months (Magee and Barnes, 1956) and other N-
nitrosamines when orally ingested for long periods have been causally associated 
with cancerous lesions of the liver, kidney, stomach and oesophagus in rats (Magee 
and Barnes, 1967). Other studies have shown that N-nitrosamines are carcinogenic 
in many animal species (Bogovski and Bogovski, 1981). In humans incubation of 
gastric juice, NO2
- and secondary amines forms N-nitrosamines in vitro (Sen et al., 
1969) and also in vivo following consumption of NO2
- containing foods (Fine et al., 
1977). Reassuringly, there has been a lot of epidemiological research focusing on 
the possible link between NO3
- and human cancer which has not resulted in any 
compelling evidence proving such a link (for review see (McKnight et al., 1999)). A 
comprehensive review undertaken by the World Health Organization and other 
parties in 2003 concluded there was no evidence that NO3
- ingestion was associated 
with carcinogenesis in humans (Speijers, 2003). In addition to this, large study 
groups comprising over 100,000 people showed that those with the greatest NO3
- 
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intake have no increased cancer incidence or mortality (Hung et al., 2004). Indeed 
mortality may even be reduced (Boffetta et al., 2010). 
  
6.5 Conclusion 
In summary, inorganic NO3
- supplementation in the form of KNO3 capsules 
decreases platelet aggregation in healthy males but not females. The mechanism 
underlying this sex difference is uncertain although entero-salivary processing to 
NO2
- appears to be taking place in both sexes and subsequent conversion to NO in 
the vicinity of the platelet, is occurring in males. In addition I have shown that the 
NO2
- reductase activity facilitating the conversion of NO2
- to NO requires a whole 
blood environment and does not occur at the level of the platelet indicating that 
the site of reduction is likely the erythrocyte. There may be a role for inorganic NO3
- 
in inhibiting platelet reactivity in primary prevention or even as an adjunct to anti-
platelet therapies in secondary prevention of atherothrombotic events since dietary 
NO3
- also reduced platelet reactivity in hypercholesterolaemic patients. Such a 
strategy may also offer cardiovascular protection to males who ordinarily are at 
higher risk of CVD.  
 
In addition, the study in hypercholesterolaemic patients supports the use of dietary 
NO3
- as a safe, well tolerated and potentially powerful primary prevention strategy 
in CVD in those with early endothelial dysfunction. This is evidenced by 
improvements in endothelial function, vascular stiffness as well as platelet 
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inflammatory profile. Long term outcome studies are now required to test the 
merits of a dietary NO3
- strategy. 
  
Platelet and endothelial dysfunction are critical for the development of 
atherosclerosis. I have shown that inorganic NO3
- clearly has a beneficial effect on 
dampening platelet reactivity and in improving endothelial function. Such a simple 
dietary NO3
- strategy may well be instrumental in preventing both the development 
and also progression of CVD and could easily be adopted worldwide, potentially 
leading to a substantial reduction in morbidity and mortality. Thus the health 
benefits through implementation of this novel treatment are immense, and I 
strongly advocate assessment of this potential in large phase 3 trials. 
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